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ABSTRACT: Type-2 diabetes is a complex disease with multiple risk factors and health 
consequences whose prevention is a major public health priority. We have developed a 
microsimulation model written in the R programming language that can evaluate the 
effectiveness and cost-effectiveness of a comprehensive range of different diabetes 
prevention interventions, either in the general population or in subgroups at high risk of 
diabetes. Within the model individual patients with different risk factors for diabetes follow 
metabolic trajectories (for body mass index, cholesterol, systolic blood pressure and 
glycaemia), develop diabetes, complications of diabetes and related disorders including 
cardiovascular disease and cancer, and eventually die. Lifetime costs and quality-adjusted 
life-years are collected for each patient. The model allows assessment of the wider social 
impact on employment and the equity impact of different interventions. Interventions may 
be population-based, community-based or individually targeted, and administered singly or 
layered together. The model is fully enabled for probabilistic sensitivity analysis (PSA) to 
provide an estimate of decision uncertainty. This discussion paper provides a detailed 
description of the model background, methods and assumptions, together with details of all 
parameters used in the model, their sources and distributions for PSA. 
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2 BACKGROUND 
This project aims to provide a coherent framework for the evaluation of strategies for the prevention 
of type 2 diabetes. Specifically, the focus is to enable the design of preventive strategies that are 
effective and cost-effective in combination, and support decision making around these. This is to 
enable a rational allocation of resources between population/community level interventions, which 
aim to alter the distribution of risk factors for diabetes, and targeted identification/screening 
interventions such as the NHS health checks programme, which aim to identify and provide 
management for individuals at increased risk.   
There are a number of necessary steps involved in translating knowledge from epidemiological 
studies in diabetes into preventive action: Identification of individuals or groups who are at increased 
risk; description of the important risk factors that can be altered; identification of key influences on 
risk factors (e.g. attitudes or environmental aspects); development of interventions to act on risk 
factors (e.g. promoting walking); development of methods to identify people likely to benefit from an 
intervention; evaluation of the success of an intervention and estimation of its potential impact on 
public health.  
Modelling can play a key role in developing our understanding of this complex system. Firstly it can 
estimate the potential impact of different risk identification and management strategies on public 
health outcomes and help in pinpointing the most cost-effective strategies for intervention. 
Furthermore, it can play a key role in facilitating the iterative research cycle by helping us identify 
and analyse key current uncertainties, focus further research and input into the design of the next 
generation of interventions. 
As part of this project we conducted a review of previous decision analytic models used to evaluation 
diabetes prevention interventions (1). This review confirmed that no other diabetes models were 
sufficient to meet the objectives of this project and identified some areas of development from 
previous models to consider in the model design.  
  
3 DEVELOPING THE CONCEPTUAL MODEL 
A conceptual model of the problem and a model-based conceptual model were developed according 
to a new conceptual modelling framework for complex public health models (2). In line with this 
framework the conceptual models were developed in collaboration with a project stakeholder group 
comprising health economists, public health specialists, research collaborators from other SPHR 
groups, diabetologists, local commissioners and lay members. The conceptual model of the problem 
mapped out all relevant factors associated with diabetes based upon iterative literature searches. 
Key initial sources were reports of two existing diabetes prevention models used for National 
Institute for Health and Care Excellence public health guidance (3;4). This conceptual model of the 
problem was presented at a Stakeholder Workshop. Discussion at the workshop led to modifications 
of the model, identifying additional outcomes such as depression and helping to identify a suitable 
conceptual model boundary for the cost-effectiveness model structure. Table 1 describes which 
factors included within the conceptual model of the problem were chosen to be included and 
excluded from the health economic model as agreed by stakeholders following the workshop. This 
final model boundary based upon Table 1 provided the final scope for the simulation model 
developed. A review of previous economic evaluations of diabetes prevention was also instrumental 
in deciding on the final boundary of the economic model (1).  
 
 
Table 1: Diabetes model boundary selection 
Factor Include/Exclude Reason for inclusion/exclusion 
Risk factors Include Key component of causal diagram 
Gestational diabetes/ pregnancy 
complications 
Exclude This is a small subgroup and is not considered to be a focus of this project. 
Osteoarthritis Include Diabetes has been found to be an independent risk factor for osteoarthritis independent of the effect of BMI (5). In addition, the report by Gillett et al. 
suggests that the cost of osteoarthritis is comparable to the cost of diabetes (6). 
Risk factors of next generation Exclude Within the high risk group, only a minority of people will parent a young child due to the age of the people affected, thus there would be limited impact 
upon the next generation. Within the general population, Whitaker et al. suggest that parental obesity more than doubles the risk of adult obesity 
among their children. This could bear substantial future costs and effects; however because these costs and outcomes would occur so far in the future, 
by applying a discount rate to both costs and effects, there would be minimal impact upon the model results. Time would be better spent elsewhere.  
Blood glucose levels/ Non-diabetic 
hyperglycaemia/ Diabetes 
Include Key component of causal diagram. 
Hypoglycaemia & weight gain 
associated with pharmacological 
interventions 
Include (but not as a 
separate factor) 
The quality of life implications of hypoglycaemia and weight gain are likely to be captured within the quality of life of people with diabetes. There are 
likely to be minimal additional costs associated with hypoglycaemia and weight gain above those associated with treating the disease. 
Non-alcoholic fatty liver Include (but not as a 
separate factor) 
This is likely to be included within the costs and quality of life estimates associated with diabetes and obesity. 
Fatigue Include (but not as a 
separate factor) 
The quality of life implications of fatigue are likely to be captured within the quality of life of people with disease. There are likely to be minimal 
additional costs associated with fatigue above those associated with treating disease.  
Neuropathy Include Key outcome associated with diabetes. 
Erectile dysfunction Include (but not as a 
separate factor) 
This is likely to be included within the costs and quality of life impacts of neuropathy. 
Nephropathy Include Key outcome associated with diabetes. 
Retinopathy Include Key outcome associated with diabetes 
Cancers (post-menopausal breast 
cancer, colorectal cancer) 
Include The report by the World Cancer Research Fund (WCRF) Panel on Food, Nutrition, Physical Activity and the Prevention of Cancer suggests that BMI has a 
significant impact upon the incidence and mortality of post-menopausal breast cancer, colorectal cancer, oesophagus cancer, kidney cancer, 
endometrial cancer, gall bladder cancer and pancreatic cancer (7). It also suggests that physical activity is associated with colorectal cancer, 
postmenopausal breast cancer and endometrial cancer.  
CVD including hypertension, 
coronary heart disease (leading to 
heart attacks & angina), congestive 
heart failure, and cerebrovascular 
disease (incl. stroke & dementia) 
Include Has a substantial impact upon both costs and effects. 
Mental illness (incl. dementia) Partially include 
(but not as a 
separate factor for 
all illnesses) 
Depression was included as a separate factor. However, the relationship between mental illness and diabetes is complex and currently not completely 
understood. Part of the relationship is associated with the incidence of cerebrovascular disease and the impact of mental illness will be captured within 
these costs and outcomes. The remaining associations, such as the direct increase in mental illness as a result of being diagnosed and living with 
diabetes, are difficult to untangle and are expected to have a small impact upon the model outcomes relative to other model factors. 
Obstructive sleep apnoea Include (but not as a 
separate factor) 
The relationship between risk factors and CVD is expected to capture those events resulting from obstructive sleep apnoea. The quality of life 
associated with people who are overweight is likely to include poorer quality of life resulting from obstructive sleep apnoea. In the instances where 
sleep apnoea is treated, the cost is minimal. 
Infectious diseases Exclude Relative to other model factors, this is likely to have a smaller impact upon the model outcomes. 
Environmental outcomes 
(congestion, CO2, pollutants)  
Not currently clear This depends upon the choice of interventions within the model (see Section 1). 
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4 MODEL STRUCTURE 
We developed an individual patient simulation that estimates individuals’ health in yearly cycles until 
death. The simulation draws baseline demographic and clinical status for individuals sampled from 
the Health Survey for England (HSE) 2011 (8). The simulation estimates yearly changes in metabolic 
risk factors based upon the individuals’ baseline characteristics. Within each annual cycle the 
individuals may be screened for hypertension, dyslipidaemia or diabetes during a visit to the GP. The 
opportunistic screening is used to determine diabetes diagnosis or the initiation of anti-hypertensive 
treatment or statins. Baseline characteristics and metabolic risk factors determine the individuals’ 
probability of cardiovascular events, diabetes microvascular complications, cancer, osteoarthritis and 
depression. Individuals within the model may die in any cycle as a result of cardiovascular disease, 
cancer or from other causes.  
Figure 1 illustrates the sequence of updating clinical characteristics and clinical events that are 
estimated within a cycle of the model. This sequence is repeated for every annual cycle of the model. 
The first stage of the sequence updates the age of the individual. The second stage estimates how 
many times the individual attends the GP. The third stage estimates the change in BMI of the 
individual from the previous period. In the fourth stage, if the individual has not been diagnosed as 
diabetic (Diabetes_Dx=0) their change in glycaemia is estimated using the Whitehall II model. If they 
are diabetic (Diabetes_Dx=1), it is estimated using the UKPDS model. In stages five and six the 
individual’s blood pressure and cholesterol are updated using the Whitehall II model if the individual 
is not identified as hypertensive or receiving statins. In stage seven, the individual may undergo 
assessment for diabetes, hypertension and dyslipidaemia during a GP consultation. From stage eight 
onwards the individual may experience cardiovascular outcomes, diabetes related complications, 
cancer, osteoarthritis or depression.  If the individual has a history of cardiovascular disease (CVD 
history=1), they follow a different pathway in stage eight to those without a history of cardiovascular 
disease (CVD history=0). Individuals with HbA1c greater than 6.5 are assumed to be at risk of 
diabetes related complications. Individuals who do not have a history of cancer (Cancer history=0) 
are at risk of cancer diagnosis, whereas those with a diagnosis of cancer (Cancer history=1) are at risk 
of mortality due to cancer. Individuals without a history of osteoarthritis or depression may develop 
these conditions in stages 12 and 13. Finally, all individuals are at risk of dying due to causes other 
than cardiovascular or cancer mortality. Death from renal disease is included in the estimate of 
other-cause mortality. 
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Figure 1: Model Schematic 
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5 DATA SELECTION 
Having developed and agreed the model structure and boundary with the stakeholder group the 
project team sought suitable sources of data for the baseline population, GP attendance, metabolic 
risk trajectories, treatment algorithms, and risk models for long term health outcomes, health care 
and health related. Given the complexity of the model it was not possible to use systematic review 
methods to identify all sources of data for these model inputs. As a consequence we used a series of 
methods to identify the most appropriate sources of data within the time constraints of the project.  
Firstly, we discussed data sources with the stakeholder groups and identified key studies in the UK 
that have been used to investigate diabetes and its complications and comorbidities. The stakeholder 
group included experts in the epidemiology of non-communicable disease who provided useful 
insight into the strengths and limitations of prominent cohort studies and trials that have studies the 
risks of long term health outcomes included in the model. The stakeholder group included diabetes 
prevention cost-effectiveness modellers, whose understanding of studies that could be used to 
inform risk parameters, costs and health related quality of life estimates.  Secondly, we used a review 
of economic evaluations of diabetes prevention and weight management cost-effectiveness studies 
to identify sources of data used in similar economic evaluations (1). Thirdly, we conducted targeted 
literature searches where data could not be identified from large scale studies of a UK population, or 
could be arguably described as representative of a UK population through processes described 
above. Justification for data inputs for all model parameters are described below. 
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6 BASELINE POPULATION CHARACTERISTICS 
6.1 CHOICE OF HEALTH SURVEY FOR ENGLAND 2011 DATASET 
The model required demographic, anthropometric and metabolic characteristics that would be 
representative of the UK general population. The Heath Survey for England (HSE) was suggested by 
the stakeholder group because it collects up-to-date cross-sectional data on the characteristics of all 
ages of the English population. It also benefits from being a reasonably good representation of the 
socioeconomic profile of England. A major advantage of this dataset is that includes important 
clinical risk factors such as HbA1c, SBP, and cholesterol. The characteristics of individuals included in 
the cost-effectiveness model were based sampled from the HSE 2011 dataset (8). The HSE 2011 
focused on CVD and associated risk factors. The whole dataset was obtained from the UK Data 
Service. 
6.2 EXCLUSION CRITERIA 
The total sample size of the HSE 2011 was 10,617. Individuals from the HSE dataset who met the 
following criteria were excluded from the sample. The list of exclusion criteria and the number of 
individuals that met these criteria are listed below.  
1. Individuals younger than 16 years (N=2007) 
2. Individuals with a previous diagnosis of diabetes (N=572) 
This left a final sample size of 8038 individuals.  
6.3 DATA EXTRACTION 
Only a subset of variables reported in the HSE 2011 cohort was needed to inform the baseline 
characteristics in the economic model. A list of model baseline characteristics and the corresponding 
variable name and description from the HSE 2011 are listed below in Table 2. Two questions for 
smoking were combined to describe smoking status according to the QRISK2 algorithm in which 
former smokers and the intensity of smoking are recorded within one measure. The number of 
missing data for each observation in the HSE data is detailed in Table 2 and summary statistics for the 
data extracted from the HSE2011 dataset are reported in Table 3. 
Table 2: HSE variable names and missing data summary 
Model requirements HSE 2011 HSE 2011 variable description No. Missing 
18 
 
variable name data entries 
(N=8038) 
Age Age Age last birthday 0 
Sex Sex Sex 0 
Ethnicity Origin Ethnic origin of individual 36 
Deprivation (Townsend) qimd Quintile of IMD SCORE 0 
Weight wtval Valid weight (Kg) inc. estimated>130kg 1284 
Height htval  Valid height (cm) 1207 
BMI bmival Valid BMI 1431 
Waist circumference wstval Valid Mean Waist (cm) 2871 
Waist-Hip ratio whval Valid Mean Waist/Hip ratio 2882 
Total Cholesterol cholval Valid Total Cholesterol Result 4760 
HDL cholesterol hdlval Valid HDL Cholesterol Result 4760 
HbA1c glyhbval Valid Glycated HB Result 4360 
FPG   N/A 
2-hr glucose   N/A 
Systolic Blood pressure omsysval Omron Valid Mean Systolic BP 3593 
Hypertension treatment medcinbp Currently taking any medicines, tablets or pills for 
high BP 
6050 
Gestational diabetes pregdi Whether pregnant when told had diabetes 8008 
Anxiety/depression Anxiety Anxiety/Depression 930 
Smoking cigsta3 Cigarette Smoking Status: Current/Ex-Reg/Never-
Reg 
75 
cigst2 Cigarette Smoking Status - Banded current smokers 74 
Statins lipid Lipid lowering (Cholesterol/Fibrinogen) - 
prescribed 
5804 
Rheumatoid Arthritis compm12 XIII Musculoskeletal system 5 
Atrial Fibrillation murmur1 Doctor diagnosed heart murmur (excluding 
pregnant) 
2008 
Family history diabetes   N/A 
History of 
Cardiovascular disease 
cvdis2 Had CVD (Angina, Heart Attack or Stroke) 3 
Economic Activity econact Economic status 37 
 
Table 3: Characteristics of final sample from HSE 2011 (N=8038) 
 Number  Percentage  
Male 3506 43.6  
White 7212 89.7  
IMD 1 (least deprived) 1700 21.1  
IMD 2  1699 21.1  
IMD 3 1696 21.1  
IMD 4 1479 18.4  
IMD 5 (most deprived) 1464 18.2  
Non-smoker 6415 79.8  
Anti-hypertensive treatment 2092 26.0  
Statins 665 8.3  
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Employed 4525 56.3  
Unemployed 385 4.8  
Retired 1945 24.2  
Economically Inactive 1183 14.7  
 Mean Standard deviation Median  
Age 48.59 18.49 47.00 
BMI 27.13 5.18 26.40 
Total Cholesterol 5.42 1.07 5.40 
HDL Cholesterol 1.53 0.44 1.50 
HbA1c 5.61 0.47 5.60 
Systolic Blood Pressure 125.90 16.92 123.50 
EQ-5D (TTO) 0.836 0.232 0.883 
BMI Body Mass Index; IMD  Index of Multiple Deprivation; EQ-5D 5 dimensions Euroqol (health related quality of life index) 
 
A complete dataset was required for all individuals at baseline. However, no measurements for 
Fasting Plasma Glucose (FPG) or 2 hour glucose were obtained for the HSE 2011 cohort. In addition, 
the questionnaire did not collect information about individual family history of diabetes or family 
history of Cardiovascular Disease (CVD). These variables were imputed from other datasets. 
Many individuals were lacking responses to some questions but had data for others. One way of 
dealing with this is to exclude all individuals with incomplete data from the sample. However, this 
would have reduced the sample size dramatically, which would have been detrimental to the 
analysis. It was decided that it would be better to make use of all the data available to represent a 
broad range of individuals within the UK population. With this in mind, we decided to use 
assumptions and imputation models to estimate missing data. 
6.4 MISSING DATA IMPUTATION 
 Ethnicity 6.4.1
Only a small number of individuals had missing data for ethnicity. In the QRISK2 algorithm the 
indicator for white includes individuals for whom ethnicity is not recorded. In order to be consistent 
with the QRISK2 algorithm we assumed that individuals with missing ethnicity data were white. 
 Anthropometric data 6.4.2
A large proportion of anthropometric data was missing in the cohort. Table 4 reports the number of 
individuals with two or more anthropometric records missing. This illustrates that only 758 
individuals had no anthropometric data at all. Imputation models for anthropometric data were 
developed utilising observations from other measures to help improve their accuracy.  
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Table 4: Multi-way assessment of missing data 
Conditions Number of individuals 
No weight and no height 1060 
No weight and no waist circumference 907 
No weight and no hip circumference  906 
No height and no waist circumference 818 
No height and no hip circumference  817 
No hip and no waist 2865 
No anthropometric data 758 
 
Two imputation models were generated for each of the following anthropometric measures: weight, 
height, waist circumference and hip circumference. The first imputation method included an 
alternative anthropometric measure to improve precision. The second included only age and/or sex, 
to be used if the alternative measure was also missing. Simple ordinary least squares (OLS) regression 
models were used to predict missing data. Summary data for each measure confirmed that the data 
were approximately normally distributed. Covariate selection was made by selecting the 
anthropometric measure that maximised the Adjusted R-squared statistic, and age and sex were 
included if the coefficients were statistically significant (P<0.1). 
The imputation models for weight are reported in Table 5. Individuals’ sex and age were included in 
both models. A quadratic relationship between age and weight was identified. Waist circumference 
had a positive and significant relationship with weight. The R2 for model 1 suggested that 80% of the 
variation in weight is described by the model. The R2 for model 2 was much lower as only 18% of the 
variation in weight was described by age and sex. The residual standard error is reported for both 
models.  
Table 5: Imputation model for weight 
Coefficient Model 1  Model 2 
Intercept -17.76 50.249 
Sex 2.614 13.036 
Age 0.064 0.903 
Age*Age -0.0027 -0.0086 
Waist circumference 1.060  
R-squared 0.7981 0.1831 
Residual standard error 7.483 15.31 
 
The imputation models for height are reported in Table 6. Individuals’ sex and age were included in 
both models. A quadratic relationship between age and height was identified. Waist circumference 
had a positive and significant relationship with height. The R2 for model 1 suggested that 53% of the 
variation in height is described by the model suggesting a fairly good fit. The R2 for model 2 was 
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slightly lower in which 52% of the variation in height was described by age and sex. The residual 
standard error is reported for both models.  
Table 6: Imputation model for height 
Coefficient Model 1  Model 2 
Intercept 157.4 162.1 
Sex 12.82 13.43 
Age 0.081 0.1291 
Age*Age -0.0021 -0.0025 
Waist circumference 0.071  
R-squared 0.532 0.5244 
Residual standard error 6.617 6.682 
 
The imputation models for waist circumference are reported in Table 7. Individuals’ sex and age were 
included in both models. A quadratic relationship between age and waist circumference fit to the 
data better than a linear relationship. Weight had a positive and significant relationship with waist 
circumference. The R2 for model 1 suggested that 81% of the variation in waist circumference is 
described by the model suggesting a very good fit. The R2 for model 2 was much lower in which only 
22% of the variation in waist circumference was described by age and sex which is a moderately poor 
fit. The residual standard error is reported for both models.  
Table 7: Imputation model for waist 
Coefficient Model 1  Model 2 
Intercept 28.73 65.327 
Sex 0.5754 9.569 
Age 0.1404 0.7617 
Age*Age 0.0007 -0.0053 
Weight 0.7098  
R-squared 0.8096 0.2196 
Residual standard error 6.122 12.44 
 
The imputation models for hip circumference are reported in Table 8. Individuals’ sex and age were 
included in both models. A quadratic relationship between age and hip circumference fit to the data 
better than a linear relationship. Weight had a positive and significant relationship with hip 
circumference. The R2 for model 1 suggested that 80% of the variation in hip circumference is 
described by the model suggesting a very good fit. The R2 for model 2 was much lower in which only 
2% of the variation in hip circumference was described by age and sex which is a very poor fit. The 
residual standard error is reported for both models.  
22 
 
Table 8: Imputation model for hip 
Coefficient Model 1  Model 2 
Intercept 66.9145 96.891 
Sex -8.3709 -0.9783 
Age -0.1714 0.3528 
Age*Age 0.0021 -0.0029 
Weight 0.5866  
R-squared 0.7949 0.023 
Residual standard error 4.539 10.1 
 
 Metabolic data 6.4.3
A large proportion of metabolic data was missing in the cohort, ranging from 2997-4309 observations 
for each metabolic measurement. Table 9 reports the number of individuals with two or more 
metabolic records missing. This illustrates that 2987 individuals have no metabolic data. Imputation 
models for metabolic data were developed utilising observations from other measures to help 
improve their accuracy.   
Table 9: Multi-way assessment of missing data 
Conditions Number of individuals 
No HbA1c and no cholesterol 4309 
No HbA1c and no blood pressure 2997 
No cholesterol and no blood pressure  3050 
No metabolic data 2987 
 
Two imputation models were generated for each of the following metabolic measures: total 
cholesterol, high density lipoprotein (HDL) cholesterol, HbA1c and systolic blood pressure (SBP) and. 
The first imputation method included an alternative metabolic measure to improve precision. The 
second included only age and/or sex, to be used if the alternative measure was also missing. Simple 
ordinary least squares (OLS) regression models were used to predict missing data. Summary data for 
each measure confirmed that the data were approximately normally distributed. Covariate selection 
was made by selecting the metabolic measure that maximised the adjusted R-squared statistic, and 
age and sex were included if the coefficients were statistically significant (P<0.1). 
These imputation models were developed to estimate metabolic data from information collected in 
the HSE. An alternative approach would have been to use estimates of these measures from the 
natural history statistical models. At the time of the analysis it was uncertain what form and design 
the natural history models would take, therefore the HSE imputation models were developed for use 
until a better alternative was found.  
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The imputation models for total cholesterol are reported in Table 10. Individuals’ age was included in 
both models. A quadratic relationship between age and weight was identified. Diastolic blood 
pressure had a positive and significant relationship with total cholesterol. The R2 for model 1 
suggested that 20% of the variation in total cholesterol is described by the model. The R2 for model 2 
was lower in which only 18% of the variation in total cholesterol was described by age. The residual 
standard error is reported for both models. 
Table 10: Imputation model for total cholesterol 
Coefficient Model 1  Model 2 
Intercept 1.973 2.821 
Age 0.0774 0.0904 
Age*Age -0.0006 -0.0007 
Diastolic blood pressure 0.0159  
R-squared 0.2035 0.1792 
Residual standard error 0.9526 0.9741 
 
The imputation models for HDL cholesterol are reported in Table 11. Individuals’ sex and age were 
included in both models. A quadratic relationship between age and height was identified. Diastolic 
blood pressure had a negative and significant relationship with HDL cholesterol. The R2 for model 1 
suggested that only 13% of the variation in HDL cholesterol is described by the model suggesting a 
relatively poor fit. The R2 for model 2 suggested that 12% of the variation in HDL cholesterol was 
described by age and sex. The residual standard error is reported for both models. 
Table 11: Imputation model for HDL Cholesterol  
Coefficient Model 1  Model 2 
Intercept 1.501 1.383 
Sex -0.279 -0.274 
Age 0.0086 0.0075 
Age*Age -0.0001 -0.00004 
Diastolic blood pressure -0.0018  
R-squared 0.1198 0.1157 
Residual standard error 0.4122 0.417 
 
The imputation models for HbA1c are reported in Table 12. Individuals’ age was included in both 
models. A quadratic relationship between age and HbA1c fit to the data better than a linear 
relationship. SBP had a positive and significant relationship with HbA1c. The R2 for model 1 suggested 
that only 19% of the variation in HbA1c is described by the model, suggesting a modest fit. The R2 for 
model 2 described 18% of the variation in HbA1c by age alone. The residual standard error is 
reported for both models.  
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Table 12: Imputation model for HbA1c  
Coefficient Model 1  Model 2 
Intercept 4.732 4.962 
Age 0.0141 1.422 
Age*Age -0.00003 -0.00003 
Systolic blood pressure 0.002  
R-squared 0.1941 0.1835 
Residual standard error 0.4243 0.4228 
 
The imputation models for SBP are reported in Table 13. Individuals’ sex and age were included in 
both models. A linear relationship between age and SBP fit to the data better than a quadratic 
relationship. Total cholesterol and HbA1c had a positive and significant relationship with SBP, 
whereas HDL cholesterol had a negative significant relationship with SBP. The R2 for model 1 
suggested that 22% of the variation in SBP is described by the model suggesting a modest fit. The R2 
for model 2 was similar in which only 20% of the variation in SBP was described by age and sex. The 
residual standard error is reported for both models.  
Table 13: Imputation model for Systolic Blood Pressure  
Coefficient Model 1  Model 2 
Intercept 84.983 104.132 
Sex 6.982 6.396 
Age 0.330 0.380 
Total cholesterol 2.093  
HDL cholesterol -0.746  
HbA1c 1.986  
R-squared 0.2235 0.2047 
Residual standard error 14.59 15.1 
 
 Treatment for Hypertension and Statins  6.4.4
A large proportion of individuals had missing data for questions relating to whether they received 
treatment for hypertension or high cholesterol. The majority of non-responses to these questions 
were coded to suggest that the question was not applicable to the individual. As a consequence it 
was assumed that individuals with missing treatment data were not taking these medications. 
 Gestational Diabetes  6.4.5
Only 30 respondents without current diabetes reported that they had been diagnosed with diabetes 
during a pregnancy in the past. Most individuals had missing data for this question due to it not being 
applicable. The missing data was assumed to indicate that individuals had not had gestational 
diabetes.  
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 Anxiety/Depression 6.4.6
Most individuals who had missing data for anxiety and depression did so because the question was 
not applicable. A small sample N=69 refused to answer the question. We assumed that individuals 
with missing data for anxiety and depression did not have severe anxiety/depression. 
 Smoking 6.4.7
Individuals with missing data for smoking status were assumed to be non-smokers, without a history 
of smoking.  
 Rheumatoid Arthritis and Atrial Fibrillation  6.4.8
A very small sample of individuals had missing data for musculoskeletal illness (N=5) and atrial 
fibrillation (N=1). These individuals were assumed to not suffer from these illnesses.  
 Family history of diabetes 6.4.9
No questions in the HSE referred to the individual having a family history of diabetes, so this data had 
to be imputed. It was important that data was correlated with other risk factors for diabetes, such as 
HbA1c and ethnicity. We analysed a cross-section of the Whitehall II dataset to generate a logistic 
regression to describe the probability that an individual has a history of diabetes conditional on their 
HbA1c and ethnic origin. The model is described in Table 14. 
Table 14: Imputation model for history of diabetes 
 Coefficient 
Intercept -3.29077 (0.4430) 
HbA1c 0.28960 (0.0840) 
HDL Cholesterol 0.81940 (0.13878) 
 
 Economic Activity 6.4.10
Individuals without information about their employment status were assumed to be retired if aged 
65 or over and in employment if under 65. 
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7 GP ATTENDANCE IN THE GENERAL POPULATION 
GP visit frequency was simulated in the dataset for two reasons; firstly, to estimate the healthcare 
utilisation for the general population without diabetes and cardiovascular disease and secondly, to 
predict the likelihood that individuals participate in opportunistic screening for diabetes and vascular 
risks. Analysis of wave 1 of the Yorkshire Health Study (Table 15: Model 1) investigated whether 
disease comorbidity, BMI, IMD deprivation score, ethnicity and EQ-5D contributed to the rate of GP 
attendance. The analysis used a negative binomial regression model to estimate self-reported rate of 
GP attendance per 3 months. The results show that non-white individuals and those from poorer 
backgrounds visit the GP more frequently.  This suggested that GP attendance would be a poor proxy 
for uptake of screening and prevention services, which are known to be lower in deprived groups. It 
is possible that higher GP attendance in deprived and ethnic groups reflect poorer health amongst 
these communities. Model 2 was used in the final model to describe GP attendance conditional on 
age, sex, BMI, ethnicity, and health outcomes. We did not relate GP attendance to IMD, because we 
did not have accurate IMD data in the HSE 2011, and EQ-5D was removed to avoid double counting 
with disease outcomes.  The estimated number of GP visits was multiplied by 4 to reflect the annual 
number of visits per year. 
Table 15: GP attendance reported in the Yorkshire Health Study (N= 18,437) 
 Model 1 Model 2 
 Mean Standard error Mean Standard error 
Age 0.0057 0.0005 0.0076 0.0005 
Male  -0.1502 0.0155 -0.1495 0.0159 
BMI 0.0020 0.0015 0.0110 0.0015 
IMD score 2010 0.0043 0.0005   
Ethnicity (Non-white) 0.1814 0.0370 0.2620 0.0375 
Heart Disease 0.1588 0.0281 0.2533 0.0289 
Depression 0.2390 0.0240 0.6127 0.0224 
Osteoarthritis 0.0313 0.0240 0.2641 0.0238 
Diabetes 0.2023 0.0270 0.2702 0.0278 
Stroke 0.0069 0.0460 0.1659 0.0474 
Cancer 0.1908 0.0400 0.2672 0.0414 
Intercept 0.6275 0.0590 -0.5014 0.0468 
Alpha 0.3328 0.0097 0.3423 0.0108 
 
The coefficients of the Negative Binomial model described in Table 15, were used to estimate the 
first parameter of the Negative Binomial distribution 𝜇𝑖.  
 𝜇𝑖 = exp (𝑥𝑖𝛽)  
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The dispersion parameter of the Negative Binomial distribution 𝑣𝑖 was sampled from a gamma 
distribution with mean 1 and variance 𝛼 based on estimates reported in. The dose was estimated 
from the Poisson function.  
 
𝑝(𝑌 = 𝑦|𝑦 > 0, 𝑥) =
(𝑣𝑖𝜇𝑖)
𝑦𝑒−(𝑣𝑖𝜇𝑖)
𝑦!
 
 
 
In the probabilistic sensitivity analysis the parameters of the Yorkshire Health Study negative 
binomial model are sampled from a multivariate normal distribution, using the mean estimates 
described in Table 15 and covariance matrix in Table 16. 
Table 16: Variance-covariance matrix for GP attendance regression 
 Age Male  BMI 
Ethnicity 
(Non-
white) 
Heart 
Disease 
Depressi
on 
Osteoarth
ritis Diabetes Stroke Cancer Intercept Alpha 
Age 
0.0000            
Male  
0.0000 0.0003                       
BMI 
0.0000 0.0000 0.0000                      
Ethnicity 
(Non-white) 
0.0000 0.0000 0.0000 0.0014                     
Heart Disease 
0.0000 0.0000 0.0000 0.0000 0.0008                    
Depression 
0.0000 0.0000 0.0000 0.0000 0.0000 0.0005                   
Osteoarthritis 
0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0006                  
Diabetes 
0.0000 0.0000 0.0000 0.0000 -0.0001 0.0000 0.0000 0.0008                 
Stroke 
0.0000 0.0000 0.0000 0.0000 -0.0002 -0.0001 0.0000 -0.0001 0.0022                
Cancer 
0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 -0.0001 0.0017               
Intercept 
0.0000 0.0000 -0.0001 -0.0002 0.0002 0.0000 0.0002 0.0003 0.0000 0.0001 0.0022              
Alpha 
0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0010 
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8 LONGITUDINAL TRAJECTORIES OF METABOLIC RISK FACTORS 
A search of epidemiology studies of metabolic risk factor trajectories identified a number of studies 
estimating changes in HbA1c, SBP, total cholesterol, and HDL cholesterol over time from longitudinal 
studies. However, no analysis had looked at the correlations and associations between these risk 
factors. Including the correlation between risk factor trajectories was would affect the long term risk 
profile for cardiovascular disease and other complications, therefore a statistical analysis of the 
Whitehall II cohort study (9) was developed to describe correlated longitudinal changes in metabolic 
risk factors. The analysis was developed in collaboration with epidemiologists at University College 
London, and in consultation with the stakeholder group.  
8.1 WHITEHALL II DATA ANALYSIS 
Changes in BMI, latent blood glucose, total cholesterol, HDL cholesterol and systolic blood pressure 
were estimated from statistical analysis of the Whitehall II cohort. The growth factors for all 5 risk 
factors were estimated using parallel latent growth modelling. This enabled the growth factors for 
BMI to be implemented as covariates for the growth processes of glycaemia, systolic blood pressure, 
and total cholesterol 1. The structural assumptions of the analysis are described in more detail below.  
In the Whitehall II data analysis we assume that individuals have an underlying level of glycaemia, 
which cannot be observed but can be measured by HbA1c, fasting plasma glucose (FPG) and 2-hour 
glucose. We describe this underlying propensity for diabetes as latent glycaemia. The statistical 
model estimated the unobservable latent glycaemia and from this identified associations with test 
results for HbA1c, FPG, and 2-hour glucose. The longitudinal changes in BMI, glycaemia, systolic 
blood pressure, total and HDL cholesterol could then be estimated through statistical analysis.  
These growth factors are conditional on several individual characteristics including age, sex, 
ethnicity, smoking, family history of CVD, and family history of type 2 diabetes. Deprivation was 
excluded from the final analysis because it was not associated with the growth models, and it 
estimated counter-intuitive coefficients. Last known employment grade was considered to be an 
alternative specification of socioeconomic status. However, this was excluded from the final analysis 
because it was not a statistically significant predictor of glycaemia. We related the effect of changes 
in BMI to changes in glycaemia, systolic blood pressure and total cholesterol. Unobservable 
                                                          
1 The model did not converge when BMI slope was included as a predictor for HDL growth. 
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heterogeneity between individual growth factors not explained by patient characteristics was 
incorporated into the growth models as random error terms. Correlation between the random error 
terms for glycaemia, total cholesterol, HDL cholesterol and systolic blood pressure was estimated 
from the Whitehall II cohort. This means that in the simulation, an individual with a higher growth 
rate for glycaemia is more likely to have a higher growth rate of total cholesterol and systolic blood 
pressure.  
An advantage of our parallel growth analysis is that we were able to estimate the effect of growth in 
BMI on the other metabolic risk factors. We were also able to estimate correlation between changes 
in glycaemia, systolic blood pressure, total cholesterol and HDL cholesterol. As a consequence, the 
growth factor random error terms were not assumed to be independent and were sampled from a 
multivariate normal distribution 𝝊~𝑁(0, 𝛺). Estimates for the covariance matrix are derived from 
the covariance estimates reported in the statistical analysis. 
The baseline observations for BMI, HbA1c, systolic blood pressure, cholesterol and HDL cholesterol 
were extracted from the Health Survey for England 2011 in order to simulate a representative 
sample. The predicted intercept for these metabolic risk factors was estimated using the Whitehall II 
analysis to give population estimates of the individuals’ starting values, conditional on their 
characteristics. The difference between the simulated and observed baseline risk factors was taken 
to estimate the individuals’ random deviation from the population expectation. The individual 
random error in the slope trajectory was sampled from a conditional multivariate normal distribution 
to allow correlation between the intercept and slope random errors.  
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Figure 2: Path analysis of final statistical analysis of the Whitehall II cohort 
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8.2 BMI TRAJECTORY 
The Whitehall II analysis estimates longitudinal trajectories for BMI. The path diagram for BMI is 
illustrated in Figure 3. 
Figure 3: The path diagram for BMI growth 
 
We simulated annual changes in BMI for all individuals within the simulation. At baseline, BMI 
estimates from the HSE determine an individual’s BMI. BMI at any time period in the model is 
estimated using the following quadratic equation. 
𝐵𝑀𝐼𝑡 = 𝛽10 + 𝛽11𝑡 + 𝛽12𝑡
2 + 𝜀1 
𝛽10 = 𝛼10 + 𝜸𝟏𝟎𝑿 + 𝜐10 
𝛽11 = 𝛼11 + 𝜸𝟏𝟏𝑿 + 𝜐11 
𝛽12 = 𝛼12 + 𝜸𝟏𝟐𝑿 
The intercept of the BMI calculation is described by 𝛽10, the linear slope 𝛽11 , quadratic term 𝛽12 and 
a measurement error term 𝜀1. The intercept 𝛽10 is conditional on the population mean intercept 𝛼10, 
coefficients, 𝜸𝟏𝟎 for patient characteristics 𝑿, and an individual level random error term 𝜐10. Annual 
change in BMI is determined by 𝛽11 and 𝛽12, which are also conditional on population intercepts and 
covariate adjustments. The linear slope includes an individual patient random error term 𝜐11, 
whereas the quadratic slope term does not contain an error term. The conceptual model for BMI 
assumes that age at baseline, sex and family history of cardiovascular disease predict the intercept, 
BMI 1
BMI 
intercept
BMI Slope
BMI 2 BMI 3 BMI 4
SEXSEX
AGE 1 AGE 1
FXCDFXCD
32 
 
slope and quadratic term in the BMI model. Figure 4 illustrates simulated changes in BMI over time 
for a man and women aged 50 at baseline. 
Figure 4: Simulated data using the Whitehall II Statistical analysis to illustrate BMI over time 
 
The growth factors are estimated in the model to be conditional on baseline BMI, age at baseline, 
sex, Townsend deprivation index, family history of cardiovascular disease and an error parameter to 
reflect unobservable variability in growth trajectories between individuals. This allows us to relate 
the rate of BMI growth to individual characteristics. For example, in our statistical analysis we found 
that the rate of BMI growth was lower in men and older adults.  
8.3 GLYCAEMIC TRAJECTORY IN NON-DIABETICS/UNDIAGNOSED DIABETES 
We simulated annual changes in HbA1c, FPG, and 2-hr glucose within the simulation. We 
conceptualised a latent glycaemic variable to describe an individual’s underlying level of hyper-
glycaemia. Latent glycaemia can be tested using 2-hr glucose, FPG or HbA1c tests, but each test is an 
imperfect measure of the individual’s true glycaemic status. The path diagram to describe changes in 
glycaemia, 2-hr glucose, FPG and HbA1c from the Whitehall II cohort is illustrated in Figure 5.  
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Figure 5: The path diagram for glycaemic growth 
 
We assume that changes in latent glycaemia have a quadratic relationship with time. Latent 
glycaemia (glyc) at any time period in the model is estimated using the following quadratic equation. 
𝑔𝑙𝑦𝑐𝑡 = 𝛽20 + 𝛽21𝑡 + 𝛽22𝑡
2 + 𝜀2 
𝛽20 = 𝛼20 + 𝜸𝟐𝟎𝑿 + 𝜏20𝛽10 + 𝜐20 
𝛽21 = 𝛼21 + 𝜸𝟐𝟏𝑿 + 𝜏21𝛽10 + 𝜏22𝛽11 + 𝜐21 
𝛽22 = 𝛼22 + 𝜸𝟐𝟐𝑿 + 𝜐22 
The intercept of the latent glycaemia is described by 𝛽20, the linear slope 𝛽21 , quadratic term 𝛽22 
and a measurement error term 𝜀2. The intercept 𝛽20 is conditional on the population mean intercept 
𝛼20, coefficients 𝜸𝟐𝟎 for patient characteristics 𝑿, the growth intercept for BMI 𝛽10, and an individual 
level random error term 𝜐20. Annual change in latent glycaemia is determined by 𝛽21 and 𝛽22, which 
are also conditional on population intercepts, covariate adjustments and individual level random 
error terms. The growth factors 𝛽20 and 𝛽21 are also conditional on the growth factors for BMI. 
The glycaemic test results (FPG, 2-hr glucose, HbA1c) were assumed to be conditional on latent 
glycaemia, glyc. The model estimates test results for each period of observation (t=1,2,3,4…t). The 
factor glycaemia is measured by three non-overlapping observations of 2-hr glucose, FPG and HbA1c. 
The scale of the factor is fixed by setting one factor loading (2-hr glucose) to 1.  
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[
𝐹𝑃𝐺𝑡
2𝐻𝑅𝑡
𝐴1𝐶𝑡
] = [
𝜇0
𝜇1
𝜇2
] + [
𝜃01
𝜃11
𝜃21
] [𝑔𝑙𝑦𝑐𝑡] + [
𝜃02
𝜃12
𝜃22
] [𝐴𝐺𝐸𝑡] + [
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𝜃23
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𝜃24
] [𝐸𝑇𝐻𝑁] + [
𝜃05
𝜃15
𝜃25
] [𝐹𝑋𝑇2] + [
𝜀20
𝜀21
𝜀22
] 
We assumed that the models to predict blood glucose were constant with time. The parameters that 
determine an individual’s latent glycaemic growth trajectory are a function of sex, ethnicity, age at 
baseline, non-white ethnicity, smoking and family history of type 2 diabetes. Furthermore, the 
statistical analysis found that an increase in BMI will accelerate the rate of growth in latent 
glycaemia. The effect of BMI on simulated HbA1c for an example individual is illustrated in Figure 6. 
The trajectory for an individual with increasing BMI (0.21kg/m2 per year) is steeper than that with 
zero change in BMI. 
Figure 6: Simulated data using the Whitehall II Statistical analysis to illustrate the effect of BMI on HbA1c trajectories 
  
At baseline, HbA1c estimates from the HSE determine HbA1c in year 1. We used this measure of 
HbA1c to estimate corresponding FPG and 2-hr glucose test results. We chose to simulate all three 
tests to allow comparisons of screening methods within the model. We have designed the model so 
that the three tests are correlated, but imperfectly so. This means that it is possible that an individual 
will be classified as diabetic using an HbA1c test, but would be below the threshold for diabetes using 
the FPG test.  
8.4 HBA1C TRAJECTORY IN TYPE 2 DIAGNOSED DIABETICS 
Following a diagnosis of diabetes in the simulation all individuals experience an initial fall in HbA1c 
due to changes in diet and lifestyle as observed in the UKPDS trial (10). We have estimated the 
expected change in HbA1c conditional on HbA1c at diagnosis by fitting a simple linear regression to 
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three aggregate outcomes reported in the study. These showed that the change in HbA1c increases 
for higher HbA1c scores at diagnosis. The regression parameters to estimate change in HbA1c are 
reported in Table 17. 
Table 17: Estimated change in HbA1c following diabetes diagnosis 
 Mean Standard error 
Change in HbA1c Intercept -2.9465 0.0444513 
HbA1c at baseline 0.5184 0.4521958 
 
After this initial reduction in HbA1c the longitudinal trajectory of HbA1c is estimated using the UKPDS 
outcomes model (11) rather than the Whitehall II statistical analysis. The UKPDs dataset is made up 
of a newly diagnosed diabetic population. As part of the UKPDS Outcomes model, longitudinal trial 
data were analysed using a random effects model (Appendix B), which means that unobservable 
differences between individuals are accounted for in the analysis. The coefficients of the model are 
reported in Table 18. 
Table 18: Coefficient estimates for HbA1c estimated from UKPDS data 
 Mean Coefficient Coefficient standard error 
Intercept -0.024 0.017 
Log transformation of year since diagnosis 0.144 0.009 
Binary variable for year after diagnosis -0.333 0.05 
HbA1c score in last period 0.759 0.004 
HbA1c score at diagnosis 0.085 0.004 
 
The model can be used to predict HbA1c over time from the point of diagnosis.  The model suggests 
that HbA1c increases with time. A graph illustrating change in HbA1c over time from two different 
HbA1c levels at diagnosis is illustrated in Figure 7. 
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Figure 7: Trajectory of HbA1c estimated from UKPDS longitudinal model 
 
It was important to maintain heterogeneity in the individual glycaemic trajectories before and after 
diagnosis. Therefore, the random error terms used to determine individual trajectories in glycaemia 
before diagnosis were used to induce random noise in the trajectory after diagnosis. We sampled the 
expected random error term for each individual after diagnosis conditional on pre-diagnosis slope, 
assuming a 0.8 correlation between these values. 
8.5 TOTAL CHOLESTEROL AND HDL CHOLESTEROL TRAJECTORIES IN INDIVIDUALS NOT 
RECEIVING STATINS 
In the simulation, individuals had annual changes in total and HDL cholesterol according to the 
estimates from the statistical analysis of the Whitehall II cohort. The path diagram for total and HDL 
cholesterol is illustrated in Figure 8. 
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Figure 8: The path diagram for total and HDL cholesterol growth 
 
Total cholesterol (TC) at any time period in the model is estimated using the following linear 
equation. 
𝑇𝐶𝑡 = 𝛽40 + 𝛽41𝑡 + 𝜀4 
𝛽40 = 𝛼40 + 𝜸𝟒𝟎𝑿 + 𝜏40𝛽10 + 𝜐40 
𝛽41 = 𝛼41 + 𝜸𝟒𝟏𝑿 + 𝜏41𝛽10 + 𝜏41𝛽11 + 𝜐41 
The intercept of the systolic blood pressure growth model is described by 𝛽40, the linear slope 𝛽41  
and a measurement error term 𝜀4. The intercept 𝛽40 is conditional on the population mean intercept 
𝛼40, coefficients 𝜸𝟒𝟎 for patient characteristics 𝑿, a factor 𝜏40, describing the association with the 
growth intercept for BMI 𝛽10, and an individual level random error term 𝜐40. Annual change in TC is 
determined by 𝛽41, which is also conditional on population intercepts, covariate adjustments and an 
individual level random error term. Growth in total cholesterol is conditional on baseline BMI and the 
growth rate of BMI. 
HDL cholesterol (HDL) at any time period in the model is estimated using the following linear 
equation. 
𝐻𝐷𝐿𝑡 = 𝛽50 + 𝛽51𝑡 + 𝜀5 
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𝛽50 = 𝛼50 + 𝜸𝟓𝟎𝑿 + 𝜏51𝛽10 + 𝜐50 
𝛽51 = 𝛼51 + 𝜸𝟓𝟏𝑿 + 𝜏51𝛽10 + 𝜐51 
The intercept of the systolic blood pressure growth model is described by 𝛽50, the linear slope 𝛽51  
and a measurement error term 𝜀5. The intercept 𝛽50 is conditional on the population mean intercept 
𝛼50, coefficients 𝜸𝟓𝟎 for patient characteristics 𝑿, a factor 𝜏50, describing the association with the 
growth intercept for BMI 𝛽10, and an individual level random error term 𝜐50. Annual change in HDL 
cholesterol is determined by 𝛽51, which is also conditional on population intercepts, covariate 
adjustments and an individual level random error term.  Growth in HDL is conditional on baseline 
BMI only. 
At baseline, an individual’s total and HDL cholesterol is determined from the HSE 2011 data. The 
slope of total and HDL cholesterol are assumed to be linear with time. These growth factors are 
estimated in the model to be conditional on cholesterol at baseline, age at baseline, sex, and an error 
parameter to reflect unobservable variability in growth trajectories between individuals. As with 
latent glycaemia, changes in total cholesterol are also influenced by the trajectory of BMI. Figure 9 
illustrates the trajectories for total and HDL cholesterol according to changes in BMI. We did not 
identify if changes in BMI impact upon changes in HDL cholesterol. 
Figure 9: Simulated data using the Whitehall II Statistical analysis to illustrate the effect of BMI on cholesterol 
 
0
1
2
3
4
5
6
7
0 2 4 6 8 10 12 14 16
C
h
o
le
st
e
ro
l m
m
o
l/
L
Years
Simulated Change in Cholesterol 
Cholesterol Stable
BMI
Cholesterol
Increasing BMI
HDL Stable BMI
HDL increasing BMI
39 
 
8.6 TOTAL CHOLESTEROL AND HDL CHOLESTEROL TRAJECTORIES IN INDIVIDUALS 
RECEIVING STATINS 
During the simulation process, individuals are prescribed statins to reduce their risk of cardiovascular 
disease. It is assumed within the model that the statins are effective in reducing an individual’s total 
cholesterol, and an average effect is applied to all patients receiving statins. A recent HTA reviewed 
the literature on the effectiveness and cost-effectiveness of statins in individuals with acute coronary 
syndrome (12). This report estimated the change in LDL cholesterol for four statin treatments and 
doses compared with placebo from a Bayesian meta-analysis. The analysis estimated a reduction in 
LDL cholesterol of -1.45 for simvastatin. This estimate was used to describe the effect of statins in 
reducing total cholesterol. It was assumed that the effect was instantaneous upon receiving statins 
and maintained as long as the individual receives statins. It was also assumed that individuals 
receiving statins no longer experienced annual changes in cholesterol. HDL cholesterol was assumed 
constant over time if patients receive statins. 
Non-adherence to statin treatment is a common problem. Two recent HTAs reviewed the literature 
on continuation and compliance with statin treatment. They both concluded that there was a lack of 
adequate reporting, but that the proportion of patients fully compliant with treatment appears to 
decrease with time, particularly in the first 12 months after initiating treatment, and can fall below 
60% after five years (12;13). Although a certain amount of non-compliance is included within trial 
data, clinical trials are not considered to be representative of continuation and compliance in general 
practice. A yearly reduction in statin compliance used in the HTA analysis is reported in Table 19. It is 
based on the published estimate of compliance for the first five years of statin treatment for primary 
prevention in general clinical practice (13). Compliance declines to a minimum of 65% after five years 
of treatment. It is assumed that there is no further drop after five years.  
Table 19: Proportion of patients assumed to be compliant with statin treatment, derived from Table 62 in (12) 
Year after statin initiation  1 2 3 4 5 
Proportion compliant 0.8 0.7 0.68 0.65 0.65 
 
In the simulation, we assume in the base case that only 65% of individuals initiate statins when they 
are deemed eligible. However those that initiate statins remain on statins for their lifetime. Those 
who refuse statins may be prescribed them again at a later date. 
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8.7 SYSTOLIC BLOOD PRESSURE TRAJECTORIES IN INDIVIDUALS NOT RECEIVING ANTI-
HYPERTENSIVE TREATMENT 
In the simulation, individuals’ systolic blood pressure changes every year according to the estimates 
from the statistical analysis of the Whitehall II cohort. The Path diagram for systolic blood pressure is 
illustrated in Figure 10. 
Figure 10: Systolic blood pressure path diagram for Whitehall II Statistical analysis 
 
Systolic blood pressure at any time period in the model is estimated using the following linear 
equation. 
𝑆𝐵𝑃𝑡 = 𝛽30 + 𝛽31𝑡 + 𝜀3 
𝛽30 = 𝛼30 + 𝜸𝟑𝟎𝑿 + 𝜏30𝛽10 + 𝜐30 
𝛽31 = 𝛼31 + 𝜸𝟑𝟏𝑿 + 𝜏31𝛽10 + 𝜏32𝛽11 + 𝜐31 
The intercept of the systolic blood pressure growth model is described by 𝛽30, the linear slope 𝛽31  
and a measurement error term 𝜀3. The intercept 𝛽30 is conditional on the population mean intercept 
𝛼30, coefficients 𝜸𝟑𝟎 for patient characteristics 𝑿, the growth intercept for BMI, and an individual 
level random error term 𝜐30. Annual change in SBP is determined by 𝛽31, which is also conditional on 
population intercepts, covariate adjustments and an individual level random error term.  Growth in 
SBP is also conditional on baseline BMI and the growth rate of BMI. 
The annual change in systolic blood pressure is assumed to be linear with time. At baseline an 
individual’s systolic blood pressure is determined from the HSE 2011 data. The growth factors are 
estimated in the model to be conditional on systolic blood pressure at baseline, age at baseline, sex, 
ethnicity, family history of cardiovascular disease, smoking and an error parameter to reflect 
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unobservable variability in growth trajectories between individuals. Changes in systolic blood 
pressure are also influenced by the trajectory of BMI as illustrated in Figure 11.  
Figure 11: Simulated data using the Whitehall II Statistical analysis to illustrate the effect of BMI on blood pressure 
 
8.8 SYSTOLIC BLOOD PRESSURE TRAJECTORIES IN INDIVIDUALS RECEIVING ANTI-
HYPERTENSIVE TREATMENT 
During the simulation process, if individuals are identified as having systolic blood pressure higher 
than 160mm Hg, or higher than 140mm Hg with comorbid diabetes, cardiovascular disease, or 10 
year risk of cardiovascular disease greater than 20%, they will be prescribed anti-hypertensive 
treatment (14). The change in systolic blood pressure following initiation of calcium channel blockers 
was estimated in a meta-analysis of anti-hypertensive treatments (15). This study identified an 
average change in systolic blood pressure of -8.4 for monotherapy with calcium channel blockers. It 
is assumed that this reduction in systolic blood pressure is maintained for as long as the individual 
receives anti-hypertensive treatment. For simplicity we do not assume that the individual switches 
between anti-hypertensive treatments over time. Once an individual is receiving anti-hypertensive 
treatment it is assumed that their systolic blood pressure is stable and does not change over time. 
8.9 METABOLIC RISK FACTOR SCREENING 
We assume that individuals eligible for anti-hypertensive treatment or statins will be identified 
through opportunistic screening if they meet certain criteria and attend the GP for at least one visit 
in the simulation period.  
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1. Individuals with a history of cardiovascular disease; 
2. Individuals with a major microvascular event (foot ulcer, blindness, renal failure or 
amputation); 
3. Individuals with diagnosed diabetes; 
4. Individuals identified with Impaired Glucose Regulation;  
5. Individuals with systolic blood pressure greater than 160mmHg. 
Individuals may also be detected for diabetes through opportunistic screening if the following criteria 
are met. 
1. Individuals with a history of cardiovascular disease; 
2. Individuals with a major microvascular event (foot ulcer, blindness, renal failure or 
amputation); 
3. Individuals identified with impaired glucose regulation; 
4. At baseline individuals are assigned an HbA1c threshold above which diabetes is detected 
opportunistically, individuals with an HbA1c above their individual threshold will attend the 
GP to be diagnosed with diabetes. The threshold is sampled from the distribution of HbA1c 
tests in a cohort of recently diagnosed patients in clinical practice (16). 
The base case has been designed to represent a health system with moderate levels of screening for 
hypertension, diabetes, and dyslipidaemia. Alternative assumptions for more or less intensive 
opportunistic screening can be assumed.  
8.10 DIAGNOSIS AND TREATMENT INITIATION  
It is assumed that there are three, non-mutually exclusive outcomes from the vascular checks or 
opportunistic screening. Firstly, that the patient receives statins to reduce cardiovascular risk. 
Secondly, that the patient has high blood pressure and should be treated with anti-hypertensive 
medication. Thirdly, the model evaluates whether the blood glucose test indicates a diagnosis with 
type 2 diabetes. The following threshold estimates were used to determine these outcomes. 
1. Statins are initiated if the individual has greater than or equal to 20% 10 year CVD risk 
estimated from the QRISK2 2012 algorithm (17). 
2. Anti-hypertensive treatment is initiated if systolic blood pressure is greater than 160. If the 
individual has a history of CVD, diabetes or a CVD risk >20%,  the threshold for systolic blood 
pressure is 140 (14). 
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3. Type 2 diabetes is diagnosed if the individual has an HbA1c test greater than 6.5. In the base 
case it is assumed that FPG and 2-hr glucose are not used for diabetes diagnosis. However, 
future adaptations of the model could use these tests for diagnosis. 
Recent guidelines for hypertension have recommended that hypertension be confirmed with 
ambulatory blood pressure monitoring (ABPM) (14). The cost of ABPM assessment is included in the 
cost of diagnosis (£53.40) (18), however, we assume that the test does not alter the initial diagnosis.  
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9 COMORBID OUTCOMES AND MORTALITY 
In every model cycle individuals within the model are evaluated to determine whether they have a 
clinical event, including mortality, within the cycle period. In each case the simulation estimates the 
probability that an individual has the event and uses a random number draw to determine whether 
the event occurred. 
9.1 CARDIOVASCULAR DISEASE 
 First Cardiovascular event  9.1.1
Several statistical models for cardiovascular events were identified in a review of economic 
evaluations for diabetes prevention (1). The UKPDS outcomes model (19), Framingham risk equation 
(20) and QRISK2 (21) have all been used in previous models to estimate cardiovascular events. The 
Framingham risk equation was not adopted because, unlike the QRISK2 model, it is not estimated 
from a UK population. The UKPDS outcomes model would be ideally suited to estimate the risk of 
cardiovascular disease in a population diagnosed with type 2 diabetes. Whilst this is an important 
outcome of the cost-effectiveness model, there was concern that it would not be representative of 
individuals with normal glucose tolerance or impaired glucose regulation. It was important that 
reductions in cardiovascular disease risk in these populations were represented to capture the 
population-wide benefits of public health interventions. The QRISK2 model was selected for use in 
the cost-effectiveness model because it is a validated model of cardiovascular risk in a UK population 
that could be used to generate probabilities for diabetic and non-diabetic populations. We 
considered using the UKPDS outcomes model specifically to estimate cardiovascular risk in patients 
with type 2 diabetes. However, it would not be possible to control for shifts in absolute risk 
generated by the different risk scores due to different baselines and covariates. This would lead to 
some individuals experiencing counterintuitive and favourable shifts in risk after onset of type 2 
diabetes. Therefore, we decided to use diabetes as a covariate adjustment to the QRISK2 model to 
ensure that the change in individual status was consistent across individuals. 
We accessed the 2012 version of the QRISK from the website (22). The QRISK2 equation estimates 
the probability of a cardiovascular event in the next year conditional on ethnicity, smoking status, 
age, BMI, ratio of total/HDL cholesterol, Townsend score, atrial fibrillation, rheumatoid arthritis, 
renal disease, hypertension, diabetes, and family history of cardiovascular disease. Data on all these 
variables was available from the HSE 2011. Table 20 reports the coefficient estimates for the QRISK2 
algorithm. The standard errors were not reported within the open source code. Where possible, 
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standard errors were imputed from a previous publication of the risk equation (23). Coefficients that 
were not reported in this publication were assumed to have standard errors of 20%.  
Table 20: Coefficients from the 2012 QRISK2 risk equation and estimate standard errors 
 Estimated coefficients adjusting for individual characteristics 
 Women Men  Women Men 
Covariates Mean Standard 
error 
Mean Mean Interaction terms Mean Standard 
error 
Mean Standard 
error 
White 0.0000 0.0000 0.0000 0.0000 Age1*former smoker 0.1774 0.035 -3.881 0.776 
Indian 0.2163 0.0537 0.3163 0.0425 Age1*light smoker -0.3277 0.066 -16.703 3.341 
Pakistani 0.6905 0.0698 0.6092 0.0547 Age1*moderate 
smoker 
-1.1533 0.231 -15.374 
3.075 
Bangladeshi 0.3423 0.1073 0.5958 0.0727 Age1*Heavy smoker -1.5397 0.308 -17.645 3.529 
Other Asian 0.0731 0.1071 0.1142 0.0845 Age1*AF -4.6084 0.922 -7.028 1.406 
Caribbean -0.0989 0.0619 -0.3489 0.0641 Age1*renal disease -2.6401 0.528 -17.015 3.403 
Black African -0.2352 0.1275 -0.3604 0.1094 Age1*hypertension -2.2480 0.450 33.963 6.793 
Chinese -0.2956 0.1721 -0.2666 0.1538 Age1*Diabetes -1.8452 0.369 12.789 2.558 
Other -0.1010 0.0793 -0.1208 0.0734 Age1*BMI -3.0851 0.617 3.268 0.654 
Non-smoker 0.0000 0.0000 0.0000 0.0000 Age1*family history 
CVD 
-0.2481 0.050 -17.922 
3.584 
Former smoker 0.2033 0.0152 0.2684 0.0108 Age1*SBP -0.0132 0.003 -0.151 0.030 
Light smoker 0.4820 0.0220 0.5005 0.0166 Age1*Townsend -0.0369 0.007 -2.550 0.510 
Moderate smoker 0.6126 0.0178 0.6375 0.0148 Age2*former smoker -0.0051 0.001 7.971 1.594 
Heavy smoker 0.7481 0.0194 0.7424 0.0143 Age2*light smoker -0.0005 0.000 23.686 4.737 
Age 1* 5.0327  47.3164  Age2*moderate 
smoker 
0.0105 0.002 23.137 
4.627 
Age 2* -0.0108  -101.2362  Age2*Heavy smoker 0.0155 0.003 26.867 5.373 
BMI* -0.4724 0.0423 0.5425 0.0299 Age2*AF 0.0507 0.010 14.452 2.890 
Ratio Total / HDL 
chol 
0.1326 0.0044 0.1443 0.0022 Age2*renal disease 0.0343 0.007 28.270 
5.654 
SBP 0.0106 0.0045 0.0081 0.0046 Age2*hypertension 0.0258 0.005 -18.817 3.763 
Townsend 0.0597 0.0068 0.0365 0.0048 Age2*Diabetes 0.0180 0.004 0.963 0.193 
AF 1.3261 0.0310 0.7547 0.1018 Age2*BMI 0.0345 0.007 10.551 2.110 
Rheumatoid arthritis 0.3626 0.0319 0.3089 0.0445 Age2*family history 
CVD 
-0.0062 0.001 26.605 
5.321 
Renal disease 0.7636 0.0639 0.7441 0.0702 Age2*SBP 0.0000 0.000 0.291 0.058 
Hypertension 0.5421 0.0115 0.4978 0.0112 Age2*Townsend -0.0011 0.000 3.007 0.601 
Diabetes 0.8940 0.0199 0.7776 0.0175      
Family history of 
CVD 
0.5997 0.0122 0.6965 0.0111      
AF Atrial Fibrillation CVD Cardiovascular disease SBP systolic blood pressure * covariates transformed with fractional 
polynomials 
 
The QRISK2 risk equation can be used to calculate the probability of a cardiovascular event including 
coronary heart disease (angina or myocardial infarction), stroke, transient ischaemic attacks and 
fatality due to cardiovascular disease. The equation estimates the probability of a cardiovascular 
event in the next period conditional on the coefficients listed in Table 20. The equation for the 
probability of an event in the next period is calculated as 
𝑝(𝑌 = 1) = 1 − 𝑆(1)𝜃 
𝜃 = ∑ 𝛽𝑋 
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The probability of an event is calculated from the survival function at 1 year raised to the power of 𝜃, 
where 𝜃 is the sum product of the coefficients reported in Table 20 multiplied by the individual’s 
characteristics. Underlying survival curves for men and women were extracted from the QRISK2 open 
source file. Mean estimates for the continuous variables were also reported in the open source files.  
We modified the QRISK assumptions regarding the relationship between IGR, diabetes and 
cardiovascular disease. Firstly, we assumed that individuals with HbA1c>6.5 have an increased risk of 
cardiovascular disease even if they have not received a formal diagnosis. Secondly, risk of 
cardiovascular disease was assumed to increase with HbA1c for test results greater than 6.5 to 
reflect observations from the UKPDS that HbA1c increases the risk of MI and Stroke(19) . Thirdly, 
prior to type 2 diabetes (HbA1c>6.5) HbA1c is linearly associated with cardiovascular disease. A study 
from the EPIC Cohort (Khaw 2004) has found that a unit increase in HbA1c increases the risk of 
coronary heart disease by a hazard ratio of 1.25, after adjustment for other risk factors. Individuals 
with an HbA1c greater than the mean HBA1c observed in the HSE 2011 cohort were at greater risk of 
CVD than those with an HbA1c lower than the HSE mean.  
The QRISK algorithm identifies which individuals experience a cardiovascular event but does not 
specify the nature of the event.  The nature of the cardiovascular event was determined 
independently. A targeted search of recent Health Technology appraisals of cardiovascular disease 
was performed to identify a model for the progression of cardiovascular disease following a first 
event. All QRISK events are assigned to a specific diagnosis according to age and sex specific 
distributions of cardiovascular events used in a previous Health Technology Assessment (HTA) (13). 
Table 21 reports the probability of cardiovascular outcomes by age and gender. Stakeholders 
suggested that there may be different relationships between the risk factors and the different types 
of CVD (eg. hypertension is more of a risk factor for stroke). However, we decided not to incorporate 
these factors in evaluating the risk of cardiovascular event types due to a lack of evidence.  
Table 21: The probability distribution of cardiovascular events by age and gender 
 Age Stable 
angina 
Unstable 
angina 
MI rate Fatal 
CHD 
TIA Stroke Fatal 
CVD 
Men 45-54 0.307 0.107 0.295 0.071 0.060 0.129 0.030 
 55-64 0.328 0.071 0.172 0.086 0.089 0.206 0.048 
 65-74 0.214 0.083 0.173 0.097 0.100 0.270 0.063 
 75-84 0.191 0.081 0.161 0.063 0.080 0.343 0.080 
 85+ 0.214 0.096 0.186 0.055 0.016 0.351 0.082 
Women 45-54 0.325 0.117 0.080 0.037 0.160 0.229 0.054 
 55-64 0.346 0.073 0.092 0.039 0.095 0.288 0.067 
 65-74 0.202 0.052 0.121 0.081 0.073 0.382 0.090 
 75-84 0.149 0.034 0.102 0.043 0.098 0.464 0.109 
 85+ 0.136 0.029 0.100 0.030 0.087 0.501 0.117 
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 Subsequent Cardiovascular events  9.1.2
After an individual has experienced a cardiovascular event, it is not possible to predict the transition 
to subsequent cardiovascular events using QRISK2. Instead, as with assigning first CVD events, the 
probability of subsequent events was estimated from the HTA evaluating statins (13). This study 
reported the probability of future events, conditional on the nature of the previous event. Table 22 
to Table 26 report the probabilities within a year of transitioning from stable angina, unstable angina, 
myocardial infarction (MI), transient ischemic attack (TIA) or stroke for individuals in different age 
groups. The tables suggests that, for example 99.46% of individuals with stable angina will remain in 
the stable angina state, but 0.13%, 0.32% and 0.01% will progress to unstable angina, MI or death 
from coronary heart disease (CHD) respectively. 
Table 22: Probability of cardiovascular event conditional on age and status of previous event (age 45-54) 
Age 45-54 To 
Stable 
angina 
Unstable 
angina 1 
Unstable 
angina 2 
MI 1 MI 2 TIA Stroke 1 Stroke 2 CHD 
death 
CVD 
death 
          
Fr
o
m
 
Stable angina 0.9946 0.0013 0 0.0032 0 0 0 0 0.0009 0 
Unstable angina 
(1
st
 yr) 
0 0 0.9127 0.0495 0 0 0 0 0.0362 0.0016 
Unstable angina 
(subsequent) 
0 0 0.9729 0.0186 0 0 0 0 0.0081 0.0004 
MI (1
st
 yr) 0 0 0 0.128 0.8531 0 0.0015 0 0.0167 0.0007 
MI (subsequent) 0 0 0 0.0162 0.978 0 0.0004 0 0.0052 0.0002 
TIA 0 0 0 0.0016 0 0.9912 0.0035 0 0.0024 0.0013 
Stroke (1
st
 yr) 0 0 0 0.0016 0 0 0.0431 0.9461 0.0046 0.0046 
Stroke 
(subsequent) 
0 0 0 0.0016 0 0 0.0144 0.9798 0.0021 0.0021 
MI Myocardial Infarction; TIA Transient Ischemic Attack; CHD Coronary Heart Disease; CVD Cerebrovascular disease 
 
Table 23: Probability of cardiovascular event conditional on age and status of previous event (age 55-64) 
Age 55-64 To 
Stable 
angina 
Unstable 
angina 1 
Unstable 
angina 2 
MI 1 MI 2 TIA Stroke 1 Stroke 2 CHD 
death 
CVD 
death 
          
Fr
o
m
 
Stable angina 0.9880 0.0033 0 0.0057 0 0 0 0 0.0030 0 
Unstable angina 
(1
st
 yr) 0 0 0.8670 0.0494 0 0 0 0 0.0800 0.0036 
Unstable angina 
(subsequent) 0 0 0.9415 0.0471 0 0 0 0 0.0109 0.0005 
MI (1
st
 yr) 0 0 0 0.1087 0.8409 0 0.0047 0 0.0439 0.0019 
MI (subsequent) 0 0 0 0.0183 0.9678 0 0.0015 0 0.0119 0.0005 
TIA 0 0 0 0.0029 0 0.9666 0.0159 0 0.0079 0.0068 
Stroke (1
st
 yr) 0 0 0 0.0029 0 0 0.0471 0.9159 0.0171 0.0171 
Stroke 
(subsequent) 0 0 0 0.0029 0 0 0.0205 0.9622 0.0072 0.0072 
MI Myocardial Infarction; TIA Transient Ischemic Attack; CHD Coronary Heart Disease; CVD Cerebrovascular disease 
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Table 24: Probability of cardiovascular event conditional on age and status of previous event (age 65-74) 
Age 65-74 To 
Stable 
angina 
Unstable 
angina 1 
Unstable 
angina 2 
MI 1 MI 2 TIA Stroke 1 Stroke 2 CHD 
death 
CVD 
death 
          
Fr
o
m
 
Stable angina 0.9760 0.0060 0 0.0110 0 0 0 0 0.0070 0 
Unstable angina 
(1
st
 yr) 0 0 0.8144 0.0479 0 0 0 0 0.1319 0.0059 
Unstable angina 
(subsequent) 0 0 0.9021 0.0844 0 0 0 0 0.0129 0.0006 
MI (1
st
 yr) 0 0 0 0.0948 0.8106 0 0.0098 0 0.0811 0.0036 
MI (subsequent) 0 0 0 0.0183 0.9585 0 0.0032 0 0.0191 0.0008 
TIA 0 0 0 0.0055 0 0.9174 0.0423 0 0.0185 0.0163 
Stroke (1
st
 yr) 0 0 0 0.0055 0 0 0.0485 0.8673 0.0393 0.0393 
Stroke 
(subsequent) 0 0 0 0.0055 0 0 0.0237 0.9412 0.0148 0.0148 
MI Myocardial Infarction; TIA Transient Ischemic Attack; CHD Coronary Heart Disease; CVD Cerebrovascular disease 
 
Table 25: Probability of cardiovascular event conditional on age and status of previous event (age 75-84) 
Age 75-84 To 
Stable 
angina 
Unstable 
angina 1 
Unstable 
angina 2 
MI 1 MI 2 TIA Stroke 1 Stroke 2 CHD 
death 
CVD 
death 
          
Fr
o
m
 
Stable angina 0.9680 0.0087 0 0.0163 0 0 0 0 0.0070 0 
Unstable angina 
(1
st
 yr) 0 0 0.7366 0.0448 0 0 0 0 0.2093 0.0093 
Unstable angina 
(subsequent) 0 0 0.8360 0.1484 0 0 0 0 0.0149 0.0007 
MI (1
st
 yr) 0 0 0 0.0794 0.7502 0 0.0200 0 0.1440 0.0064 
MI (subsequent) 0 0 0 0.0171 0.9466 0 0.0066 0 0.0286 0.0013 
TIA 0 0 0 0.0082 0 0.8514 0.0878 0 0.0185 0.0342 
Stroke (1
st
 yr) 0 0 0 0.0082 0 0 0.0471 0.7736 0.0856 0.0856 
Stroke 
(subsequent) 0 0 0 0.0082 0 0 0.0251 0.9107 0.0280 0.0280 
MI Myocardial Infarction; TIA Transient Ischemic Attack; CHD Coronary Heart Disease; CVD Cerebrovascular disease 
 
Table 26: Probability of cardiovascular event conditional on age and status of previous event (age 85-94) 
Age 85-94 To 
Stable 
angina 
Unstable 
angina 1 
Unstable 
angina 2 
MI 1 MI 2 TIA Stroke 1 Stroke 2 CHD 
death 
CVD 
death 
          
Fr
o
m
 
Stable angina 0.9600 0.0114 0 0.0216 0 0 0 0 0.0070 0 
Unstable angina 
(1
st
 yr) 0 0 0.6315 0.0396 0 0 0 0 0.3149 0.0140 
Unstable angina 
(subsequent) 0 0 0.7255 0.2568 0 0 0 0 0.0170 0.0008 
MI (1
st
 yr) 0 0 0 0.0623 0.6498 0 0.0380 0 0.2393 0.0106 
MI (subsequent) 0 0 0 0.0148 0.9311 0 0.0124 0 0.0399 0.0018 
TIA 0 0 0 0.0108 0 0.7967 0.1286 0 0.0185 0.0453 
Stroke (1
st
 yr) 0 0 0 0.0108 0 0 0.0409 0.6153 0.1665 0.1665 
Stroke 
(subsequent) 0 0 0 0.0108 0 0 0.0248 0.8655 0.0494 0.0494 
MI Myocardial Infarction; TIA Transient Ischemic Attack; CHD Coronary Heart Disease; CVD Cerebrovascular disease 
 
 Congestive Heart Failure 9.1.3
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The review of previous economic evaluations of diabetes prevention cost-effectiveness studies found 
that only a small number of models had included congestive heart failure as a separate outcome. 
Discussion with the stakeholder group identified that the UKPDS Outcomes model would be an 
appropriate risk model for congestive heart failure in type 2 diabetes patients. However, it was 
suggested that this would not be an appropriate risk equation for individuals with normal glucose 
tolerance or impaired glucose tolerance. The Framingham risk equation was suggested as an 
alternative. The main limitation of this equation is that it is quite old and is based on a non-UK 
population. However, a citation search of this article did not identify a more recent or UK based 
alternative. 
Congestive heart failure was included as a separate cardiovascular event because it was not included 
as an outcome of the QRISK2. The Framingham Heart Study has reported logistic regressions to 
estimate the 4 year probability of congestive heart failure for men and women (24). The equations 
included age, diabetes diagnosis (either formal diagnosis or a HbA1c>6.5), BMI and systolic blood 
pressure to adjust risk based on individual characteristics. We used this risk equation to estimate the 
probability of congestive heart failure in the SPHR diabetes prevention model. Table 27 describes the 
covariates for the logit models to estimate the probability of congestive heart failure in men and 
women. 
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Table 27: Logistic regression coefficients to estimate the 4-year probability of congestive heart failure from the 
Framingham study 
Variables Units 
Regression 
Coefficient 
OR (95% CI) P 
Men 
Intercept 
 
-9.2087 
  
Age 10 y 0.0412 1.51 (1.31-1.74) <.001 
Left ventricular hypertrophy Yes/no 0.9026 2.47 (1.31-3.77) <.001 
Heart rate 10 bpm 0.0166 1.18 (1.08-1.29) <.001 
Systolic blood pressure 20 mm Hg 0.00804 1.17 (1.04-1.32) 0.007 
Congenital heart disease Yes/no 1.6079 4.99 (3.80-6.55) <.001 
Valve disease Yes/no 0.9714 2.64 (1.89-3.69) <.001 
Diabetes Yes/no 0.2244 1.25 (0.89-1.76) 0.2 
Women 
Intercept 
 
-10.7988 
  
Age 10 y 0.0503 1.65 (1.42-1.93) <.001 
 left ventricular hypertrophy Yes/no 1.3402 3.82 (2.50-5.83) <.001 
Heart rate 100 cL 0.0105 1.11 (1.01-1.23) 0.03 
Systolic blood pressure 10 bpm 0.00337 1.07 (0.96-1.20) 0.24 
congenital heart disease 20 mm Hg 1.5549 4.74 (3.49-6.42) <.001 
Valve disease Yes/no 1.3929 4.03 (2.86-5.67) <.001 
Diabetes Yes/no 1.3857 4.00 (2.78-5.74) <.001 
BMI kg/m2 0.0578 1.06 (1.03-1.09) <.001 
Valve disease and diabetes Yes/no -0.986 0.37 (0.18-0.78) 0.009 
*OR indicates odds ratio; CI, confidence interval; LVH, left ventricular hypertrophy; CHD, 
congenital heart disease; and BMI, body mass index. Predicted probability of heart failure can be 
calculated as: p = 1/(1+exp(-xbeta)), where xbeta = Intercept + Sum (of regression 
coefficient*value of risk factor) 
 
Many of the risk factors included in this risk equation were not simulated in the diabetes model, 
therefore they could not be included in the model to predict CHD. We adjusted the baseline odds of 
CHD to reflect the expected prevalence of these symptoms in a UK population.  
The proportion of the UK population with left ventricular hypertrophy was assumed to be 5% in line 
with previous analyses of the Whitehall II cohort (25). The heart rate for men was assumed to be 
63.0bpm and for women 65.6bpm based on data from previous Whitehall II cohort analyses (26). The 
prevalence of congenital heart disease was estimated from an epidemiology study in the North of 
England. The study reports the prevalence of congenital heart disease among live births which was 
used to estimate the adult prevalence (27). This may over-estimate the prevalence, because the life 
expectancy of births with congenital heart disease is reduced compared with the general population. 
However, given the low prevalence it is unlikely to impact on the results. The prevalence of valve 
disease was estimated from the Echocardiographic Heart of England Screening study (28).  
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Using the estimated population values we adjusted the intercept values to account for the 
population risk in men and women. This resulted in a risk equation with age, systolic blood pressure, 
diabetes, and BMI in women to describe the risk of congestive heart failure for the policy analysis 
model.  
9.2 MICROVASCULAR COMPLICATIONS 
The review of previous economic evaluations identified that the UKPDS data was commonly used to 
estimate the incidence of microvascular complications (1). This data has the advantage of being 
estimated from a UK diabetic population. Given that the events described in the UKPDS outcomes 
model are indicative of late stage microvascular complications, we did not believe it was necessary to 
seek an alternative model that would be representative of an impaired glucose tolerance population.  
We adopted a simple approach to modelling microvascular complications. We used both versions of 
the UKPDS Outcomes model to estimate the occurrence of major events relating to these 
complications, including renal failure, amputation, foot ulcer, and blindness (11;19). These have the 
greatest cost and utility impact compared with earlier stages of microvascular complications, so are 
more likely to have an impact on the SPHR diabetes prevention outcomes. As a consequence, we 
assumed that microvascular complications only occur in individuals with HbA1c>6.5. Whilst some 
individuals with hyperglycaemia (HbA1c>6.0) may be at risk of developing microvascular 
complications, it is unlikely that they will progress to renal failure, amputation or blindness before a 
diagnosis of diabetes. Importantly, we did not assume that only individuals who have a formal 
diagnosis of diabetes are at risk of these complications. This allows us to incorporate the costs of 
undetected diabetes into the simulation. 
The UKPDS includes four statistical models to predict foot ulcers, amputation with no prior ulcer, 
amputation with prior ulcer and a second amputation (19). In order to simplify the simulation of 
neuropathy outcomes we consolidated the models for first amputation with and without prior ulcer 
into a single equation. The parametric survival models were used to generate estimates of the 
cumulative hazard in the current and previous period. From which the probability of organ damage 
being diagnosed was estimated.  
 𝑝(𝐷𝑒𝑎𝑡ℎ) = 1 − exp (𝐻(𝑡) − 𝐻(𝑡 − 1)) (1.1) 
The functional form for the microvascular models included exponential and Weibull. The logistic 
model was also used to estimate the probability of an event over the annual time interval. 
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 Retinopathy 9.2.1
We used the UKPDS outcomes model v2 to estimate the incidence of blindness in individuals with 
HbA1c>6.5. The exponential model assumes a baseline hazard 𝜆, which can be calculated from the 
model coefficients reported in Table 28 and the individual characteristics for 𝑿.  
𝜆 = 𝑒𝑥𝑝(𝛽0 + 𝑿𝜷𝒌) 
Table 28: Parameters of the UKPDS2 Exponential Blindness survival model 
 Mean 
coefficient 
Standard error Modified mean 
coefficient 
Lambda -11.607 0.759 -10.967 
Age at diagnosis 0.047 0.009 0.047 
HbA1c 0.171 0.032 0.171 
Heart rate 0.080 0.039  
SBP 0.068 0.032 0.068 
White Blood Count 0.052 0.019  
CHF History 0.841 0.287 0.841 
IHD History 0.0610 0.208 0.061 
 
The age at diagnosis coefficient was multiplied by age in the current year if the individual had not 
been diagnosed with diabetes or by the age at diagnosis if the individual had received a diagnosis. 
The expected values for the risk factors not included in the SPHR model (heart rate and white blood 
count) were taken from Figure 3 of the UKPDS publication in which these are described (19). 
Assuming these mean values, it was possible to modify the baseline risk without simulating heart 
rate and white blood cell count.   
 Neuropathy 9.2.2
We used the UKPDS outcomes model v2 to estimate the incidence of ulcer and amputation in 
individuals with HbA1c>6.5. The parameters of the ulcer and first amputation models are reported in 
Table 29. 
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Table 29: Parameters of the UKPDS2 Exponential model for Ulcer, Weibull model for first amputation with no prior ulcer 
and exponential model for 1
st
 amputation with prior ulcer 
 Ulcer 1
st
 Amputation no 
prior ulcer 
1
st
 Amputation prior 
ulcer 
2
nd
 Amputation 
 Logistic Weibull Exponential Exponential 
 Mean Standard 
error 
Mean Standard 
error 
Mean Standard 
error 
Mean Standard 
error 
lambda -11.295 1.130 -14.844 1.205 -0.881 1.39 -3.455 0.565 
Rho   2.067 0.193     
Age at 
diagnosis 
0.043 0.014 0.023 0.011 -0.065 0.027   
Female -0.962 0.255 -0.0445 0.189     
Atrial 
fibrillation 
  1.088 0.398     
BMI 0.053 0.019       
HbA1c 0.160 0.056 0.248 0.042   0.127 0.06 
HDL   -0.059 0.032     
Heart rate   0.098 0.050     
MMALB   0.602 0.180     
PVD 0.968 0.258 1.010 0.189 1.769 0.449   
SBP   0.086 0.043     
WBC   0.040 0.017     
Stroke 
History 
  1.299 0.245     
  
The exponential model assumes a baseline hazard 𝜆, which can be calculated from the model 
coefficients reported in Table 29 and the individual characteristics for 𝑿.  
𝜆 = 𝑒𝑥𝑝(𝛽0 + 𝑿𝜷) 
The Weibull model for amputation assumes a baseline hazard: 
ℎ(𝑡) = 𝜌𝑡𝜌−1exp (𝜆) 
where 𝜆 is also conditional on the coefficients and individual characteristics at time t. The logistic 
model for ulcer is described below. 
Pr(y = 1|𝐗) =
exp (𝐗𝛃)
1 + exp (𝐗𝛃))
 
The ulcer and amputation models include a number of covariates that were not included in the 
simulation. As such it was necessary to adjust the statistical models to account for these measures. 
We estimated a value for the missing covariates and added the value multiplied by the coefficient to 
the baseline hazard.  
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The expected values for the risk factors not included in the SPHR model (heart rate, white blood 
count, micro-/macroalbuminurea, peripheral vascular disease and atrial fibrillation) were taken from 
Figure 3 of the UKPDS publication in which these are described (19). In the ulcer model we assumed 
that 2% of the population had peripheral vascular disease.  
The amputation risk model with a history of ulcer was not included in the simulation, but was used to 
estimate an additional log hazard ratio to append onto the amputation model without a history of 
ulcer. The log hazard was estimated for each model assuming the same values for other covariates. 
The difference in the log hazard between the two models was used to approximate the log hazard 
ratio for a history of ulcer in the amputation model (10.241). The final model specifications are 
reported in Table 30.  
Table 30: Coefficients estimates for Ulcer and 1
st
 Amputation 
 Ulcer 1
st
 Amputation  2
nd
 Amputation  
 Logistic Weibull  Exponential 
 Mean Standard 
error 
Mean Standard 
error 
Mean Standard 
error 
Lambda -11.276 1.13 -13.954 1.205 -3.455 0.565 
Rho   2.067 0.193   
Age at Diagnosis 0.043 0.014 0.023 0.011   
Female -0.962 0.255 -0.445 0.189   
BMI 0.053 0.019     
HbA1c 0.160 0056 0.248 0.042 0.127 0.06 
HDL   -0.059 0.032   
Stroke   1.299 0.245   
Foot Ulcer   10.241    
 
 Nephropathy 9.2.3
We used the UKPDS outcomes model v1 to estimate the incidence of renal failure in individuals with 
HbA1c>6.5. Early validation analyses identified that the UKPDS v2 model implements in the SPHR 
model substantially overestimated the incidence of renal failure. The Weibull model for renal failure 
assumes a baseline hazard: 
ℎ(𝑡) = 𝜌𝑡𝜌−1exp (𝜆) 
where 𝜆 is also conditional on the coefficients and individual characteristics at time t. The parameters 
of the renal failure risk model are reported in Table 31. 
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Table 31: Parameters of the UKPDS2 Weibull renal failure survival model 
 Mean Standard error 
Lambda -10.016 0.939 
Shape parameter 1.865 0.387 
SBP 0.404 0.106 
BLIND History 2.082 0.551 
 
9.3 CANCER 
The conceptual model identified breast cancer and colorectal cancer risk as being related to BMI. 
However, these outcomes were not frequently included in previous cost-effectiveness models for 
diabetes prevention. Discussion with stakeholders identified the EPIC Norfolk epidemiology cohort 
study as a key source of information about cancer risk in a UK population. Therefore, we searched 
publications from this cohort to identify studies reporting the incidence of these risks. In order to 
obtain the best quality evidence for the relationship between BMI and cancer risk we searched for a 
recent systematic review and meta-analysis using key terms ‘Body Mass Index’ and ‘Cancer’, filtering 
for meta-analysis studies. 
 Breast cancer 9.3.1
Incidence rates for breast cancer in the UK were estimated from the European Prospective 
Investigation of Cancer (EPIC) cohort. This is a large multi-centre cohort study looking at diet and 
cancer. In 2004 the UK incidence of breast cancer by menopausal status was reported in a paper 
from this study investigating the relationship between body size and breast cancer (29). The 
estimates of the breast cancer incidence in the UK are reported in Table 32. 
Table 32: UK breast cancer incidence  
 Number of 
Cases 
Person 
Years Mean BMI 
Incidence Rate of 
per person-year 
Reference 
UK pre-menopause 102 103114.6 24 0.00099 (29) 
UK post-menopause 238 84214.6 24 0.00283 (29) 
  
A large meta-analysis that included 221 prospective observational studies has reported relative risks 
of cancers per unit increase in BMI, including breast cancer by menopausal status (30). We included a 
risk adjustment in the model so that individuals with higher BMI have a higher probability of pre-and 
post-menopausal breast cancer (30). In the simulation we adjusted the incidence of breast cancer by 
multiplying the linear relative risk by the difference in the individual’s BMI and the average BMI 
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reported in the EPIC cohort. The relative risk and confidence intervals per 5mg/m2 increase in BMI 
are reported in Table 33. 
Table 33: Relative risk of Breast cancer by BMI 
 Mean Relative risk 2.5
th
 Confidence 
Interval 
97.5
th
 Confidence 
Interval 
Reference 
UK pre-menopause 0.89 0.84 0.94 (30) 
UK post-menopause 1.09 1.04 1.14 (30) 
 
 Colorectal cancer  9.3.2
Incidence rates for colorectal cancer in the UK were reported from the European Prospective 
Investigation of Cancer (EPIC) cohort. The UK incidence of colorectal cancer is reported by gender in 
a paper from this study investigating the relationship between body size and colon and rectal cancer 
(29). The estimates of the colorectal cancer incidence are reported in Table 34. 
Table 34: UK colorectal cancer incidence  
 
Number of 
Cases Person Years 
Mean Age 
Mean BMI 
Incidence 
Rate of per 
person-year 
Reference 
Male 125 118468 53.1 25.4 0.00106 (31) 
Female 145 277133 47.7 24.5 0.00052 (31) 
 
The risk of colorectal cancer has been linked to obesity. We included a risk adjustment in the model 
to reflect observations that the incidence of breast cancer is increased in individuals with higher BMI. 
A large meta-analysis that included 221 prospective observational studies has reported relative risks 
of BMI and cancers, including colon cancer by gender (30). We selected linear relative risk estimates 
estimated from pooled European and Australian populations. In the simulation we adjusted the 
incidence of colorectal cancer by multiplying the relative risk by the difference in the individual’s BMI 
and the average BMI reported in the EPIC cohort. The relative risk and confidence intervals per 
5mg/m2 increase in BMI are reported in Table 35. 
Table 35: Relative risk of colon cancer by BMI 
 Mean Relative risk 2.5
th
 Confidence 
Interval 
97.5
th
 Confidence 
Interval 
Reference 
UK pre-menopause 1.21 1.18 1.24 (30) 
UK post-menopause 1.04 1 1.07 (30) 
 
9.4 OSTEOARTHRITIS 
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The stakeholder group requested that BMI and diabetes be included as independent risk factors for 
osteoarthritis based on recent evidence (5). Osteoarthritis had not been included as a health state in 
previous cost-effectiveness models.  A search for studies using key words ‘Diabetes’, ‘Osteoarthritis’ 
and ‘Cohort Studies’ did not identify a UK based study with diabetes and BMI included as 
independent covariates in the risk model. The Bruneck cohort, a longitudinal study of inhabitants of a 
town in Italy reported diabetes and BMI as independent risk factors for osteoarthritis (5). The cohort 
may not be representative of the UK. However, the individuals are from a European country, the 
study has a large sample size and has estimated the independent effects of BMI and diabetes on the 
risk of osteoarthritis. No UK based studies identified in our searches met these requirements. The 
data used to estimate the incidence of osteoarthritis is reported in Table 36. 
Table 36: Incidence of osteoarthritis and estimated risk factors 
 No cases Person years Mean BMI Incidence rate Reference 
No diabetes 73 13835 24.8 0.0053 (5) 
 Hazard ratio 2.5th 97.5th  Reference 
HR Diabetes 2.06 1.11 3.84  (5) 
HR BMI 1.076 1.023 1.133  (5) Personal communication 
 
9.5 DEPRESSION 
Depression was not included as a health state in previous cost-effectiveness models for diabetes 
prevention. However, a member of the stakeholder group identified that a relationship between 
diabetes and depression was included in the CORE diabetes treatment model (32). With this in mind, 
we decided to include depression as a health state in the model, but not to model its severity. 
Some individuals enter the simulation with depression at baseline according to individual responses 
in the Health Survey for England 2011 questionnaire. Depression is described as a chronic state from 
which individuals do not completely remit. We did not estimate the effect of depression on the 
longitudinal changes for BMI, glycaemia, systolic blood pressure and cholesterol. As a consequence it 
was not possible to relate the impact of depression to the incidence of diabetes and cardiovascular 
risk. 
In the simulation, individuals can develop depression in any cycle of the model. The baseline 
incidence of depression among all individuals without a history of depression was estimated from a 
study examining the bidirectional association between depressive symptoms and type 2 diabetes 
(33). Although the study was not from a UK population, the US cohort included ethnically diverse 
men and women aged 45 to 84 years.  We assumed that diagnosis of diabetes and/or cardiovascular 
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disease increases the incidence of depression in individuals who do not have depression at baseline. 
We identified a method for inflating risk of depression for individuals with diabetes from the US 
cohort study described above (33). The risk of depression in individuals who have had a stroke was 
also inflated according to a US cohort study (34). Odds of depression and odds ratios for inflated risk 
of depression due to diabetes or stroke are presented in Table 37. 
Table 37: Baseline incidence of depression 
Baseline Risk of depression 
 Mean 2.5
th
 CI 97.5th 
Depression cases in NGT 336   
Person years 9139   
Odds of depression 0.0382   
Log odds of depression -3.266   
Inflated risk for Diabetes 
Odds ratio of diabetes 1.52 1.09 2.12 
Log odds ratio of diabetes 0.419   
Inflate risk of stroke 
Odds ratio of stroke 6.3 1.7 23.2 
Log odds ratio stroke 1.8406   
NGT Normal Glucose Tolerance 
 
9.6 MORTALITY 
 Cardiovascular Mortality  9.6.1
Cardiovascular mortality is included as an event within the QRISK2 and the probability of subsequent 
cardiovascular events obtained from an HTA assessing statins (13) as described in the cardiovascular 
disease section above. 
 Cancer Mortality  9.6.2
Cancer mortality rates were obtained from the Office of National statistics (35). The ONS report one 
and five year net survival rates for various cancer types, by age group and gender. Net survival was 
an estimate of the probability of survival from the cancer alone. It can be interpreted as the survival 
of cancer patients after taking into account the background mortality that the patients would have 
experienced if they had not had cancer.  
The age-adjusted 5-year survival rate for breast cancer and colorectal cancer were used to estimate 
an annual risk of mortality assuming a constant rate of mortality. We assume that the mortality rate 
does not increase due to cancer beyond 5 years after cancer diagnosis. The five year survival rate for 
breast cancer is 84.3%, which translated into a 3.37% annual probability of death from breast cancer. 
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The five year survival rate for persons with colorectal cancer is 55.3%, which translated into an 
11.16% annual probability of death from colorectal cancer.  
9.6.2.1 Other cause Mortality (including diabetes risk)  
Other cause mortality describes the risk of death from any cause except cardiovascular disease and 
cancer. All-cause mortality rates by age and sex were extracted from the Office of National Statistics 
(36). The mortality statistics report the number of deaths by ICD codes for 5-year age groups. We 
subtracted the number of cardiovascular disease, breast and colorectal cancer related deaths from 
the all-cause mortality total to estimate other cause mortality rates by age and sex (Table 35).  
  
60 
 
Table 38: All cause and derived other cause mortality from the Office of National statistics 
 All cause All cause Other 
cause 
Other cause  All cause All cause Other 
cause 
Other cause 
 Men Women Men Women  Men Women Men Women 
1 0.0004 0.0003 0.0003 0.0003 51 0.0034 0.0024 0.0025 0.0017 
2 0.0002 0.0002 0.0002 0.0002 52 0.0039 0.0026 0.0029 0.0019 
3 0.0001 0.0001 0.0001 0.0001 53 0.0044 0.0028 0.0032 0.0020 
4 0.0001 0.0001 0.0001 0.0001 54 0.0045 0.0032 0.0034 0.0022 
5 0.0001 0.0001 0.0001 0.0001 55 0.0051 0.0033 0.0037 0.0024 
6 0.0001 0.0001 0.0001 0.0001 56 0.0057 0.0037 0.0041 0.0027 
7 0.0001 0.0001 0.0001 0.0000 57 0.0061 0.0041 0.0044 0.0030 
8 0.0001 0.0001 0.0001 0.0000 58 0.0069 0.0041 0.0050 0.0030 
9 0.0001 0.0001 0.0001 0.0001 59 0.0071 0.0050 0.0052 0.0036 
10 0.0001 0.0000 0.0001 0.0000 60 0.0081 0.0054 0.0059 0.0040 
11 0.0001 0.0001 0.0001 0.0001 61 0.0086 0.0057 0.0063 0.0042 
12 0.0001 0.0001 0.0001 0.0001 62 0.0096 0.0062 0.0070 0.0046 
13 0.0001 0.0001 0.0001 0.0001 63 0.0104 0.0067 0.0076 0.0050 
14 0.0001 0.0001 0.0001 0.0001 64 0.0108 0.0072 0.0079 0.0053 
15 0.0002 0.0001 0.0002 0.0001 65 0.0125 0.0082 0.0091 0.0061 
16 0.0002 0.0001 0.0002 0.0001 66 0.0141 0.0090 0.0103 0.0067 
17 0.0003 0.0002 0.0003 0.0002 67 0.0148 0.0097 0.0108 0.0072 
18 0.0004 0.0002 0.0004 0.0002 68 0.0162 0.0107 0.0118 0.0079 
19 0.0004 0.0002 0.0004 0.0002 69 0.0181 0.0118 0.0132 0.0087 
20 0.0005 0.0002 0.0005 0.0002 70 0.0218 0.0138 0.0157 0.0101 
21 0.0005 0.0002 0.0005 0.0002 71 0.0234 0.0145 0.0168 0.0106 
22 0.0005 0.0002 0.0005 0.0002 72 0.0252 0.0167 0.0182 0.0122 
23 0.0005 0.0002 0.0005 0.0002 73 0.0269 0.0173 0.0193 0.0127 
24 0.0005 0.0002 0.0005 0.0002 74 0.0310 0.0200 0.0223 0.0147 
25 0.0006 0.0003 0.0006 0.0002 75 0.0327 0.0222 0.0233 0.0157 
26 0.0006 0.0003 0.0005 0.0002 76 0.0375 0.0249 0.0267 0.0176 
27 0.0006 0.0004 0.0005 0.0003 77 0.0411 0.0284 0.0293 0.0202 
28 0.0007 0.0003 0.0006 0.0003 78 0.0458 0.0321 0.0326 0.0228 
29 0.0007 0.0003 0.0006 0.0003 79 0.0523 0.0358 0.0372 0.0254 
30 0.0007 0.0004 0.0006 0.0003 80 0.0585 0.0411 0.0418 0.0289 
31 0.0008 0.0004 0.0007 0.0004 81 0.0652 0.0456 0.0465 0.0321 
32 0.0007 0.0005 0.0007 0.0004 82 0.0745 0.0530 0.0531 0.0372 
33 0.0008 0.0005 0.0007 0.0004 83 0.0833 0.0606 0.0594 0.0426 
34 0.0009 0.0005 0.0008 0.0004 84 0.0931 0.0678 0.0664 0.0476 
35 0.0010 0.0006 0.0008 0.0005 85 0.1040 0.0760 0.0738 0.0537 
36 0.0011 0.0006 0.0010 0.0005 86 0.1147 0.0872 0.0814 0.0617 
37 0.0013 0.0006 0.0011 0.0005 87 0.1300 0.0977 0.0923 0.0692 
38 0.0013 0.0007 0.0011 0.0006 88 0.1468 0.1106 0.1042 0.0782 
39 0.0013 0.0007 0.0011 0.0006 89 0.1643 0.1242 0.1166 0.0879 
40 0.0015 0.0009 0.0012 0.0006 90 0.2285 0.1982 0.1660 0.1425 
41 0.0016 0.0010 0.0013 0.0007 91 0.2285 0.1982 0.1660 0.1425 
42 0.0018 0.0010 0.0015 0.0008 92 0.2285 0.1982 0.1660 0.1425 
43 0.0018 0.0012 0.0015 0.0009 93 0.2285 0.1982 0.1660 0.1425 
44 0.0020 0.0012 0.0017 0.0009 94 0.2285 0.1982 0.1660 0.1425 
45 0.0022 0.0014 0.0017 0.0010 95 0.2285 0.1982 0.1751 0.1509 
46 0.0023 0.0016 0.0018 0.0011 96 0.2285 0.1982 0.1751 0.1509 
47 0.0023 0.0015 0.0018 0.0011 97 0.2285 0.1982 0.1751 0.1509 
48 0.0027 0.0017 0.0021 0.0012 98 0.2285 0.1982 0.1751 0.1509 
49 0.0028 0.0019 0.0022 0.0014 99 0.2285 0.1982 0.1751 0.1509 
50 0.0030 0.0021 0.0023 0.0015 100 0.2285 0.1982 0.1751 0.1509 
 
The rate of other cause mortality by age and sex was treated as the baseline hazard. Following input 
from stakeholders, an increased risk of mortality was assigned to individuals with diabetes using data 
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from a published meta-analysis (37). This study used data from 820,900 people from 97 prospective 
studies to calculate hazard ratios for cause-specific death, according to baseline diabetes status (37). 
Cause of death was separated into vascular disease, cancer and other cause mortality. From this 
study we estimated that individuals with a diagnosis of diabetes have a fixed increased risk of other 
cause mortality (Hazard ratio 1.8 (95% CI 1.71-1.9)). The estimates reported in the meta-analysis 
include increased risk of death from renal disease, therefore mortality from renal disease was not 
simulated separately to avoid double counting of benefits.  
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10 DIRECT HEALTH CARE COSTS 
At any given time period of the model individuals can have multiple health complications that incur 
direct healthcare costs. Some of the health states are mutually exclusive; however an individual can 
accrue multiple complications within the model. Each health state is associated with an average cost, 
which is accrued by all individuals for every time period for which the state is indicated. Resource use 
for each comorbidity is added together and no savings are assumed to be made from the use of the 
same resources for two or more comorbidities for an individual. An exception to this is an assumed 
adjustment to the utilisation of GP services for individuals with chronic diseases.  
In some instances we have adopted costs and prices from old studies. We have inflated all prices and 
costs to 2013 prices using inflation indices reported in the Personal Social Services Research Unit 
(PSSRU) (38). This documents health related inflation up to 2011/12 prices. Price inflation was 
assumed at 2% per year to inflate costs to 2012/2013 prices. 
Primary care and community care costs were sought from the Personal Social Services Research Unit 
(PSSRU) (38), and secondary care costs from UK reference costs (39). Drug costs were obtained from 
the British National Formulary (40). In most instances costs for long term health outcomes were 
sought from recent Health Technology Appraisals as this was thought to be the best source of 
evidence for costs and resource use by disease area in the UK. If an HTA appraisal were not 
identified, searches for good quality cost-effectiveness analyses for the relevant disease area were 
conducted to identify the appropriate UK costs.  
10.1 GP ATTENDANCE 
The costs of each visit to a General Practitioner were estimated at £43 from the Personal Social 
Services Research Unit (PSSRU) (38).  
10.2 DIABETES  
We were advised by stakeholders to model a simplified diabetes treatment pathway. It was 
recommended that a single annual cost of prescriptions be applied to all patients diagnosed with 
diabetes. Initially we explored this as an option but concluded that the timing of more costly 
treatments for type 2 diabetes is important because treatment costs will be discounted. The model 
assesses interventions that lower HbA1c and so have the potential to impact on the level of 
treatment required. 
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We decided to implement a three stage treatment regimen as a trade-off between model simplicity 
and capturing key cost differences between the interventions. At diagnosis all patients are prescribed 
low cost treatments, such as Metformin and Sulfonylurea. We chose Metformin, 500mg/day to 
describe the average cost of these medications. If HbA1c increases above a threshold the individual is 
prescribed a more expensive Gliptins in addition to Metformin. The individual continues to receive 
Metformin plus Gliptins for a period of time until they require insulin. 
 Metformin Monotherapy 10.2.1
Cost estimates from the British National Formulary indicate that the cost of Metformin is 
approximately £11 per tablet. The use of blood glucose self-monitoring strips was described in a 
recent UK based study in which 36% of patients used monitoring strips at a mean weekly 
consumption of 3.1 (41) for individuals prescribed Metformin only, at a cost of 31p per strip as 
reported in the BNF.  Other resource use costs and utilisation assumptions for diabetics receiving 
Metformin monotherapy are detailed in Table 39. 
Table 39: Drug costs and resource utilisation costs for low cost diabetes monotherapy 
Resource Assumption for costs Unit cost Source Inflation Annual 
utilisation 
Source Cost per 
year 
Metformin 500mg 56 tab pack £0.11 BNF 65 1 730 Assumption £80.04 
Nurse at GP Nurse advanced per surgery 
consultation with 
qualifications 
£25 (38) 1 1 Stakeholder 
workshop 
£25.00 
Health care 
assistant 
Clinical support worker 
patient work 10 mins 
£4.17 (38) 1 1 Stakeholder 
workshop 
£4.17 
Urine sample Biochemistry £1  1 3 Stakeholder 
workshop 
£1 
Eye screening Optometrist test 2006 price £18.39 (42) 1.235 1 Stakeholder 
workshop 
£22.71 
HbA1c Haematology £3  1 1 Stakeholder 
workshop 
£3.00 
Lipids Chemistry £1  1 1 Stakeholder 
workshop 
£1.00 
Liver function Chemistry £1  1 1 Stakeholder 
workshop 
£1.00 
B12 Chemistry £1  1 1 Stakeholder 
workshop 
£1.00 
Smoking 
cessation 
Nicotine replacement 
therapy 
£102 (38) 1 0.3* Stakeholder 
workshop 
£30.6 
 £169.51 
* Assumed 20% smoking prevalence and 50%  uptake of smoking cessation services 
 
The cost of diabetes in the year after diagnosis is assumed to be greater than subsequent years 
because the individual will receive more contact time whilst their diabetes is being controlled. The 
additional costs of diabetes in the year after diagnosis are reported in Table 40. 
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Table 40: Drug costs and resource utilisation costs for the first year of low cost diabetes treatment 
Resource Assumption for costs Unit cost Source Inflation Annual 
utilisation 
Source Cost per 
year 
Nurse at GP Nurse advanced per surgery 
consultation with 
qualifications 
£25 (38) 1 1 Stakeholder 
workshop 
£50.00 
Health care 
assistant 
Clinical support worker 
patient work 10 mins 
£4.17 (38) 1 1 Stakeholder 
workshop 
£8.33 
Urine sample Biochemistry £1  1 3 Stakeholder 
workshop 
£2 
HbA1c Haematology £3  1 1 Stakeholder 
workshop 
£6.00 
Lipids Chemistry £1  1 1 Stakeholder 
workshop 
£2.00 
Liver function Chemistry £1  1 1 Stakeholder 
workshop 
£2.00 
B12 Chemistry £1  1 1 Stakeholder 
workshop 
£2.00 
 £72.33 
 
 Metformin plus Gliptins 10.2.2
Simulated individuals experience an annual increase in HbA1c. Gillett et al. (2012) assume that 
individuals switch to dual treatment if HbA1c increases above 7.4% (6). Within the model, the 
individual is switched to a dual treatment in the first annual cycle in which HbA1c exceeds 7.4%. For 
costing purposes the second drug to be added to Metformin was Sitagliptin, which is reported in the 
British National Formulary to cost £1.41 per day. Belsey et al. (2009) report that 48% of patients used 
monitoring strips at a mean weekly consumption of 3.3 (reference needed). Table 41 reports the 
other resource use costs and utilisation assumptions for diabetics receiving Metformin plus Gliptins. 
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Table 41: Drug costs and resource utilisation costs for Metformin and Gliptins 
Resource Assumption for costs Unit cost Source Inflation Annual 
utilisation 
Source Cost per 
year 
Sitagliptin 100mg per day 28 tab pack £1.19 BNF 65 1 730 Assumption £867.14 
Metformin 5mg per day, 28 tab pack £0.11 BNF 65  1 730 Assumption £80.04 
Self-monitoring 
strips 
50 strip pack Active® £0.314 BNF 65 1 82.20 (41) £25.81 
Nurse at GP Nurse advanced per surgery 
consultation with qualifications 
£25 (38) 1 1 Stakeholder 
workshop 
£25.00 
Health care 
assistant 
Clinical support worker patient 
work 10 mins 
£4.17 (38) 1 3 Stakeholder 
workshop 
£4.17 
Urine sample Biochemistry £1  1 1 Stakeholder 
workshop 
£1 
Eye screening Optometrist test 2006 price £18.39 (42) 1.235 1 Stakeholder 
workshop 
£22.71 
HbA1c Haematology £3  1 3 Stakeholder 
workshop 
£3.00 
Lipids Chemistry £1  1 3 Stakeholder 
workshop 
£1.00 
Liver function Chemistry £1  1 3 Stakeholder 
workshop 
£1.00 
B12 Chemistry £1  1 3 Stakeholder 
workshop 
£1.00 
Smoking 
cessation 
Nicotine replacement therapy £102 (38) 1 0.3* Stakeholder 
workshop 
£30.60 
 £1062.46 
* Assumed 20% smoking prevalence and 50%  uptake of smoking cessation services 
 
 Insulin plus Oral Anti-diabetics 10.2.3
The second major treatment change is assumed to be initiation of insulin. Gillett et al. (2012) 
assumed that individuals switch to insulin if HbA1c increases above 8.5% (6). Within the model the 
individual is switched to insulin in the first annual cycle at which HbA1c exceeds 8.5%. The insulin 
Glargine was chosen to represent insulin treatment in the UK and is consistent with Gillett et al. 
(2012) (6). Furthermore, recent cost studies from the UK have promoted the use of Glargine to 
reduce costs (43). The total resource use and costs of this health state are reported in Table 42 and 
Table 43. 
Table 42: Costs of insulin treatment 
 Price Source  
Glargine £628.44 (43) (2006 prices) 
Oral anti-diabetics £43.68 (43) (2006 prices) 
Reagent test strips £221.43 (43) (2006 prices) 
Hypoglycaemic rescue £23.43 (43) (2006 prices) 
Pen delivery devices £54.79 (43) (2006 prices) 
Sharps £68.82 (43) (2006 prices) 
Total cost per year £1,013.51  
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Table 43: Drug costs and resource utilisation costs for insulin and oral anti-diabetics 
Resource Assumption for costs Unit cost Source Inflation 
(2013) 
Annual 
utilisation 
Source Cost per 
year 
Insulin 
treatment 
costs 
Total annual cost £1,013.51 (43) 1.235 NA N/A £1251.53 
Nurse at GP Nurse advanced per 
surgery consultation 
with qualifications 
£25 (38) 1 3 Stakeholder 
workshop 
£75.00 
Health care 
assistant 
Clinical support worker 
patient work 10 mins 
£4.17 (38) 1 3 Stakeholder 
workshop 
£12.50 
Urine sample Biochemistry £1  1 3 Stakeholder 
workshop 
£3.00 
Eye screening Optometrist test 2006 
price 
£18.39 (42) 1.235 1 Stakeholder 
workshop 
£22.71 
HbA1c Haematology £3  1 3 Stakeholder 
workshop 
£9.00 
Lipids Chemistry £1  1 3 Stakeholder 
workshop 
£3.00 
Liver function Chemistry £1  1 3 Stakeholder 
workshop 
£3.00 
B12 Chemistry £1  1 3 Stakeholder 
workshop 
£3.00 
Smoking 
cessation 
Nicotine replacement 
therapy 
£102 (38) 1 0.3* Stakeholder 
workshop 
£30.60 
 £1413.34 
* Assumed 20% smoking prevalence and 50%  uptake of smoking cessation services 
 
10.3 STATINS 
We assumed that individuals who are prescribed statins receive a daily dose of 40mg of generic 
Simvastatin. The British National Formulary reports a cost of approximately 3p per day. The 
individual remains on statins for the rest of their life. Table 44 reports the derived annual costs for 
statins. 
Table 44: Annual treatment costs of statins 
 Assumption for costs Unit cost Source Inflation Annual 
utilisation 
Cost per year 
Statins Simvastatin 20mg £0.0325 BNF 65 1 730 £23.72 
 
10.4 ANTI-HYPERTENSIVES 
A search of the literature did not identify any recent publications of anti-hypertensive prescriptions 
in the UK. As a consequence the best estimates of cost of anti-hypertensive treatment dated from 
2004. These were inflated to current prices (44). Due to the number of different anti-hypertensive 
treatments available and possibilities for combination therapies, using the cost from this study of 
prescriptions was preferred to using costs directly from the BNF. 
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Table 45: Annual cost of anti-hypertensive prescription expenditure per patient  
 Price Inflation  Cost per year Source  
Anti-hypertensive prescriptions £144 1.2709 £183.01 (44)  
 
10.5 CARDIOVASCULAR EVENTS 
Costs for cardiovascular disease were obtained from a 2009 HTA for high dose lipid-lowering therapy 
(12). Table 46 describes the costs and resource use assumptions that were used for this study. It also 
reports the health states to which we have applied each cost in the model. The costs of congestive 
heart failure were estimated from the UKPDS costing study for complications related to diabetes 
(45). The unit costs for cardiovascular events are detailed in Table 47. 
Table 46: Resources use assumptions and costs for cardiovascular outcomes 
 Resource assumptions Cost 
(2009) 
Cost 
(2012/13) 
Health 
States 
applied 
Unstable Angina 
year 1 
Secondary care costs: 100% hospitalisation, 50% 
revascularisation procedure, three outpatient 
appointments). 
Primary care costs (three GP visits) and medications 
£3880 £4365.52 UANG1 
MI year 1 Secondary care costs: 100% hospitalisation, 
50% revascularisation procedure, three outpatient 
appointments) 
Primary care costs (three GP visits) and medications. 
£3996 £4482.81 MI1 
Subsequent ACS 
care costs 
Secondary care costs (one outpatient appointment). 
Primary care costs (three GP visits) and medications. 
£340 £382.53 SANG, 
UANG, 
MI, TIA 
Stroke year 1 Costs of acute events reported in Youman et al. (46) 
weighted by the distribution of severity of stroke (13). 
£8066 £9075.02 STRO1 
Stroke 
subsequent costs 
The costs of ongoing care at home or in an institution 
weighted by the distribution of severity of stroke and 
discharge locations. 
£2266 £2549.59 STRO2 
Fatal CHD Palmer  et al. (47). Assumed that 50% of fatalities incurred 
cost. 
£592 £665.50  
Fatal non cardiac 
vascular event 
Youman et al. (46). Assumed 50% fatalities incurred cost 
 
£3688 £4149.52  
 Source Cost 
(2004) 
Cost 
(2012/13) 
 
Congestive heart 
failure 
UKPDS (45) £2221 £2887.20  
 
Table 47: Unit costs for Cardiovascular cost estimates taken from HTA report (12) 
Unit Cost Mean Inflation Mean 
(2012/13) 
Standard 
error 
Distribution 
Unstable Angina hospital: EB05SZ £1059 1.13829 £1205.45 120.5447 GAMMA 
Revasc. Hospital mixture of HRG codes £5011.81 1.13829 £5704.88 570.4883 GAMMA 
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MI Hospital: EB107 £1290.88 1.13829 £1469.39 146.9393 GAMMA 
First Outpatient £137.28 1.13829 £156.26 15.62642 GAMMA 
Subsequent appointment £91.37 1.13829 £104.01 10.40054 GAMMA 
GP visit year1  £102 1.13829 £116.11   CONSTANT 
GP visit year 2 £91.37 1.13829 £104.01   CONSTANT 
Fatal CHD (Palmer (47) Inflated) £591.52 1.13829 £673.32 67.332 GAMMA 
Fatal stroke (Youman (46) inflated) £3688.23 1.13829 £4198.27 419.8267 GAMMA 
First year stroke £8066.18 1.13829 £9181.63 918.1635 GAMMA 
Subsequent year stroke £2266.16 1.13829 £2579.54 257.9542 GAMMA 
Glytrin Spray £10.47 1.13829 £11.92   CONSTANT 
Isosorbide mononitrate £11.24 1.13829 £12.79   CONSTANT 
Verapamil  £41.98 1.13829 £47.79   CONSTANT 
Atenolol £30.24 1.13829 £34.42   CONSTANT 
Aspirin £6.65 1.13829 £7.57   CONSTANT 
Ramipril £75.09 1.13829 £85.47   CONSTANT 
ARB £210.27 1.13829 £239.35   CONSTANT 
Clopidogrel £460.27 1.13829 £523.92   CONSTANT 
 
10.6 MICROVASCULAR EVENTS 
 Renal Failure 10.6.1
The cost of renal failure was estimated for the UK using relevant published studies. A recent costing 
study reported the costs of dialysis types (48). The prevalence of dialysis and transplants were taken 
from a second study reporting the prevalence of renal failure in the UK in 2008 (49). The cost of renal 
transplantation was taken from a costing study investigating the cost-effectiveness of renal 
transplantation (50). The overall cost was estimated as a weighted average of the treatment 
outcomes. All costs were inflated to 2012/13 prices.  
Table 48: Unit costs for renal failure 
 Cost (£) Source Inflation 
Cost 
(2012/13) 
Proportion 
Haemodialysis with overheads 34,236 (48) 1.14719 39,275 0.469 
Automated peritoneal dialysis 
(APD) 
22,160 (48) 1.14719 25422 0.045* 
Continuous ambulatory 
peritoneal dialysis (CAPD) 
16,074 (48) 1.14719 18440 0.045* 
Transplant 17,000 (50) 1.29995 22099 0.442 
Immunosuppressant 5000 (50) 1.29995 6499  
* Assumed 50% split of peritoneal dialysis types 
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 Foot Ulcers 10.6.2
The cost of foot ulcers was estimated from a US Cost of Illness study (51). The costs were converted 
from dollars to pounds using Purchasing Power Parities reported by the OECD (52). The costs were 
also inflated to UK 2012/13 prices.  
Table 49: Estimated cost of foot ulcers 
Resource component Not Infected With Cellulitis With Osteomyelitis 
Prevalence 0.874 0.09 0.036 
Mean cost per patient $178.97 $472.73 $876.52 
Mean cost per patient 
(2012/13 £) 
£158.53 £418.73 £776.40 
Standard error 15.85 41.87 77.64 
Total Cost PPP (2012/13 £) £204.19 
 
 Amputation 10.6.3
The cost of amputation in the first year of surgery and subsequent years has been reported In a 
UKPDS costing study (45). The costs were extracted and inflated to 2012/13 prices. The cost of 
amputation in the first year was £11,125 (standard error £2,123) and in subsequent years was £395 
(standard error £98). 
 Blindness 10.6.4
The cost of blindness in the first year of surgery and subsequent years has been reported In a UKPDS 
costing study (45). The costs were extracted and inflated to 2012/13 prices. The cost of blindness in 
the first year was £1,147 (standard error £232) and in subsequent years was £370 (standard error 
£62). 
10.7 CANCER 
A recent appraisal for cancer screening estimated the overall cost of breast cancer as a weighted 
average depending on the prognosis at diagnosis to be £10,452 in 2006/7 prices and £13,058 when 
inflated to 2012/13 prices (53).  
The cost of colorectal cancer was taken from a screening appraisal which reported the lifetime costs 
of colorectal cancer according to the Dukes stage of the tumour (54). The appraisal also reported the 
proportion of cancers identified at each stage, which allowed us to estimate the weighted average 
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cost of colorectal cancer. Table 50 reports the overall cost of colorectal cancer by stage of disease at 
diagnosis. 
Table 50: Estimated cost of colorectal cancer 
Resource component Dukes’ Stage A Dukes’ Stage B Dukes’ Stage C Stage D 
Number of patients 3241.92 9,431.04 7,662.72 8,841.60 
Prevalence 0.111 0.323 0.263 0.303 
Mean cost per patient £7,250.84 £12,441.41 £19,076.90 £11,945.78 
Price Inflation 1.296 
Mean cost per patient 
(2012/13) 
£9,536 £16,363 £25,090 £15,711 
Standard error  (2012/13) £953.64 £1,636.32 £2,509.03 £1,571.13 
Total Cost (2012/13) £17,699.07 
 
10.8 OSTEOARTHRITIS 
The annual cost of osteoarthritis were estimated in a report in 2010 (55). In this report the authors 
estimated the expected cost of osteoarthritis from three previous costing studies. The costs include 
GP attendance, nurse consultations, replacement surgery, help at home and prescription 
medications.  The estimated annual cost of osteoarthritis was £783 in £2008. This was inflated to 
2012/13 prices at £908 (standard error £90.88). 
10.9 DEPRESSION 
A recent trial to prevent secondary depressive episodes collected comprehensive cost data from a 
sample of individuals with depression (56). The resource uses identified in the control arm were 
extracted to estimate the costs of depression. The costs from this data (inflated to 2013 prices) were 
not implemented directly into the SPHR diabetes prevention model as this would have over-
estimated the number of GP visits. The model already accounts for GP attendance due to depression 
as described in Section 10.1. Therefore, a revised estimate of the cost of depression, excluding GP 
consultation was estimated using updated unit costs. The resource use estimates and revised unit 
cost estimates used to generate a cost of depression excluding GP utilisation are reported in Table 
51. 
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Table 51: Depression utilisation of services and total estimated cost 
 Assumption for costs Unit cost Source Inflation Annual 
utilisation 
Source Cost per 
year 
Practice nurse at surgery GP nurse face to face assume 
10 mins  
£8.83 (38) 1 2.28 (56) £20.14 
Practice nurse at home visit GP nurse face to face assume 
30 mins 
£26.50 (38) 1 0.03 (56) £0.80 
Practice nurse telephone GP nurse face to face assume 
10 mins 
£8.83 (38) 1 0.17 (56) £1.46 
Health visitor Health visitor per hour visit 30 
mins 
£35.50 (38) 1 0.08 (56) £2.66 
District nurse Community nurse 30 mins £24.50 (38) 1 0.02 (56) £0.37 
Other nurse GP nurse face to face assume 
10 mins 
£8.83 (38) 1 0.20 (56) £1.72 
HCA phelbotomist Clinical support worker 10 
mins  
£4.17 (38) 1 0.47 (56) £1.94 
Other primary care Advanced nurse with 
qualifications  
£25.00 (38) 1 0.29 (56) £7.13 
Out of hours Inflated of trial costs £22.30 (56) 1.122 0.35 (56) £8.63 
NHS direct Inflated of trial costs £21.00 (56) 1.122 0.14 (56) £3.18 
Walk-in centre Inflated of trial costs £32.24 (56) 1.122 0.32 (56) £11.39 
Prescribed medications Inflated of trial costs £7.98 (56) 1.122 11.61 (56) £103.96 
Secondary care Emergency Medicine, Any 
Investigation 
£109.0 Referen
ce costs 
1 0.39 (56) £42.51 
 £205.88 
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11 EMPLOYER COSTS 
In order to capture wider social benefits of interventions for diabetes prevention, the model was 
designed to estimate the number of sickness days taken conditional on health status. The model 
utilises data from a study that estimates productivity loss due to poor health, using days absent from 
paid employment and normal activities, EQ-5D score, International Classification of Disease (ICD) 
chapter and socio-demographic data (57). The results can be used to predict the level of productivity 
loss associated with EQ-5D values and specific disease diagnosis, measured by number of days 
absent from work. Data was used from a prospective survey of inpatients discharged from a hospital 
in Wales, United Kingdom from April 2002 to January 2009. The number of days absent from paid 
employment due to ill health (N=51,326) in the six weeks following discharge was estimated using a 
zero-inflated negative binomial regression model, which produced large spikes at 0 (zero days off 
paid employment/normal activities) and 42 days. 
The following disease diagnoses were used in the model to estimate the impact of disease on work 
productivity. 
1. Colorectal or breast cancer were associated with ICD group for neoplasms. 
2. Diabetes diagnosis was associated with ICD group for Endocrine, nutritional and metabolic 
diseases. 
3. Depression was associated with ICD group for Mental and behavioural disorders. 
4. Cardiovascular disease was associated with ICD group for diseases of the circulatory system. 
The statistical model estimated the number of days absent from work from an employed population. 
In the SPHR model the number of days absent from work was only applied to individuals in the HSE 
who reported being in employment and less than 65 years old. The simulated number of days of sick 
leave was multiplied by 8.67 to scale up the 6 week estimate to the annual cycle of the model. 
The cost of sick days to the employer was calculated based on a method derived from a previous 
study of work absenteeism (58). In the SPHR model it is assumed that the employee’s usual salary is 
not included in the employer cost because the productivity of the replacement worker would 
generate gains to the employer to compensate for the absent worker. Therefore the employer cost 
calculation includes excess costs incurred and/or loss of productivity during periods of worker 
absence. The cost to the employer of work absence due to ill health is based on the number of days 
of absence, losses due to work not completed, occupational sick pay and the cost of a replacement 
worker. Productivity losses were estimated based on the friction method, which assumes that there 
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are sufficient number of unemployed people within the UK in order to replace workers on sick leave 
after a given friction period. In this analysis we assumed a friction period of 10 weeks during which 
the employer incurs a cost due to productivity losses. After the friction period a replacement worker 
is assumed to be as productive as the employee on sick leave. During the sick leave period there are 
costs incurred because the employer is obliged to pay statutory sick pay for 28 weeks and many 
employers also provide occupational sick pay (OSP). In this analysis we assumed that the employee 
receives full pay for 15 weeks. Within the friction period this payment is subsumed into the 
employee’s usual salary, which would have been paid by the employer in the absence of sick leave. 
However, after the friction period the OSP is included in our estimate of the employer’s cost, because 
in this period the employer would be paying for the employee on sick leave in addition to a 
replacement worker. If the period of absence exceeds 15 weeks (75 days) the employer pays half the 
salary for a maximum of 16.4 weeks, and no further payments for the remaining period.  Table 52 
summarises the timing of costs incurred due to periods of absence from work. 
The average salary per day is based on a UK national average salary plus national insurance 
contributions at this salary (59) . The cost of a replacement worker was calculated in a recent report 
which estimated the logistical costs of advertising spend for a new employee, the cost of using an 
agency to recruit for a new employee and the number of days taken for internal HR processes related 
to a new employee (60). We assume that there are no additional costs to training the replacement 
worker.  
Table 52: Employer cost algorithm for days absent from work due to ill health 
Days 
absence 
Productivity lost over 
friction period 
Occupational sick pay Cost replacement worker 
1-50 £103.4 per day   
51-75  Full pay £103.4 per day Cost of advertising and 
recruitment temporary 
worker £5433. 
76-157  Half pay £51.7 per day  
157-260  None  
 
If an individual of working age dies whilst in employment, the cost of recruiting a replacement 
worker is included in the calculation of employer costs. 
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12 UTILITIES 
12.1 BASELINE UTILITY 
Baseline utilities for all individuals in the cohort were extracted from the HSE 2011. The tariffs for the 
responses to the 3 level EQ-5D were derived from a UK population study (61). Baseline utility was 
assumed to decline due to ageing. In the simulation, utility declines by an absolute decrement of 
0.004 per year. This estimate is based on previous HTA modelling in cardiovascular disease (13).  
12.2 BMI AND UTILITY 
We assumed that changes in BMI will impact on an individual’s utility. In a previous HTA for diabetes 
screening, weight loss from education interventions was associated with an increase in utility of 
0.0025 per kg change in weight. This estimate was derived from weight loss trial data in which all 
participants were overweight or obese. In the HSE population a large proportion of individuals are 
normal or underweight so it would not be appropriate to extrapolate the effects of weight loss on 
utility to these individuals. The change in utility due to changes in BMI was added to an individual’s 
EQ-5D if they had a BMI greater than 25. As a consequence, individuals with an increasing BMI above 
25 will experience a reduction in EQ-5D and obese individuals who lose weight will experience an 
increase in EQ-5D. 
12.3 UTILITY DECREMENTS 
The utility decrements for long term chronic conditions were applied to the age and BMI adjusted 
EQ-5D score. We assumed that a diagnosis of diabetes was not associated with a reduction in EQ-5D 
independent of the utility decrements associated with complications, comorbidities or depression. 
Cardiovascular disease, renal failure, amputation, foot ulcers, blindness, cancer, osteoarthritis and 
depression were all assumed to result in utility decrements. The utility decrements are measured as 
a factor which is applied to the individual’s age and BMI adjusted baseline. If individuals have 
multiple chronic conditions the utility decrements are multiplied together to give the individual’s 
overall utility decrement from comorbidities and complications, in line with current NICE guidelines 
for combining comorbidities (62).   
Due to the number of health states it was not practical to conduct a systematic review to identify 
utility decrements for all health states. A pragmatic approach was taken to search for health states 
within existing health technology assessments for the relevant disease area or by considering studies 
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used in previous economic models for diabetes prevention. Discussions with experts in health 
economic modeling were also used to identify prominent sources of data for health state utilities.  
Two sources of data were identified for diabetes related complications. A recent study from the 
UKPDS estimated the impact of changes in health states from a longitudinal cohort (63). They 
estimated the impact of myocardial infarction, ischaemic heart disease, stroke, heart failure, 
amputation and blindness on quality of life using seven rounds of EQ-5D questionnaires administered 
between 1997 and 2007.  This data was used to estimate the utility decrement for amputation and 
congestive heart failure. The absolute decrement for amputation was converted into utility 
decrement factors that could be multiplied by the individuals’ current EQ-5D to estimate the relative 
effect of the complication.  Blindness was included in the statistical model used for this analysis 
however the UKPDS analysis reported an increase in health state utility following a diagnosis with 
blindness. Discussions with the authors highlighted that this was due to treatment following formal 
classification with blindness and it was decided that this increase in health state utility should not be 
included in the cost-effectiveness model.  
Utility decrements for renal failure and foot ulcers were not available from the UKPDS study 
described above. A study by Coffey et al. (2000) was used to estimate utility decrements for renal 
failure and foot ulcers (64).  In this study, 2,048 subjects with type 1 and type 2 diabetes were 
recruited from specialty clinics. The Self-Administered Quality of Well Being index (QWB-SA) was 
used to calculate a health utility score.  
Utility decrements for cardiovascular events were taken from an HTA assessing statins to reflect the 
utility decrements in all patients (13) rather than using the UKPDS, which is only representative of a 
diabetic population. The study conducted a literature review to identify appropriate utility multipliers 
for stable angina, unstable angina, myocardial infarction and stoke. We used these estimates in the 
model and assume that transient ischaemic attack is not associated with a utility decrement in line 
with this HTA. 
We identified a systematic review of breast cancer utility studies following consultation with 
colleagues with experience in this area. The review highlighted a single burden of illness study with a 
broad utility decrement for cancer (65), rather than utilities by cancer type or disease status. This 
study was most compatible with the structure of the cost-effectiveness structure. Within this study 
1823 cancer survivors and 5469 age-, sex-, and educational attainment-matched control subjects 
completed EQ-5D questionnaires to estimate utility with and without cancer. 
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The utility decrement for osteoarthritis was taken from a Health Technology Assessment that 
assessed the clinical effectiveness and cost-effectiveness of glucosamine sulphate/hydrochloride and 
chondroitin sulphate in modifying the progression of osteoarthritis of the knee (66). 
A review of cost-effectiveness studies highlights the scarcity of studies of health-related quality of life 
in depression (67). The utility studies identified in the review described depression states by severity 
and did not adjust for comorbid conditions. Furthermore, the valuations were variable between 
studies suggesting poor consistency in the estimations. Therefore, it was difficult to apply these in 
the model. We decided to use a study which had used the EQ-5D in an RCT, for consistency with our 
utility measure (68). They report an average post treatment utility of 0.67, from which we estimated 
the utility decrement compared with the average utility reported in the HSE dataset.  The decrement 
was then converted into a relative utility reduction. 
Table 53 reports the multiplicative utility factors that are used in the model to describe health utility 
decrements from comorbid complications. The mean absolute decrement estimated in each study is 
reported alongside the baseline utility for each study. The utility factor was estimated by dividing the 
implied health utility with the comorbidity by the baseline utility. 
Table 53: Utility decrement factors  
 Mean 
Absolute 
decrement 
St. error 
absolute 
decrement 
Baseline 
Utility 
Multiplicative 
Utility Factor 
Source 
Foot ulcer -0.099 0.013 0.689 0.856 Coffey (64) 
Amputation -0.172 0.045 0.807 0.787 UKPDS (69) 
Blind 0.033 0.027 0.807 1.041 UKPDS (69) 
Renal failure -0.078 0.026 0.689 0.887 Coffey (64) 
Stable Angina    0.801 Ward HTA (13) 
Unstable Angina y1    0.770 Ward HTA (13) 
Unstable Angina y2    0.770 Ward HTA (13) 
Myocardial 
Infarction y1 
   0.760 Ward HTA (13) 
Myocardial 
Infarction y2 
   0.760 Ward HTA (13) 
Transient Ischaemic 
Attack  
   1.000 Ward HTA (13) 
Stroke y1    0.629 Ward HTA (13) 
Stroke y2    0.629 Ward HTA (13) 
Breast Cancer -0.060  0.800 0.913 Yabroff (65) 
Colorectal Cancer -0.060  0.800 0.913 Yabroff (65) 
Osteoarthritis -0.101    Black HTA (66) 
Depression 
-0.116  0.7905 0.875 Benedict (68) 
Congestive Heart 
Failure 
-0.101 0.032  0.875 UKPDS (69) 
UKPDS baseline utility 0.807; HSE baseline 0.7905 
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13 MODEL VALIDATION 
The SPHR model has undergone a thorough process of error checking and internal and external 
validations. Model verification (comprising error checking and internal validation) included ensuring 
that mean PSA sampling values corresponded to mean parameter values, following individuals over 
time as they went through the model to ensure that trajectories were behaving as expected in 
response to treatments and interventions, and building the QRISK2 (21) separately in Excel to ensure 
that CVD predictions were accurate. We also tested the ability of the model to predict the results of 
the UKPDS outcomes model v2 (19), which acted as an internal validation for those outcomes 
encoded by UKPDS in the SPHR model, and an external validation for cardiovascular outcomes that 
were encoded in the SPHR model using QRISK2 (see below). As a consequence of this we realised 
that the SPHR model was vastly overestimating the incidence of renal failure, and resulted in our 
switching to UKPDS v1 for this outcome (11). 
We developed four tests to compare model outcomes with reported data from external data 
sources. The first test assessed the incidence of type-2 diabetes in the population and sub-groups of 
the population and compared the results with incidence data from the EPIC study. This tested 
whether the Whitehall II glycaemia trajectories were performing adequately. The second validation 
study simulated data from the HSE 2003 cohort for eight years to observe predicted distributions of 
metabolic risk factors and the prevalence of health outcomes and compared them with the HSE 2011 
cohort. The third validation exercise simulated the ADDITION diabetes trial and observed whether 
similar outcomes were observed compared with the data. Finally, a diabetic cohort was simulated in 
the model to compare outcomes with the UKPDS data. 
13.1 PREDICTION OF DIABETES INCIDENCE 
This validation assessed whether the Whitehall II model for glycaemia trajectories predicted 
incidence of diabetes diagnosed by the HbA1c test in sub-groups of patients from the HSE2003 
cohort. Its objective was to assess the ability of the Whitehall II trajectories in the model to predict 
the recorded incidence of diabetes.  
 Methods 13.1.1
Data summarising the incidence of type 2 diabetes was obtained from the EPIC Norfolk cohort (70), 
which of similar studies was thought to be the most likely to represent the population distribution 
found in the HSE. EPIC Norfolk consists of 5735 individuals aged between 40 and 74, without 
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diabetes at baseline, who were followed for three years after an initial HbA1c test in the late 1990s. 
Diabetes incidence rates included both doctor diagnosed diabetes and diagnosis due to HbA1c≥6.5 in 
the follow-up period. Diabetes incidence was recorded for the total population and for sub-groups 
based upon their initial HbA1c status. 
The model was run over a three year time course sampling only those individuals aged between 40 
and 74 at the start of simulation. The starting population was generated from HSE 2003 rather than 
HSE 2011, as the dataset was more contemporaneous with the EPIC study and better reflected the 
population distribution within the IGR categories. Individuals with diabetes were excluded from the 
starting population. Diabetes incidence after three years of simulation was determined for subgroups 
of individuals who were initially measured with a high level of impaired glucose regulation (IGR) 
(HbA1c = 6.0-6.4%) or moderate IGR (HbA1c = 5.5-5.9%), and for the total population. Diabetes 
incidence in the model was represented by the total percentage of individuals in which HbA1c was 
measured as ≥6.5 in two consecutive health checks, rather than those with a diagnosis of diabetes, in 
order to reflect the EPIC data. 
 Results & Discussion 13.1.2
The incidence of diabetes in the simulation is summarised in Table 54. The diabetes model 
overestimates diabetes incidence in both the total population and in the high IGR population, but 
underestimates diabetes incidence in the moderate IGR population. The overestimation of total 
population incidence is likely to be a consequence of the overestimation of diabetes incidence in the 
high IGR group. 
Baseline populations are relatively similar and cannot account for the large differences in diabetes 
incidence in the high and moderate IGR subgroups. We investigated whether the differences in 
incidence between high and moderate groups are due to differences between the Whitehall II cohort 
and the EPIC data. HbA1c values were collected in phases 7 and 9 of the Whitehall II cohort. The 
incidence of diabetes (defined by HbA1c greater than 6.5) after 5 years observation in the cohort was 
2.5%. The incidence among high IGR was 44.2% and among moderate IGR was 5.12%. Therefore, the 
Whitehall II cohort does observe a much greater incidence of diabetes among those individuals with 
high IGR than the EPIC cohort. However, the low incidence of diabetes among those individuals with 
moderate IGR is not reflected in the Whitehall II cohort data.  
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Table 54: Comparison of simulated outcomes with the EPIC-Norfolk cohort  
 Diabetes Prevention Model 
(N=50000) 
EPIC-Norfolk (N=5735) 
Baseline characteristics 
 Mean  Standard 
deviation 
Mean  Standard deviation 
Age (years) 55.1 9.8 57.4 9.4 
Male (%) 45.2 N/A 43.3 N/A 
BMI (kg/m
2
) 27.7 5.0 25.9 3.7 
Diabetes incidence after 3 years 
Subset of individuals Percentage of 
total 
individuals 
Mean diabetes 
incidence (%)* 
Percentage of 
total 
individuals 
Mean diabetes 
incidence 
(%)** 
95% CI 
High IGR  
(HbA1c = 6.0-6.4) 
5.9 11.2 6.5 7.0 4.8-10.1 
Moderate IGR (HbA1c 
= 5.5-5.9) 
27.9 0.2 24.4 1.5 1.0-2.3 
Total Population 100 2.2 100 1.3 1.0-1.5 
BMI Body Mass Index; CI Confidence Interval 
*HbA1c≥6.5 in two consecutive health checks; **HbA1c≥6.5 and/or doctor diagnosis of diabetes 
 
The low diabetes incidence among individuals with moderate IGR is likely to be a consequence of the 
way the trajectories for HbA1c work in the model. Most individuals have a gradually increasing 
HbA1c as they age, meaning that three years is insufficient in the vast majority of cases for a 
someone with moderate IGR to progress to diabetes. Equally, many more people with high IGR will 
progress to diabetes as they are already close to the threshold. We suggest that the model may be 
more accurate at predicting diabetes incidence over a longer time period due to the nature of the 
quadratic equations used to predict HbA1c.  
Finally, it is possible that some individuals within the EPIC study who learnt they had high IGR at the 
beginning of the study would have changed their behaviour as a consequence of their high risk of 
diabetes or as a consequence of undergoing health screening (although this was not reported). 
Changes to diet and exercise would impact upon HbA1c and lead to underestimates of diabetes 
incidence. No such effect would occur in the model as individuals are unaware of their HbA1c status. 
13.2 USING DATA FROM HSE 2003 TO PREDICT HSE 2011 
This validation aimed to observe whether the Whitehall II statistical model predicted the future 
distribution of metabolic risk factors and prevalence of diabetes in age-selected sub-groups from the 
HSE 2003 data.  We were aware that the Whitehall II cohort does not necessarily describe 
prospective changes in the population metabolic risk factors that were forecast. This analysis 
identified the potential error in the Whitehall II statistical models to describe temporal changes in 
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the risk profile of the population. The analysis also monitored whether the prevalence of diabetes 
and cardiovascular disease were correctly estimated for the age-groups. The objective was to 
evaluate the ability of the model to reproduce observed changes in population wide metabolic data 
between two time points.  
 Methods 13.2.1
Data from HSE 2003 was chosen as a starting point as values were obtainable for most of the 
parameters used in HSE 2011 (71). The total sample size of HSE 2003 is 18,553, which is considerably 
larger than the sample size of HSE 2011 (10,617).  
Data was extracted from HSE 2003 using similar methods to those used for extraction of data from 
HSE 2011. A value for one of the parameters used in HSE 2011 was unavailable.  This referred to 
diagnosis of “diabetes from blood sample or doctor diagnosis”. However, the question on “doctor 
diagnosed diabetes” was thought to be adequate to assign individuals a diagnosis of diabetes. 
Individuals with a prior diagnosis of diabetes were included for the purposes of validation, but 
individuals under the age of 16 (n=3717) were removed from the dataset, resulting in a final sample 
size of 14,836. Missing data was estimated in the same way as described in section 6.4. 
As for HSE 2011, QRISK scores and EQ-5D scores were calculated for all individuals. To align ethnicity 
in HSE 2003 to QRISK, all ‘Asian’ and ‘British Asian’ individuals were assumed to be ‘Indian’ (largest 
Asian subgroup and median risk ratio within all Asian subgroups in QRISK), all ‘Black’ and ‘British 
Black’ individuals were assumed to be ‘Black Caribbean’ (largest Black subgroup) and ‘Mixed Race’ 
individuals were assumed to be ‘Other’. For those with a history of cardiovascular disease, the nature 
of the illness was randomly assigned according to age and sex-related probabilities of different types 
of cardiovascular event. The characteristics of HSE 2003 are described in Table 55.  
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Table 55: Characteristics of the final sample from HSE 2003 (N=14836), including individuals with diagnosed diabetes 
 Number Percentage  
Male 6602 44.50  
White 13661 92.08  
IMD1 (least deprived) 3334 22.47  
IMD2 2950 19.88  
IMD3 2929 19.74  
IMD4 3059 20.62  
IMD5 (most deprived) 2564 17.28  
Non-smoker 7445 50.18  
Anti-hypertensive treatment 2178 14.68  
Statins 791 5.33  
Diagnosed Diabetes 611 4.12  
Cardiovascular Disease (CVD) 1119 7.54  
SUBTYPES OF CVD Number Percentage of CVD   
Stable Angina 411 36.73  
Unstable Angina 122 10.90  
MI 246 21.98  
TIA 69 6.17  
Stroke 271 24.22  
 Mean Standard Deviation Median 
Age (years) 48.21 18.49 47.00 
BMI (kg/m
2
) 26.96 5.01 26.35 
Total Cholesterol (mmol/L) 5.70 1.18 5.60 
HDL Cholesterol (mmol/L) 1.53 0.39 1.50 
HbA1c (%) 5.34 0.73 5.20 
Systolic Blood Pressure (mm Hg) 129.30 19.13 126.50 
EQ-5D (TTO) 0.862 0.223 1.000 
BMI Body Mass Index; IMD Index of Multiple Deprivation; EQ-5D 5 dimensions Euroqol (health related quality of 
life index); MI Myocardial Infarction; TIA Transient Ischaemic Attack 
 
For the purposes of validation, it was also necessary to include the characteristics of patients with 
diagnosed diabetes in the HSE 2011 sample as a comparison with the projected HSE 2003 data. The 
characteristics of HSE 2011 including diagnosed diabetics are summarised in Table 56. 
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Table 56: Characteristics of the final sample from HSE 2011 (N=8610), including individuals with diagnosed diabetes 
 Number Percentage  
Male 3822 44.39  
White 7719 89.65  
IMD1 (least deprived) 1774 20.60  
IMD2 1823 21.17  
IMD3 1830 21.25  
IMD4 1597 18.55  
IMD5 (most deprived) 1586 18.42  
Non-smoker 4550 52.85  
Anti-hypertensive treatment 1544 17.93  
Statins 929 10.79  
Diagnosed Diabetes 572 6.64  
Cardiovascular Disease (CVD) 639 7.42  
SUBTYPES OF CVD Number Percentage of CVD   
Stable Angina 232 36.31  
Unstable Angina 83 12.99  
MI 137 21.44  
TIA 40 6.26  
Stroke 147 23.00  
 Mean Standard Deviation Median 
Age (years) 49.64 18.70 49.00 
BMI (kg/m
2
) 27.39 5.36 26.64 
Total Cholesterol (mmol/l) 5.42 1.07 5.40 
HDL Cholesterol (mmol/l) 1.52 0.44 1.50 
HbA1c (%) 5.73 0.78 5.60 
Systolic Blood Pressure (mm Hg) 126.50 17.00 124.50 
EQ-5D (TTO) 0.825 0.244 0.848 
BMI Body Mass Index; IMD Index of Multiple Deprivation; EQ-5D 5 dimensions Euroqol (health related quality of 
life index); MI Myocardial Infarction; TIA Transient Ischaemic Attack 
 
Individuals from HSE 2003 were grouped into five different age bands (A=20-29, B=30-39, C=40-49, 
D=50-59, E=60-69), which were simulated separately. 50,000 individuals were generated for each age 
group then the model was run over a time course of 8 years to simulate the aging of individuals 
between 2003 and 2011. For each age group, separate sets of distribution statistics were obtained 
for HbA1c, BMI, systolic blood pressure, total and HDL cholesterol, diabetes prevalence and 
cardiovascular disease prevalence before and after simulation. This was compared with data 
extracted from equivalent age bands for HSE 2011 (A’=28-37, B’=38-47, C’=48-57, D’=58-67, E’=68-
77).  
 Results & Discussion 13.2.2
Distribution statistics for each age group are presented in Table 57 -  
Table 61. The differences between the HSE 2003 modelled projection and the HSE 2011 data are 
summarised as follows: 
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- There is a general tendency for the model to slightly under-predict mean HbA1c (Figure 12). 
- There is a general over-prediction of systolic blood pressure in the model in all age groups ( 
- Figure 13). 
- BMI is over-predicted in the model, particularly in younger age groups ( 
- Figure 14). 
- The model slightly over-predicts cholesterol levels in the youngest age group, but under-
predicts it for the older groups (Figure 15).  
- EQ-5D is slightly over-predicted in the model ( 
- Figure 16). 
- The model over-predicts diabetes diagnoses in all age groups apart from the middle one (age 
48-47), where the HSE 2011 has an unexpected peak in diabetes diagnoses (Figure 17). The 
over-prediction is most evident in the youngest age groups. 
- The model predicts cardiovascular disease quite accurately, although slightly over-predicts in 
the oldest age groups ( 
- Figure 18). 
Table 57: Comparison of simulated outcomes from HSE 2003 with actual data from HSE 2011: Age group A - 20-29 
A HSE 2003: Before simulation 
(n=1855) 
HSE 2003: After simulation 
(n=49607) 
HSE 2011:  
(n=1339) 
Age 20-29 Age 28-37 Age 28-37 
Mean SD Median Mean SD Median Mean SD Median 
Age (years) 24.8 2.9 25.0 32.8 2.8 33.0 32.5 2.9 33.0 
HbA1c (%) 5.0 0.4 5.0 5.2 1.0 5.2 5.4 0.6 5.4 
BMI kg/m
2
 25.1 5.0 24.2 27.7 5.5 26.8 26.8 5.4 25.7 
Systolic Blood 
Pressure (mm 
Hg) 
119.0 11.9 119.0 125.2 15.6 125.3 118.2 12.6 117.5 
Total 
Cholesterol 
(mmol/l) 
4.9 1.0 4.8 5.3 0.9 5.3 5.0 1.0 4.9 
HDL 
Cholesterol 
(mmol/l) 
1.5 0.4 1.5 1.5 0.4 1.5 1.5 0.4 1.5 
EQ-5D 0.929 0.153 1.000 0.901 0.212 1.000 0.894 0.186 1.000 
  Number Percentage Number Percentage Number Percentage 
Diabetes 14 0.8 1448 2.9 16 1.2 
Cardiovascular 
Disease  
7 0.4 343 0.7 6 0.4 
BMI Body Mass Index; SD Standard Deviation 
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Table 58: Comparison of simulated outcomes from HSE 2003 with actual data from HSE 2011: Age group B - 30-39 
B HSE 2003: Before simulation 
(n=2788) 
HSE 2003: After simulation 
(n=49382) 
HSE 2011:  
(n=1595) 
Age 30-39 Age 38-47 Age 38-47 
Mean SD Median Mean SD Median Mean SD Median 
Age (years) 34.7 2.9 35.0 42.7 2.9 43.0 42.5 2.9 42.0 
HbA1c (%) 5.1 0.6 5.1 5.4 1.0 5.3 5.6 0.7 5.5 
BMI kg/m
2
 26.8 5.2 26.0 29.0 5.7 28.2 27.5 5.2 26.6 
Systolic Blood 
Pressure (mm 
Hg) 
120.0 12.6 119.0 127.4 15.1 126.9 121.0 13.9 120.0 
Total 
Cholesterol 
(mmol/l) 
5.4 1.1 5.3 5.4 0.9 5.4 5.4 0.9 5.3 
HDL 
Cholesterol 
(mmol/l) 
1.5 0.4 1.4 1.6 0.4 1.5 1.5 0.4 1.4 
EQ-5D 0.911 0.178 1.000 0.887 0.223 1.000 0.849 0.226 1.000 
  Number Percentage Number Percentage Number Percentage 
Diabetes 37 1.3 2245 4.5 50 3.1 
Cardiovascular 
Disease  
13 0.5 777 1.6 24 1.5 
BMI Body Mass Index; SD Standard Deviation 
 
Table 59: Comparison of simulated outcomes from HSE 2003 with actual data from HSE 2011: Age group C - 40-49 
C HSE 2003: Before simulation 
(n=2581) 
HSE 2003: After simulation 
(n=48882) 
HSE 2011:  
(n=1412) 
Age 40-49 Age 48-57 Age 48-57 
Mean SD Median Mean SD Median Mean SD Median 
Age (years) 44.2 2.9 44.0 52.2 2.9 52.0 52.3 2.9 52.0 
HbA1c (%) 5.3 0.8 5.2 5.6 1.1 5.4 5.8 0.9 5.6 
BMI kg/m
2
 27.4 5.2 26.7 29.1 5.7 28.4 28.4 5.5 27.5 
Systolic Blood 
Pressure (mm 
Hg) 
124.9 16.0 123.0 131.4 15.9 131.0 127.6 15.9 125.5 
Total 
Cholesterol 
(mmol/l) 
5.7 1.1 5.6 5.5 0.9 5.4 5.7 1.0 5.7 
HDL 
Cholesterol 
(mmol/l) 
1.5 0.4 1.5 1.6 0.4 1.6 1.6 0.5 1.5 
EQ-5D 0.882 0.204 1.000 0.857 0.246 1.000 0.807 0.261 0.848 
  Number Percentage Number Percentage Number Percentage 
Diabetes 57 2.2 3286 6.7 108 7.6 
Cardiovascular 
Disease  
46 1.8 2183 4.5 64 4.5 
BMI Body Mass Index; SD Standard Deviation 
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Table 60: Comparison of simulated outcomes from HSE 2003 with actual data from HSE 2011: Age group D - 50-59 
D HSE 2003: Before simulation 
(n=2564) 
HSE 2003: After simulation 
(n=47187) 
HSE 2011:  
(n=1387) 
Age 50-59 Age 58-67 Age 58-67 
Mean SD Median Mean SD Median Mean SD Median 
Age (years) 54.6 2.8 55.0 62.6 2.8 63.0 62.6 2.8 63.0 
HbA1c (%) 5.4 0.7 5.3 5.7 1.1 5.6 5.9 0.8 5.8 
BMI kg/m
2
 27.9 4.9 27.2 29.1 5.4 28.4 28.3 5.2 27.6 
Systolic Blood 
Pressure (mm 
Hg) 
131.5 17.0 130.0 136.1 15.6 136.3 132.9 17.5 131.5 
Total 
Cholesterol 
(mmol/l) 
6.1 1.1 6.0 5.4 1.0 5.4 5.9 1.1 5.9 
HDL 
Cholesterol 
(mmol/l) 
1.6 0.4 1.5 1.7 0.4 1.6 1.6 0.5 1.5 
EQ-5D 0.840 0.245 1.000 0.822 0.266 1.000 0.787 0.265 0.796 
  Number Percentage Number Percentage Number Percentage 
Diabetes 109 4.3 4814 10.2 121 8.7 
Cardiovascular 
Disease  
157 6.1 5476 11.6 139 10.0 
BMI Body Mass Index; SD Standard Deviation 
 
Table 61: Comparison of simulated outcomes from HSE 2003 with actual data from HSE 2011: Age group E - 60-69 
E HSE 2003: Before simulation 
(n=1968) 
HSE 2003: After simulation 
(n=43050) 
HSE 2011:  
(n=989) 
Age 60-69 Age 68-77 Age 68-77 
Mean SD Median Mean SD Median Mean SD Median 
Age (years) 64.2 2.9 64.0 72.1 2.9 72.0 72.2 2.8 72.0 
HbA1c (%) 5.6 0.7 5.5 5.9 1.1 5.7 6.1 0.9 5.9 
BMI kg/m
2
 28.1 4.6 27.6 28.8 5.2 28.2 28.5 4.9 28.1 
Systolic Blood 
Pressure (mm 
Hg) 
137.8 18.9 136.0 139.7 16.3 139.5 134.5 17.0 133.0 
Total 
Cholesterol 
(mmol/l) 
6.2 1.0 6.2 5.2 1.1 5.2 5.8 1.1 5.8 
HDL 
Cholesterol 
(mmol/l) 
1.6 0.4 1.5 1.6 0.4 1.6 1.6 0.5 1.5 
EQ-5D 0.813 0.250 0.848 0.790 0.272 0.802 0.744 0.278 0.796 
  Number Percentage Number Percentage Number Percentage 
Diabetes 165 8.4 6836 15.9 152 15.4 
Cardiovascular 
Disease  
299 15.2 9741 22.6 199 20.1 
BMI Body Mass Index; SD Standard Deviation 
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Figure 12: Comparison of actual mean HbA1c levels from different age groups within HSE 2011, with predicted mean 
HbA1c levels after 8 years simulation using HSE 2003 baseline data.
 
 
Figure 13: Comparison of actual mean systolic blood pressure from different age groups within HSE 2011, with predicted 
mean systolic blood pressure after 8 years simulation using HSE 2003 baseline data. 
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Figure 14: Comparison of actual mean BMI from different age groups within HSE 2011, with predicted mean BMI after 8 
years simulation using HSE 2003 baseline data. 
 
Figure 15: Comparison of actual mean total cholesterol from different age groups within HSE 2011, with predicted mean 
total cholesterol after 8 years simulation using HSE 2003 baseline data. 
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Figure 16: Comparison of actual mean EQ-5D values from different age groups within HSE 2011, with predicted mean EQ-
5D values after 8 years simulation using HSE 2003 baseline data. 
 
Figure 17: Comparison of actual diabetes prevalence from different age groups within HSE 2011, with predicted diabetes 
prevalence after 8 years simulation using HSE 2003 baseline data. 
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Figure 18: Comparison of actual cardiovascular disease prevalence from different age groups within HSE 2011, with 
predicted cardiovascular disease prevalence after 8 years simulation using HSE 2003 baseline data.  
 
 
13.3 PREDICTING THE RESULTS OF THE ADDITION STUDY 
The ADDITION trial monitored metabolic risk factors, cardiovascular disease and mortality of 
recruited patients. We compared the data reported in key publications from the ADDITION trial to 
observe whether similar outcomes were identified in the simulation. The objective was to evaluate 
the model’s ability to simulate the results of a trial comparing an intensive intervention with usual 
care. 
 Methods 13.3.1
ADDITION is a cluster-randomised controlled trial of screening for type 2 diabetes that took place in 
the UK (Cambridge and Leicester), Denmark and the Netherlands (72). The trial aimed to evaluate the 
efficacy and cost-effectiveness of population based screening for type-2 diabetes, and the effect of 
an intensive intervention compared with usual care for people diagnosed with diabetes. The second 
aspect of the study was used for validation of the model. Evaluation of the intensive intervention was 
based on cardiovascular outcomes data from the entire ADDITION trial (73).  
Baseline patient level data for the study was obtained from the ADDITION authors and used to 
populate the model. Evaluation of the model’s ability to predict the effects of the intensive 
intervention was undertaken by comparing two versions of the model in which the individuals with 
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diabetes from the ADDITION-Europe study were subjected either to usual care or to an intensive 
intervention. In the ADDITION-Europe trial, intensive intervention included extra sessions with the 
GP and practice nurse, referral to a dietician, intensive optimisation of cholesterol levels, blood 
pressure and blood glucose over the course of the first year after diagnosis, use of a glucometer and 
a pack of educational materials for the patient. Many of these features could not be added directly to 
the model, so instead the difference in five year metabolic outcomes between the two trial arms was 
used. The only metabolic parameters that showed significant changes in the study after five years of 
intensive intervention when compared with usual care were SBP (-2.86 mm Hg), total cholesterol (-
0.27 mmol/l) and HbA1c (-0.08%). For the purposes of simulation, these changes were applied for the 
first five years to all individuals in the intensive treatment arm of the model, and then cardiovascular 
outcomes were assessed. 
 Results & Discussion 13.3.2
In common with ADDITION-Cambridge, the SPHR Diabetes model does not predict a significant 
difference in mortality between screened and unscreened populations. Overall mortality rates are 
about one third higher in the Diabetes Prevention model than in the ADDITION-Cambridge study, 
indicating that the model is slightly over-predicting mortality.  
The trajectories of all four metabolic parameters differ somewhat between the model and the 
ADDITION-Europe data (Table 62). In both arms of the ADDITION study, there is a reduction after 
diagnosis in the mean values of BMI, SBP, total cholesterol and HbA1c. However, in the SPHR 
Diabetes model there is an increase in HbA1c and BMI, whilst the reduction in SBP and total 
cholesterol is lower than that seen ADDITION-Europe. This indicates that the model may not be 
accurately reflecting improvements in health that occur as a consequence of normal care after 
diabetes diagnosis. 
Table 62: Comparison of the Diabetes Prevention Model and the ADDITION-Europe study: metabolic data at baseline and 
after 5 years of follow-up/simulation 
  
SPHR Diabetes Model  ADDITION-Europe Trial  
Before 
Simulation 
After Simulation Before Treatment After Treatment 
Both Arms 
(n=50,000) 
Normal Care 
(n=50,000) 
Intensive 
Intervention 
(n=50,000) 
Normal Care 
(n=1,379) 
Intensive 
Intervention 
(n=1,678) 
Normal Care 
(n=1,285) 
Intensive 
Intervention 
(n=1,574) 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
BMI 
(kg/m
2
) 
31.6 5.5 32.3 5.8 32.3 5.8 31.6 5.6 31.6 5.6 31.0 5.6 31.1 5.7 
SBP  
(mm Hg) 
149.0 21.5 146.2 19.9 143.8 19.7 149.8 21.3 148.5 22.1 138.1 17.6 134.8 16.8 
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Total 
Cholesterol 
(mm/l) 
5.5 1.1 4.8 1.2 4.5 1.2 5.6 1.2 5.5 1.1 4.4 0.9 4.2 0.9 
HbA1c (%) 7.0 1.5 7.7 0.8 7.6 0.8 7.0 1.5 7.0 1.6 6.7 0.95 6.6 0.95 
SPHR School for Public Health Research; ADDITION Anglo-Danish-Dutch Study of Intensive Treatment in People with 
Screen Detected Diabetes in Primary Care; BMI Body Mass Index; SBP Systolic Blood Pressure; HbA1c Glycated 
Haemoglobin; SD Standard Deviation 
 
In the ADDITION-Europe study, cardiovascular events, cardiovascular mortality and all-cause 
mortality were measured at the five year time point. Table 63 summarises these results and 
compares them with the simulated outcomes from the model. CVD and mortality are slightly over-
predicted in both arms of the model compared with the trial, likely as a consequence of the higher 
metabolic values predicted by the model. However, the model predicts the slight but non-significant 
improvement in outcomes between the two arms of the trial fairly accurately. 
Table 63: The ADDITION trial: comparison of simulated outcomes with the ADDITION-Europe study 
  
SPHR Diabetes Model  ADDITION-Europe  
Normal Care 
Intensive 
Intervention 
Hazard Ratio Normal Care 
Intensive 
Intervention 
Hazard Ratio 
Percentage Percentage Mean 95% CI Percentage Percentage Mean 95% CI 
Cardiovascular 
events 
9.9 9.5 0.96 0.93-1.00* 8.5 7.2 0.83 0.65-1.05 
Cardiovascular 
mortality 
2.8 2.7 0.95 0.88-1.02 1.6 1.5 0.88 0.51-1.51 
All cause 
mortality 
9.0 8.8 0.98 0.94-1.03 6.7 6.2 0.91 0.69-1.21 
CI 95% Confidence Interval *The upper bound for the 95% CI is slightly below 1, meaning that the 
intervention is just significantly different at p=0.05 
 
13.4 UKPDS MAJOR EVENTS IN DIABETES 
The UKPDS has recorded long-term outcomes for individuals with diabetes in the UK. It is currently 
used in many economic models of diabetes to predict the incidence of micro- and macro-vascular 
events as well as mortality in diabetes. In the SPHR diabetes model it is only used to estimate the 
incidence of renal failure, blindness, amputation and ulcers. This validation is hence an internal 
validation for the microvascular outcomes of the SPHR model, and an external validation for other 
outcomes. The aim was to evaluate if the incidence of microvascular, macrovascular and fatal 
complications of diabetes are similar to those estimated in the UKPDS outcomes model. 
 Methods 13.4.1
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The UKPDS outcomes model 2 reports the simulated percentage of individuals with major events 
after 10 years from the UKPDS model (19). The SPHR diabetes model was tested by generating 
50,000 individuals aged between 25 and 65 with diabetes from the HSE 2011. The model was run 
over a time course of 10 years to obtain figures for 10 year prevalence. 
 Results & Discussion 13.4.2
The incidences of major events in the UKPDS Outcomes model and the SPHR diabetes model are 
reported in Table 64. 
Table 64: Major events in the UKPDS and SPHR simulation 
10 year prevalence (%) UKPDS Outcomes Model 2 
(N=3984) 
SPHR model (N=50000) 
Renal Failure 0.5 0.4 
Ulcer 1.8 1.8 
Amputation 1.5 1.9 
2nd Amputation 0.44 0.6 
Blindness 2.9 3.0 
MI 9.9 5.1 
Stroke 6.2 6.1 
Heart Failure 4 5.1 
Death 22.5 13.9 
 
The validation indicates that the SPHR Diabetes model predicts very similar 10 year prevalence values 
to the UKPDS outcomes model for those outcomes which are determined through the UKPDS itself. 
The exception to this is amputation, which is over-predicted in the SPHR model compared with the 
UKPDS model. In the UKPDS outcomes model, amputation is specified using a different algorithm for 
people with a pre-existing ulcer or for those without. To simplify things, the SPHR diabetes model 
uses a single algorithm to specify amputation, with the addition of an extra parameter for pre-
existing ulcer estimated from the difference in the hazard ratio for amputation between individuals 
with or without pre-existing ulcer in the UKPDS. This is likely to be the source of the discrepancy in 
estimation of amputation prevalence, as alteration of this parameter has a large effect on prevalence 
of amputation (data not shown). However, overall this validation indicates that the UKPDS model has 
been correctly implemented in the SPHR Diabetes model.  
The UKPDS model predicts a higher incidence of MI than is simulated in the SPHR model using the 
QRISK algorithm to predict first cardiovascular event. Other studies have found that the UKPDS 
Outcomes model v1 predicts higher risks for these events than are observed in other datasets (74), 
although the new UKPDS outcomes model v2 has been shown to predict lower incidence of these 
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outcomes than the UKPDS model v1. The lower still prediction of the SPHR model may reflect recent 
medical developments. Alternatively, given that the predictions for stroke are fairly accurate, the 
discrepancy may be in the way that CVD events are distributed rather than the number of CVD 
events per se.  
The incidence of heart failure is higher in the SPHR simulation compared with the UKPDS. The 
incidence of congestive heart failure is simulated from the Framingham risk algorithm in men and 
women. It is possible that the higher incidence of heart failure is due to differences in the risk of 
heart failure in the UK and US. We have sought a UK algorithm for estimating the risk of congestive 
heart failure, however none were found. We considered whether it would be best to change the 
model to use the UKPDS equation only in diabetic patients. However, we dismissed this idea because 
this would assume that non-diabetics were not at risk of congestive heart failure. However, it is likely 
that the SPHR model currently over-estimates the incidence of congestive heart failure.   
Finally, mortality is under-predicted in the SPHR model compared with the UKPDS outcomes model. 
One potential cause of this discrepancy is the incorporation in the SPHR model of improvements in 
diabetes care that may have been made since the UKPDS trial. Given that the SPHR model actually 
over-estimates mortality in some of the other validations (e.g. ADDITION) this is probably not a 
concern.  
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14 DIABETES PREVENTION INTERVENTIONS  
14.1 IDENTIFYING INTERVENTIONS 
We divided the potential interventions into the following population groups: 
a) For the general population to reduce risk factors for diabetes; 
b) For people with non-diabetic hyperglycaemia; 
c) For people within the general population who are at high risk of developing non-diabetic 
hyperglycaemia and type 2 diabetes, including identification and risk assessment (eg. 
overweight or obese, low socioeconomic status, South Asian or those with CVD). 
Systematic reviews produced for NICE projects already exist for points a and b (75;76). We have 
undertaken a literature review for population-level interventions (point c). This was limited to a 
review of systematic reviews due to the large number of studies in this area. We used interventions 
identified within a stakeholder workshop to help develop the searches. We did not identify any 
evidence for walking and cycling/ transport policy interventions within our review of systematic 
reviews. However, an existing NICE report describes a recent review of this area (77).  
All of the above reviews are made up of heterogeneous studies in terms of population, intervention, 
comparator, outcomes and country. Meta-analysis was not appropriate for many of the studies, 
therefore the effectiveness and cost of each intervention assessed was generally based upon one 
specific study. Table 65 shows the interventions we have identified for possible comparison within 
the model. It also lists interventions which we have identified, but which were not considered to be 
relevant or have studies of sufficient quality, based upon the criteria below:  
Intervention grouping level 
1. Intervention is not generalisable to the UK in any of the studies due to substantial differences 
in current practice (e.g. transport infrastructure in the Netherlands), or populations (e.g. 
intervention provided to only a Hispanic population);  
2. Intervention is not effective in any of the studies within the systematic reviews;  
3. Intervention already exists as standard practice within the UK. 
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Individual study level 
1. No outcomes reported related to diet, exercise or blood glucose levels (e.g. only impact upon 
traffic congestion reported for transport policy), or only subjective outcomes reported (e.g. 
only increased knowledge about diet, or intention to exercise reported); 
2. Only poor evidence exists around intervention effectiveness due to: 
a. short term follow up; 
b. poor study design; 
c. poor reporting of the study (e.g. the intervention, comparator, population, outcomes 
or study design are unclear). 
Table 65: Types of interventions considered for inclusion in the model 
Intervention Coverage Selected for Inclusion Selected for Exclusion 
General Population (Indiscriminate 
National Policy) 
Taxation Agricultural Policy 
Communities  Workplace  Transport policy 
Retailer policy 
Community education 
programme 
High-risk individuals Non-diabetic hyperglycaemic 
(including exploring frequency of 
repeat tests) 
Children/ early years / 
jobseekers/ gestational 
diabetes/ ethnicity 
 
 
Table 66 shows key details of the studies which were considered for analysis within the model. No 
effectiveness evidence was identified within our search for systematic reviews around the following 
interventions: 
1. Affordable access to healthier foods ; 
2. Change in agricultural policy; 
3. Work with supermarkets in promoting healthy food; 
4. Increase green space; 
5. Vegan lifestyle. 
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Table 66: Key Details of Studies 
Author 
(year) 
Intervention (incl. length of time 
provided & maintenance) 
Population/ setting Follow up 
period 
Sample size Study 
type 
Outcomes Effectiveness 
Oaks 
(2005) in 
Thow et 
al 
(2010)(78
)  
State tax of 5.5% of soft drinks and 
snacks. 
USA 15 years Not stated 
in SR 
Eco-
logical 
Obesity prevalence No relationship. 
Kim & 
Kawachi 
(2006) in 
Thow et 
al 
(2010)(78
) 
Change in state taxes on soft drinks 
or snack foods. 
USA  Not stated in 
systematic 
review (SR) 
Not stated 
in SR 
Eco-
logical 
Obesity prevalence No association with obesity point prevalence. With 
no tax more than 4 times as likely to experience a 
high relative increase in obesity prevalence; those 
that repealed a tax were more than 13 times as 
likely. 
Fletcher 
et al. 
(2011)(79
) 
State soft drinks tax, average 3%. USA 16 years Not stated 
in SR 
Eco-
logical 
BMI 1% tax decreased BMI by 0.003 points. 
Jenum et 
al. (2003, 
2006) in 
Sheill et 
al 
(2008)(80
) 
Community-based health 
education plus environmental 
change plus counselling. 
Intervention duration was 3 years. 
Norway, 
community setting 
(2 multi-ethnic 
districts of Oslo) 
Not stated in SR Not stated 
in SR 
Inter-
vention 
Physical activity 
(measured by self-
report); BMI 
Increase in PA in I (+9.5%, p<0.01) compared to 
minor changes in C (exact change not reported in 
original study). 
Smaller increase in BMI in I compared to C (exact 
difference not stated in SR). 
Howard 
et al. 
(2006) in 
Mernagh 
et al 
(2010)(81
) 
Community based health 
promotion to promote a decrease 
in fat intake and increases in 
vegetable, fruit, and grain 
consumption. 18 group sessions in 
year 1, then 4 per year for the 
duration of the trial. 
USA, community-
based from 4 
clinical centres, 50-
79 years old 
Mean follow-up 
7.5 years, 
change at 1 
year also 
reported in SR 
48, 835 
women 
RCT Change in body 
weight; BMI; waist 
circumference 
Change at  1 year 
Weight 
I: -2.2kg (p<0.001) 
C: No change 
 
At the end of follow-up differences were observed 
between I & C in weight (0.5kg, p=0.01), BMI 
(0.3kg/m
2
, p<0.001) and waist circumference (0.3cm, 
p=0.04). 
Kuller et 
al. (2001) 
& Simkin-
Silverman 
Community based health 
promotion. Cognitive-behavioural 
programme with duration of 5 
years. 
USA, community-
based, 44-50 years 
old 
6, 18, 30, 42 
and 54 months 
after randomis-
ation 
Up to 535 
women 
RCT Weight; BMI; Body fat 
(%); waist 
circumference 
Change at 54 months (from baseline) 
Weight  I: 0.08 C: 2.36 (p<0.01) 
BMI I: 0.05±2.0 C: 0.96±1.8 (p<0.001) 
Body fat I: -0.5±4.1 C: 1.1±3.9 
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Author 
(year) 
Intervention (incl. length of time 
provided & maintenance) 
Population/ setting Follow up 
period 
Sample size Study 
type 
Outcomes Effectiveness 
et al. 
(2003) in 
Mernagh 
et al 
(2010) 
(p<0.01) 
Waist circumference I: -2.90 
C: -0.46 (p<0.01) 
Hivert et 
al. 
(2007)(82
) 
Small-group interactive seminars to 
educate students and modify diet/ 
exercise behaviour. Fortnightly for 
the first 2 months of the semester, 
monthly for the rest of the 2 years 
(total = 23 seminars) 
Canada, university 
students 
1 year & 2 years I: 58 
C:57 
RCT Weight (kg); BMI Change at 2 years 
Weight I: -0.6±0.5 C: +0.7±0.6 
(p<0.05) 
BMI I: -0.3±0.2 C: +0.2±0.2 
(p<0.05) 
Holdswor
th 
(2004)(83
) 
Environmental (low intensity) - 
changes to cafeteria menus. 
Duration of intervention was 6 
months 
UK, workplace-
based, 4 
intervention 
workplaces and 2 
control 
1 year 577 
employees 
at 6 
worksites 
I: 453 
C: 124 
Quasi-
experi-
mental 
study 
Dietary habits 
measured using a 
food frequency 
questionnaire 
Vegetable consumption 
I: 27% made +ve changes 
C: 19% made +ve changes 
Fruit consumption 
I: 37% made +ve changes 
C: 25% made +ve changes 
Emmons 
(1999) in 
Mhurchu 
et al 
(2010)(84
) 
Workplace based environmental 
change – risk factor education 
programmes and changes to 
nutrition policy and practice.  
USA, workplace-
based intervention 
130 weeks 397 
employees 
at 22 
worksites 
Cluster 
RCT 
Total fat, fibre and 
fruit and vegetable 
intake (FFQ) 
Total fat 
I: -2.2% 
C: -1.8% 
Fruit & vegetable servings/day 
I: +0.2 
C: -0.2 
Sorensen 
(2003) in 
Mhurchu 
et al 
(2010)(84
) 
Workplace based environmental 
change – worker participation in 
programme planning, worksite 
environmental changes & 
individual behaviour change 
programmes 
USA, workplace-
based intervention 
104 weeks 5156 
employees 
at 15 manu-
facturing 
worksites 
Cluster 
RCT 
Dietary intake (fruit 
and vegetable 
screening 
questionnaire) 
Fruit and vegetable servings/day 
I: -0.1 (7 sites) 
C: +0.05 (8 sites) 
Connell 
(1995) (in 
Verweij et 
al. 
(2011)(85
) 
Workplace based health checks – 3 
intervention groups and control. Ia: 
Health promotion + Health risk 
appraisal (HRA) booklet, Ib: Health 
promotion, Ic: HRA booklet, C: 
HRA. 
USA, workplace-
based intervention 
with office workers, 
nurses & 
instructional staff 
 
1 year 801 
employees 
Ia: 142  
Ib: 248  
Ic: 253  
C: 158 
Cluster 
RCT 
BMI Significant decrease in Ia, Ib, Ic vs. C:  
ß: −0.05 (p < 0.01),  
ß: −0.05 (p < 0.01),  
ß: −0.04 (p < 0.05)  
vs. ß: 0 
Hanlon et 
al. (1995, 
1998) (in 
Maes et 
Workplace based health checks. 
Health checks followed by a health 
education package that included an 
interview backed up by written 
Scotland 5 months & 1 
year 
1,632 RCT BMI; Diet; Physical 
activity 
No significant effect on BMI or physical activity. 
Effect on diet. 
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Author 
(year) 
Intervention (incl. length of time 
provided & maintenance) 
Population/ setting Follow up 
period 
Sample size Study 
type 
Outcomes Effectiveness 
al. 
2011(86)) 
information and feedback on risks. 
Intervention duration 12 months. 
Aldana 
(2005) (in 
Anderson 
et al. 
2009(87)) 
Workplace based health 
education/promotion – lectures, 
pedometers, books, shop tours, 
cooking demonstrations, health 
knowledge test, compared to no 
contact. Intervention duration 1.5 
months, maintenance not 
reported. 
USA, workplace 
based intervention 
targeted to care 
provider 
employees. 
6 months 145 RCT Weight(kg) Significant decrease in I compared with C. 
I: -4.4 
C:-1.0 
(p<0.0001) 
Talvi 
(1999) (in 
Maes et 
al. 
2011(86)) 
Workplace based health checks and 
education/promotion - employees 
were offered special counselling 
according to their individual needs 
in 9 target areas. Intervention 
duration different for each health 
promotion action. 
Finland, oil refinery 
workers, one rig 
with intervention 
compared to one 
rig with minimal 
intervention 
3 years I: 412 
C: 473 
Non-
RCT 
BMI, Diet, Physical 
activity habits 
No effect on BMI or diet. Effect in the targeted 
direction on physical activity. 
Elberson 
(2001) (in 
Anderson 
et al. 
2009(87)) 
Workplace based health checks and 
education/promotion – Ia 
(structured): planned exercise 
classes, Ib (unstructured): access to 
gym, no classes, Ic: all of the above. 
Intervention duration 12 months, 
maintenance not reported. 
 
USA, workplace 
based intervention. 
1 year 374 Retro-
spective 
cohort 
BMI Structured: Baseline BMI 25.01, change at 12 months 
-0.57 (within group p=0.185) 
 
Unstructured: Baseline BMI 27.97, change at 12 
months +0.30 (within group p=0.001) 
Gomel 
(1993) (in 
Anderson 
et al. 
2009(87)) 
Workplace-based health checks & 
education/promotion - risk 
assessment & feedback on risk 
factor profile; up to 6 life-style 
counselling sessions over a 10-
week period; incentives incl. lottery 
tickets & money for achieving 
goals. Intervention 6 months. 
Australia, 
workplace based 
intervention with 
ambulance 
employees 
1 year 431 Cluster 
RCT 
BMI No difference between intervention groups and 
control. 
Sloman et 
al 
2010(88) 
Sustainable travel towns which 
implemented intensive town wide 
Smarter Choice Programmes to 
encourage use of non-car options; 
bus use, cycling and walking, and 
less single occupancy cars 
United Kingdom 30 Months 12,000 Eco-
logical/ 
Cluster 
RCT 
Cycle trips per head, 
walking trips per head 
Cycle trips per head grew by 26-30%. Comparison 
towns cycle trips decreased. Walking trips per head 
grew substantially by 10-13% compared to a national 
decline in similar towns. 
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Author 
(year) 
Intervention (incl. length of time 
provided & maintenance) 
Population/ setting Follow up 
period 
Sample size Study 
type 
Outcomes Effectiveness 
Baker et 
al. (2008) 
(89) 
Walking programme with goals set 
in steps using an open pedometer 
for feedback 
United Kingdom 52 Weeks 63 RCT Step counts Intervention (77%) vs.Control (54%) achieved week 4 
goals (X2= 4.752, p=0.03) 
Significant decrease in count week 16-52. 
DPS, 
Finland 
(in Jones 
et al. ) 
Control group: lifestyle advice was 
given as ‘standard care counselling' 
at baseline. Intensive intervention 
group: given individualised, 
detailed dietary counselling, with 7 
sessions during the first year & 
every 3 months thereafter. 
Finland, with IGT. 
All were middle-
aged (40–64 years) 
& BMI>25 kg/m2 at 
baseline. 
3 years  522 (172 
men and 
350 
women)  
RCT Multiple outcomes 
including BMI, 
weight, waist 
circumference and 
incidence of diabetes. 
During the first three years of the study, 22 subjects 
(9%) in the intervention group and 51 (20%) in the 
control group developed diabetes (p= 0.0001, 2 
test). 
Ashfield-
Watt et 
al. 
(2007)(90
) 
 
Initiatives that involved building 
community networks to increase 
fruit and vegetable intakes in five 
deprived communities by 
improving awareness, attitudes & 
access to fresh fruits & vegetables. 
Intervention duration 12 months. 
Residents in 5 UK 
deprived areas 
1 year 1554 Non-
RCT 
Fruit & vegetable 
intake, measured 
using a short dietary/ 
attitude 
questionnaire 
Median total fruit and vegetable intakes decreased 
significantly over one year in the control group (-0.4 
portions per day, p<0.01), but there was no 
significant change in total fruit and vegetable intakes 
in the intervention group. 
Bremner 
et al. 
(2006)(91
) 
‘5-a-day‘ community intervention 
to increase fruit & vegetable 
intake, including home delivery & 
transport links, voucher schemes, 
media campaigns, growing & 
cookery skills & encouraging 
networking in groups involved in 
promoting healthy eating. Duration 
not specified but at least 1 year. 
Residents in 66 
(former) UK health 
authorities with the 
highest levels of 
deprivation and 
poorest health 
status. 
Baseline (pre-
test) was in 
2003 and 
follow-up (post-
test) was in 
2005. 
98,640 Non-
RCT 
Fruit & vegetable 
intake and knowledge 
Fruit consumption (unadjusted): Experimental and 
control group respondents were more likely to 
consume fruit as a between meal snack at follow-up 
(significance not reported). 
 
Vegetable consumption (unadjusted):  
Experimental and control group respondents were 
more likely to consume vegetables as portions with 
main meals at follow-up (significance not reported).  
Wrieden 
et al. 
(2007)(92
)  
Informal food skills and food 
education sessions, following a 
‘CookWell‘ manual. Intervention 
duration 7 months. 
Adults in rural & 
urban communities 
in Scotland aged 30-
55 in lower SES 
groups who do not 
exercise often. 
2 & 6 months 93 Non-
RCT 
Fruit & vegetable 
intake; other eating 
habits (e.g. tuna and 
total fish intake) 
At T2, a mean change equivalent to one portion a 
week was seen in the intervention group for fruit (P= 
0.047), but no other significant changes were seen. 
This change was not sustained and there was no 
significant difference between the intervention and 
comparison groups (T1–T3). 
McKellar 
et al. 
(2007)(93
) 
Mediterranean-type diet 
intervention involving a cookery 
course, weekly 2-hour sessions. 
Intervention duration 6 weeks. 
Females with 
rheumatoid arthritis 
living in urban areas 
of deprivation in 
Glasgow. 
3 & 6 month 130 Non-
RCT 
Fruit & vegetable 
intake; weight 
control; consumption 
of high fat foods; 
physiological 
measurements 
Evaluation of cardiovascular risk factors showed a 
significant drop in systolic blood pressure by an 
average of 4 mm Hg in the intervention group 
(p=0.016), while the control group showed no 
change. 
Consumption of fruit, vegetables & legumes was 
below the recommended minimum of 5 portions a 
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Author 
(year) 
Intervention (incl. length of time 
provided & maintenance) 
Population/ setting Follow up 
period 
Sample size Study 
type 
Outcomes Effectiveness 
day, in both groups at baseline. By 3 months this had 
improved significantly in the intervention group who 
were attending cooking classes. This group also had 
a significant improvement in ratio of 
monounsaturated :saturated fats consumed. 
Cummins 
et al. 
(2008)(94
) 
Provision of a new food 
hypermarket within the 
intervention area (natural public 
health intervention). Intervention 
duration 1 year. 
Residents of 
households in two 
deprived areas of 
Glasgow. 
1 year 603 Pros-
pective 
cohort 
study 
Fruit and vegetable 
consumption, self 
reported & 
psychological health, 
& socio-demographic 
variables. 
Weak evidence for an effect of the intervention on 
mean fruit consumption (-0.03, 95% CI -0.25 to 0.30), 
mean vegetable consumption (-0.11, 95% CI -0.44 to 
0.22), and fruit and vegetables combined (-0.10, 95% 
CI -0.59 to 0.40).  
Odds ratios & 95% confidence intervals of reporting 
fair to poor self-reported health and poor 
psychological health for the intervention compared 
with comparison community. 
Gray et al 
(2009)(95
) 
Camelon weight management 
group programme, tailored to men, 
incorporating advice on physical 
activity, diet and alcohol 
consumption. Intervention 
duration 12 weeks. 
Male residents of a 
deprived 
community in 
Scotland. 
Pre-
programme, 
short-term (12-
week, 
immediately 
post-
programme, 
long-term (1 to 
49 months after 
programme) 
110 Case 
series 
Weight loss, waist 
circumference 
reduction, BMI 
reduction. 
Short-term (end of 12 weeks programme) weight 
loss for completers was a mean weight loss of 4.98 
kg. 44.3% achieved a weight loss of 5% to 10%. 
Long-term weight loss maintained an average 3.7% 
weight loss (range = 32.6 weight loss to 25.6% 
weight gain) compared with their baseline weight 
(no further information on what this actually meant). 
Compared with pre-programme weight, 14 weighed 
less, 2 were stable (±0.5 kg) 4 weighed more; no 
further detail reported. 
Schuit et 
al. (2006) 
(96) 
Over 5 years 790 interventions 
were implemented in the local 
population and targeted groups. 
Netherlands 5 years 3895 Cohort 
study 
BMI, waist 
circumference, blood 
pressure, serum 
glucose & serum total 
& HDL cholesterol 
Schuit et al. (2006) (96) 
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The interventions options were presented to a Stakeholder group in March 2013. Discussion within 
the workshop suggested that given the current rate of change in this area, it was important that the 
model was flexible and not fixed within a static environment to prevent it from becoming outdated 
very quickly. It was also suggested that the choice of interventions should not be limited by the 
evidence available. The NHS Health Checks should be incorporated into the model, but should be 
considered for possible disinvestment. The group suggested that we construct a set of interventions 
based on a stratification of intervention intensity and population risk. The spectrum of intervention 
types discussed were taxation, community education, agricultural policy, food retailer interventions, 
physical activity for transport, workplace interventions and risk assessment. Given the constraints of 
the project we needed to limit the interventions included within the final model, and based upon the 
discussion within the workshop we selected a subset of interventions for inclusion in the model.  
At the national level we opted to use a taxation policy.  
At the community level we included workplace interventions, retailer policy and community 
education programmes. Local transport policy was excluded because the final model did not include 
physical activity, therefore the modelling framework would not improve upon previous evaluations 
of physical activity interventions (97).  
At the individual level we initially planned to consider three targeted groups: (1) those identified as 
high-risk through individual risk assessment; (2) women with gestational diabetes; (3) ethnic groups. 
In the final analysis this was restricted to those identified at high risk through an individual risk 
assessment. However, we also performed a subgroup analysis which included individuals from 
certain ethnic groups as one of the high risk subgroups. Of the other targeted groups identified in the 
stakeholder meeting we opted to exclude children (and other primordial prevention rather than 
primary prevention), due to the added complexity of modelling a life course, particularly as disease 
progression is based on the Whitehall cohort (adults only). This is an area for further research. 
Jobseekers and attendees at food banks were not included in the primary analysis since the 
workshop discussion suggested that, whilst these groups are important, the three groups above 
should be prioritised. However, the model is sufficiently flexible to enable these to be explored in the 
future without requiring many changes.   
Within the intervention types listed in Table 65 there are a large number of interventions that could 
be implemented. For our taxation policy we focussed on the taxation of soft drinks.  During the 
project a high quality modelling study of soft drinks taxation in the UK was published. This provided 
sufficient evidence about the effectiveness of this policy, to implement the analysis in the model 
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(98). For the workplace intervention, we decided to focus on environmental changes, rather than 
health checks or education programmes (99).  This ensured that a broad range of intervention types 
were considered, rather than implementing similar interventions in different sub-groups of the 
population. For the retailer policy, we modelled the opening of a large supermarket in a deprived 
area to improve access to fruit and vegetables, rather than focusing on within store merchandising of 
healthy foods. We identified a large study of a new store opening in Leeds to derive this evidence 
(100). We also identified studies from three community education programmes, including promoting 
weight management in men from deprived areas, health promotion in ethnically diverse urban areas 
and increasing fruit and vegetable consumption in deprived areas (101-103).  
The high risk identification strategy targeting non-diabetic hyperglycaemia is a translation 
programme which would be feasible in practice. A study collaborator provided us with results from a 
systematic review of translational diabetes prevention programmes in high risk individuals (104). 
Identification of individuals was based upon the NHS Health Checks. However, flexibility was built 
into the model to allow for variations upon this.  
14.2 INTERVENTION A: SOFT-DRINKS TAX 
 Effectiveness 14.2.1
The effect of soft drinks taxation on BMI by age group and income has been estimated in a 
comprehensive modelling exercise (98). The effect on people aged 50 or above is not significant so 
was assumed to be zero in the base case, but allowed to vary in the probabilistic sensitivity analysis. 
These estimates were implemented straight into the Diabetes model without further assumptions.  
Table 67: Change in BMI by age given a 20% tax on sugar sweetened soft drinks (98) 
 16-29 year olds 30-49 year olds >=50 year olds 
Change in BMI -0.23 (-0.28 to -0.20) -0.05 (-0.07 to -0.03) 0.01 (-0.01 to 0.03) 
 
 Population 14.2.2
The soft drinks taxation policy was applied to the general population; however the effectiveness of 
the intervention was conditional on the age of the individual at the start of the model.  
 Cost 14.2.3
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The soft drinks taxation was assumed to not incur any costs. In theory, taxation would probably 
generate additional income, but we decided that it was outside the scope of the model to estimate 
its value. 
14.3 INTERVENTION B: FRUIT AND VEGETABLE RETAIL PROVISION 
 Effectiveness 14.3.1
The Wrigley Leeds Tesco store opening was studied to observe the impact on the local community’s 
fruit and vegetable consumption. The results informed the formulation of a regression model to 
predict change in fruit and veg after the store opened (100). Using the data reported in this study it 
was estimated that the mean increase in fruit and vegetables consumed was 0.162 portions per day2.   
The evidence for relating a change in fruit and vegetable consumption to a change in BMI is 
contradictory. We instead decided to relate changes in fruit and vegetable consumption directly to 
changes in HbA1c and systolic blood pressure using data from two different studies.  
A cross-sectional analysis from the European Prospective Investigation into Cancer and Nutrition in 
Norfolk (EPIC-Norfolk) investigated how plasma vitamin C levels relate to HbA1c (105). The study 
reported the results of a linear regression, which shows that a 20µmol/l increase in plasma vitamin C 
is associated with a reduction in HbA1c of 0.08% for men and 0.05% for women, when adjusted for 
possible confounders including age and BMI. According to the study, a 20µmol/l increase in plasma 
vitamin C is equivalent to eating an extra orange per day. Assuming that the vitamin C in one orange 
is equivalent to the vitamin C in one portion of fruit or veg, and taking the weighted mean for men 
and women, we estimated that the retail policy would reduce HbA1c by an average of 0.010% per 
person. 
A randomised controlled clinical trial testing the efficacy of an intervention promoting consumption 
of fruit and vegetables, found that there was a mean increase of 1.4 portions of fruit or vegetables 
consumed per day in the intervention group compared with the control group (106). This was 
associated with a reduction in systolic blood pressure of 4.0 mm Hg. Implementing this value straight 
into the diabetes model suggested that the retail policy would reduce blood pressure by 0.46 mm Hg.   
                                                          
2 46% of individuals switch to the new store with an incremental change in fruit and veg of 0.252.  
7.8% switch from a budget store with an additional incremental change of 0.595. 
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 Population 14.3.2
We applied this intervention to individuals in the highest quintile of the Townsend deprivation score, 
as these people are more likely to have inadequate access to fruit and vegetable provision.   
 Costs 14.3.3
The costs of this intervention were assumed to be incurred by the private sector and were not 
included in the analysis. Therefore, the evaluation only considered the health gains of the policy. 
14.4 INTERVENTION C: WORKSITE ENVIRONMENT 
 Effectiveness 14.4.1
The Heartbeat Award scheme implemented healthy food options in cafeterias in the workplace and 
observed the impact on workers dietary patterns before and after the menu changes (99). The 
results of the study reported the proportion of individuals who made a positive switch to healthier 
food options after the changes in the workplace café. The proportions were compared between 
participating and non-participating workplaces using odds ratios. The four food groups that 
demonstrated a significant improvement over the study were sweet puddings, fried food, fruit and 
milk. The magnitude of improvement or worsening was not reported in the statistical analysis.  The 
benefits of the work place intervention were measured in terms of the increase in fruit consumption 
and the switching of milk from a higher to a lower fat choice. We decided not to account for the 
reduction in fried food and sweet puddings due to a lack of evidence about nutritional content and 
food substitution. 
The study did not estimate the mean change in fruit and vegetable consumption for the 11.9% of 
individuals who made a positive change. Therefore, it was assumed that they increased their 
consumption of fruit by one portion per day. We used the same assumptions and evidence to 
translate change in fruit and vegetable consumption to HbA1c and systolic blood pressure that were 
described for the retail provision intervention (105;106); this translated to a mean reduction in 
HbA1c of 0.063%, and in systolic blood pressure of 2.86 mm Hg for the 11.9% who were reported as 
eating more fruit and vegetables. 
8.9% of individuals were reported as switching their milk choice from a higher fat to a lower fat 
option. Milk choices were not documented, so it was assumed that individuals switched from full fat 
milk to lower fat milk choices based on population-wide consumption of milk types (Table 68). 
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Calorie and fat content in different milk types was obtained from the Dairy Council (107). The 
quantity of milk drunk by each individual was assumed to be the population mean of 1506ml per 
week; this value was obtained from the Defra Family Food Survey 2012 (108). 
Table 68: Nutritional content and consumption of different milk types (107) 
Type of Milk Fat Content 
(g/100ml) 
Saturated Fat 
(g/100ml) 
Calories (per 
100ml) 
Consumption (% 
consumers) 
Full fat 4.0 2.6 68 23 
Semi-skimmed 1.8 1.1 47 63 
Skimmed 0.3 0.1 35 6 
1% 1.0 No data No data No data 
 
It was assumed that fat consumption would reduce due to milk switching by the mean change in fat 
content of full fat milk, compared with the weighted mean of lower fat alternatives. The mean 
reduction in fat consumption was calculated as 2.33g per 100ml of milk, or 5.01g per day. 
Evidence was available from a cross-sectional study from EPIC-Norfolk to relate HbA1c levels to 
dietary fat consumption as a percentage of daily calories (109). We estimated that mean daily fat 
intake would drop from 32% to 29.8% of total daily calories as a result of milk switching, which 
corresponds to a reduction in HbA1c of 0.0156%. 
Table 69: Dietary fat consumption and changes in HbA1c (109) 
Independent Variable Regression 
coefficients (per 1 
SD change in fat) 
P Mean daily intake 
(weighted male 
and female) 
Standard 
Deviation 
Total Fat  0.0420 <0.001 32% 5.9% 
Saturated Fat  0.0476 <0.001 12.5% 3.4% 
Ratio Polyunsaturated 
Fat to Saturated Fat 
-0.0200 0.013 0.51 0.22 
 
 Population 14.4.2
We applied this intervention to randomly selected individuals in employment. We assumed that 20% 
of workplaces in the population have canteens which adopt the intervention. However, only 11.9% of 
individuals in the workplace were assumed to respond positively to the programme in terms of fruit 
consumption, and 8.9% of individuals were assumed to respond positively in terms of milk switching. 
Random selection of individuals was independent for the two responses. 
 Costs 14.4.3
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The cost of the Heartbeat Award Scheme includes the cost of the environmental health officer to 
visit the premises and inspect menu changes for healthy eating options. The health authority also 
issue promotional material and certificates to the workplace and these printing costs were factored 
into the overall intervention cost (Table 70).  
Table 70: Cost estimates for the Heartbeat Award Scheme 
Cost type Description Unit cost 
Personnel  costs Environment health officer to inspect 
establishments, and assess menus. A week of 
work per workplace valued at the UK average 
salary. 
£474 
Printing costs Posters, leaflets, door stickers, flyers, certificates £25 
Total Cost per workplace £499 
Per capita cost (assuming 100 employees per workplace) £4.99 
 
14.5 INTERVENTION D: COMMUNITY EDUCATION PROGRAMMES 
 Effectiveness 14.5.1
We identified three community education programmes that could be included in the model to 
describe the effectiveness of targeted education interventions in “at risk” communities. Community 
nurses working in partnership with a community dietician in Camelon, a deprived area of Scotland, 
developed a group-based weight management intervention specifically for obese men (101). The 
second intervention was a Mediterranean diet class for socially deprived women with Rheumatoid 
Arthritis (102). The third intervention was a food skills intervention for individuals from urban 
deprived communities and was not included in the final analysis as it only reported changes in fruit 
and veg consumption and there were no significant differences in these outcomes at 6 months 
follow-up (103). As a consequence, we used the other two intervention programmes as an example 
of the effectiveness of community programmes in men and women respectively. A summary of how 
the interventions were added to the model is provided in Table 71. The increase in fruit and 
vegetable consumption was assumed to produce direct effects on HbA1c (-0.09%) and systolic blood 
pressure (-0.41 mm Hg) independently of the effects on BMI, in the same way as described in the 
fruit and vegetable retail provision intervention above (105;106). 
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Table 71: Estimates and assumptions applied in the model for community interventions 
 Eligible Uptake Change in BMI Change in fruit 
and veg 
Assumptions 
Mediterranean Females 
in 
highest 
deprivation 
quintile 
Assumed 11.4% to 
align with men 
-1.04kg/m
2 
0.143 extra 
portions per 
day 
1. No compliance data reported. 
2. Benefit at 6 months maintained 
to 12 months. 
3. Applied to non-Rheumatoid 
arthritis population 
4. Applied to highest quintile of 
Townsend score. 
Men’s diets Men 
>30kg/m
2
  
11.4% -1.29 kg/m
2
 Assumed 0.143 
extra portions 
per day to align 
with women. 
1. Benefit at 6 months maintained 
to 12 months. 
2. Applied to men with BMI>30 
kg/m
2
 
 
 Population 14.5.2
These interventions were combined such that within the same analysis, women with the highest 
deprivation quintile were offered a cooking class, whilst men with a BMI >30kg/m2 were offered the 
multi-component small scale diet programme. The assumed uptake rates for these interventions are 
reported in Table 71.  
 Costs  14.5.3
The interventions described in Table 71 were previously evaluated as part of the NICE public health 
guidance (PH35). In this evaluation the estimated costs of the intervention were £82 for the 
Mediterranean cooking class and £179 for the men’s diets per participant. 
14.6 INTERVENTION E: TRANSLATIONAL DIABETES PREVENTION PROGRAMME 
 Effectiveness 14.6.1
A meta-analysis of translational diabetes prevention programmes was used to estimate the change in 
BMI, HbA1c, systolic blood pressure and cholesterol at 12 months (110). The review included studies 
that had run diet and or exercises classes for individuals with a high risk of diabetes. The definition of 
risk of diabetes varied between studies, but many included risk classification based on increased 
blood glucose. The review reported mean changes in metabolic measurements at 12 months (Table 
72). In the model, the intervention was offered to individuals with impaired glucose regulation. The 
change in BMI was taken directly from the meta-analysis. The change in HbA1c, systolic blood 
pressure and total cholesterol were adjusted down to reflect the independent effect over and above 
the effect of changes in BMI estimated using the Whitehall statistical model. This avoided double 
counting of treatment benefits.  
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Table 72: Metabolic changes 12 months after diet and exercise interventions for individuals at high risk of diabetes 
 BMI (kg/m
2
) HbA1c (%) Systolic BP (mm 
Hg) 
Total 
Cholesterol 
(mmol/l) 
12 months after intervention -0.94 -0.121 -0.1975 -0.098 
 
 Population 14.6.2
The process of identifying individuals at high risk of diabetes replicated the process previously 
evaluated as part of the NICE Public Health guidance (PH38).  
 Costs 14.6.3
The intervention costs were designed to replicate the costing methods used in the NICE Public Health 
guidance (PH38). Given the -2.12kg mean weight loss, this intervention most closely matched to the 
moderate intensity intervention described in the guideline which cost £100 per individual in the first 
year. We assumed that individuals received 6 monthly maintenance classes after the visits in years 2-
4 at a cost of £60 per year.  
14.7 MAINTENANCE OF INTERVENTION EFFECTS 
Ideally, weight regain rates and the altered trajectories of HbA1c and systolic blood pressure would 
be modelled separately for each intervention based upon long term follow-up data. Unfortunately, 
this data was not available for most of the interventions considered. With this in mind, we decided to 
apply the full effectiveness of each intervention for the first year only, then in subsequent years, to 
assume that effectiveness would diminish linearly, reaching zero effect after 5 years.  
14.8 LAYERING INTERVENTIONS 
The model is sufficiently flexible to enable layering of interventions in order to determine which 
combinations are highly cost-effective and which combinations could be used to efficiently target 
certain subpopulations. Interventions can be layered in several different ways, to reflect what will 
occur when an individual is subject to more than one intervention. Layering can be considered to be 
either additive, synergistic (i.e. greater than additive), antagonistic (multiple interventions result in 
less effect than a single intervention) or it may have an effect that is somewhere between 
antagonistic and additive (one example being that the individual might only obtain an affect from 
one of the layered interventions).  
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14.9 TARGETING POPULATION SUBGROUPS AT HIGH RISK OF DIABETES 
We selected six sets of criteria to identify and compare alternative sub-groups of individuals at high 
risk of diabetes within the UK general population who could be targeted with intensive interventions. 
The at-risk groups included individuals of South Asian ethnicity, individuals in the lowest quintile of 
deprivation (low SES), Individuals with HbA1c>6%, individuals with BMI>35kg/m2, individuals aged 
40-65, and individuals with a Finnish Diabetes Risk (FINDRISC) Score > 0.1 (111). Summary 
characteristics for the six groups and the general population are reported in Table 73. To enable fair 
comparison between the six scenarios we can assume that there is a budget constraint meaning that 
only 2% of the total adult population can be enrolled in the intervention. 
Table 73: Summary of sub-population characteristics 
 General UK 
Population 
Age 40-65 Low 
Socioecon
omic 
status  
HbA1c >42 
mmol/mol(
6%) 
Finnish 
Diabetes 
Risk Score 
(DRS)  >0.1 
BMI >=35k
g/m
2
 
South 
Asian  
Total population 100% 48% 18% 15% 12% 8% 4% 
Male 44% 44% 44% 45% 40% 34% 42% 
White 90% 92% 80% 92% 96%  91% 0% 
Low SES 18% 15% 100% 16%  16%  24% 37% 
Age 48.6 (18.4) 54.1 (8.4) 44.7 (8.2) 61.2 (16.0) 66.3 (14.0) 50.0 (16.0) 38.3 (13.6) 
BMI, kg/m
2
 27.2 (5.4) 27.9  (5.3) 27.4 (5.9) 28.7 (5.5) 34.21 (4.0) 39.0 (4.0) 26.6 (5.3) 
HbA1c, % 5.6 (0.5) 5.7 (0.4) 5.6 (0.5) 6.2 (0.1) 5.9 (0.5) 5.7 (0.6) 5.1 (0.5) 
HbA1c, mmol/mol 38 39 38 44 41 39 32 
Systolic Blood 
pressure, mmHg 
125 (17.1) 128 (16.5) 125 (17.0) 133 (17.3) 135 (17.0) 128 (16.9) 120 (15.5) 
Total Cholesterol 
mmol/l 
5.4 (1.1) 5.7 (1.0) 5.3 (1.1) 5.8 (1.0) 5.8 (1.0) 5.5 (1.0) 5.2 (1.1) 
HDL Cholesterol, 
mmol/l 
1.5 (0.4) 1.6 (0.5) 1.5 (0.4) 1.5 (0.5) 1.5 (0.4) 1.5 (0.4) 1.4 (0.4) 
Standard deviation in brackets 
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15 PROBABILISTIC SENSITIVITY ANALYSIS 
Probabilistic sensitivity analysis (PSA) was enabled in the model to describe the uncertainty in 
parameter inputs of the model and how this translates into uncertainty in the outcomes of the 
model. A suitable distribution was selected for each parameter, based upon its mean and standard 
error. Random sampling simultaneously across all input parameter distributions allowed parameter 
uncertainty to be quantified. 1000 different random samples of parameter values were selected, and 
each was applied to a different random cohort of 20,000 individuals. For each PSA sample, the model 
was run and results compiled. Given the large number of parameters in the model and thus the 
capacity for error, a thorough process of checking that mean sampling values corresponded to mean 
parameter values was undertaken to ensure that the results were as accurate as possible. A list of 
model parameters, their distribution for PSA and their source is provided in the following tables.  
15.1 GP ATTENDANCE IN THE GENERAL POPULATION 
In the probabilistic sensitivity analysis the parameters of the Yorkshire Health Study negative 
binomial model are sampled from a multivariate normal distribution, using the mean estimates 
described in Table 15 and covariance matrix in Table 16. 
Table 74: GP attendance reported in the Yorkshire Health Study (N= 18,437) (112) 
 Mean Standard error Uncertainty Distribution 
Age 0.0076 0.0005 MULTIVARIATE NORMAL 
Male  -0.1495 0.0159 MULTIVARIATE NORMAL 
BMI 0.0110 0.0015 MULTIVARIATE NORMAL 
Ethnicity (Non-white) 0.2620 0.0375 MULTIVARIATE NORMAL 
Heart Disease 0.2533 0.0289 MULTIVARIATE NORMAL 
Depression 0.6127 0.0224 MULTIVARIATE NORMAL 
Osteoarthritis 0.2641 0.0238 MULTIVARIATE NORMAL 
Diabetes 0.2702 0.0278 MULTIVARIATE NORMAL 
Stroke 0.1659 0.0474 MULTIVARIATE NORMAL 
Cancer 0.2672 0.0414 MULTIVARIATE NORMAL 
Intercept -0.5014 0.0468 MULTIVARIATE NORMAL 
Alpha 0.3423 0.0108 MULTIVARIATE NORMAL 
 
Table 75: Variance-covariance matrix for GP attendance regression 
 Age Male  BMI 
Ethnicity 
(Non-
white) 
Heart 
Disease 
Depressi
on 
Osteo-
arthritis Diabetes Stroke Cancer Intercept Alpha 
Age 
0.0000            
Male  
0.0000 0.0003                       
BMI 
0.0000 0.0000 0.0000                      
Ethnicity 
(Non-white) 
0.0000 0.0000 0.0000 0.0014                     
Heart Disease 
0.0000 0.0000 0.0000 0.0000 0.0008                    
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Depression 
0.0000 0.0000 0.0000 0.0000 0.0000 0.0005                   
Osteoarthritis 
0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0006                  
Diabetes 
0.0000 0.0000 0.0000 0.0000 -0.0001 0.0000 0.0000 0.0008                 
Stroke 
0.0000 0.0000 0.0000 0.0000 -0.0002 -0.0001 0.0000 -0.0001 0.0022                
Cancer 
0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 -0.0001 0.0017               
Intercept 
0.0000 0.0000 -0.0001 -0.0002 0.0002 0.0000 0.0002 0.0003 0.0000 0.0001 0.0022              
Alpha 
0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0010 
 
15.2 WHITEHALL II STATISTICAL MODEL OF METABOLIC TRAJECTORIES 
The parameters derived from the Whitehall II statistical model of metabolic trajectories are 
described in Table 76 and Table 78.  
Table 76: Coefficient estimates for metabolic risk factor parallel growth models 
 Parameter Description Estimated 
Mean 
Standard 
error 
p-value 
BMI Intercept    
𝛼10 Population mean BMI intercept 2.2521 0.045 <0.001 
𝜸𝟏𝟎 Age at baseline coefficient for BMI intercept 0.0056 0.001 <0.001 
Sex coefficient for BMI intercept -0.0311 0.012 0.009 
Family history of CVD coefficient for BMI intercept -0.0079 0.012 0.515 
𝜐10 Random error term for BMI intercept 0.1165 0.003 <0.001 
BMI linear slope    
𝛼11 Population mean BMI linear slope 0.6409 0.042 <0.001 
𝜸𝟏𝟏 Age at baseline coefficient for BMI linear slope -0.0084 0.001 <0.001 
Sex coefficient for BMI linear slope -0.0285 0.011 0.009 
Family history of CVD coefficient for BMI linear slope -0.0155 0.010 0.117 
𝜐11 Random error term for BMI linear slope 0.0222 <0.001 <0.001 
BMI quadratic slope    
𝛼12 Population mean BMI quadratic slope -0.2007 0.023 <0.001 
𝜸𝟏𝟐 Age at baseline coefficient for quadratic slope 0.0026 <0.001 <0.001 
Sex coefficient for quadratic slope 0.0089 0.006 0.147 
Family history of CVD coefficient for quadratic slope 0.0104 0.006 0.061 
𝜀1 Random error term for BMI 0.0104 <0.001 <0.001 
Glyc Intercept    
𝛼20 Population mean glyc intercept 0 NA NA 
𝜸𝟐𝟎 Smoker coefficient for glyc intercept -0.1388 0.029 <0.001 
𝜏20 Association between BMI intercept and glyc intercept 0.2620 0.024 <0.001 
𝜐20 Random error term for glyc intercept 0.0851 0.008 <0.001 
Glyc linear slope    
𝛼21 Population mean glyc linear slope -0.4255 0.071 <0.001 
𝜸𝟐𝟏 Sex coefficient for glyc linear slope 0.1486 0.045 0.001 
Ethnicity coefficient for glyc linear slope -0.0218 0.081 0.786 
Family history of T2DM coefficient for glyc linear slope -0.0512 0.054 0.345 
Smoker coefficient for glyc linear slope 0.1796 0.066 0.007 
𝜏21 Association between BMI intercept and glyc linear slope 0.0821 0.024 0.001 
𝜏22 Association between BMI linear slope and glyc linear slope 0.1984 0.073 0.007 
𝜐21 Random error term for glyc linear slope 0.0222 0.011 0.053 
Glyc quadratic slope    
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𝛼22 Population mean glyc quadratic slope 0.1094 0.025 <0.001 
𝜸𝟐𝟐 Sex coefficient for glyc quadratic slope -0.0855 0.027 0.002 
Ethnicity coefficient for glyc quadratic slope 0.0899 0.049 0.067 
Family history of T2DM coefficient for glyc quadratic slope 0.0633 0.033 0.052 
Smoker coefficient for glyc quadratic slope -0.0390 0.040 0.330 
𝜐22 Random error term for glyc quadratic slope 0.0107 0.003 0.002 
𝜀2 Glyc measurement error 0.0707 0.005 <0.001 
SBP Intercept    
𝛼30 Population mean SBP intercept 0.6934 0.021 <0.001 
𝜸𝟑𝟎 Age at baseline coefficient for SBP intercept 0.0043 <0.001 <0.001 
Sex coefficient for SBP intercept 0.0380 0.004 <0.001 
Smoking coefficient for SBP intercept -0.0243 0.006 <0.001 
Ethnicity coefficient for SBP intercept 0.0078 0.007 0.300 
Family history of CVD coefficient for SBP intercept 0.0061 0.004 0.160 
𝝉𝟑𝟏 Association between BMI intercept and SBP intercept 0.1080 0.006 <0.001 
𝜐30 Random error term for SBP intercept 0.0085 0.00 <0.001 
SBP linear slope    
𝛼31 Population mean SBP linear slope -0.0227 0.021 0.278 
𝜸𝟑𝟏 Age at baseline coefficient for SBP linear slope 0.0024 <0.001 <0.001 
Sex coefficient for SBP linear slope -0.0004 0.004 0.927 
Smoking coefficient for SBP linear slope 0.0205 0.005 <0.001 
Ethnicity coefficient for SBP linear slope 0.0224 0.007 0.001 
Family history of CVD coefficient for SBP linear slope -0.0013 0.004 0.748 
𝝉𝟑𝟏 
 
Association between BMI intercept and SBP linear slope -0.0396 0.006 <0.001 
Association between BMI linear slope and SBP linear slope 0.2325 0.019 <0.001 
𝜐31 Random error term for SBP linear slope 0.0024 <0.001 <0.001 
𝜀3 SBP measurement error variance 0.0093 <0.001 <0.001 
TC Intercept    
𝛼40 Population mean TC intercept 2.9956 0.176 <0.001 
𝜸𝟒𝟎 Age at baseline coefficient for TC intercept 0.0456 0.003 <0.001 
Sex coefficient for TC intercept 0.0660 0.036 0.070 
𝜏40 Association between BMI intercept and TC intercept 0.4459 0.049 <0.001 
𝜐40 Random error term for TC intercept 0.8960 0.025 <0.001 
TC linear slope    
𝛼41 Population mean TC linear slope 2.1216 0.128 <0.001 
𝜸𝟒𝟏 Age at baseline coefficient for TC linear slope -0.0316 0.002 <0.001 
Sex coefficient for TC linear slope -0.2677 0.026 <0.001 
𝜏41 Association between BMI intercept and TC linear slope -0.4808 0.035 <0.001 
𝜏42 Association between BMI linear slope and TC linear slope 0.9802 0.108 <0.001 
𝜐41 Random error term for TC linear slope 0.1583 0.011 <0.001 
𝜀4 TC measurement error variance 0.3426 0.006 <0.001 
HDL Intercept    
𝛼50 Population mean HDL intercept 2.4124 0.054 <0.001 
𝜸𝟓𝟎 Age at baseline coefficient for HDL intercept 0.0032 0.011 <0.001 
Sex coefficient for HDL intercept -0.3710 0.001 <0.001 
𝜏51 Association between BMI intercept and HDL intercept -0.3514 0.015 <0.001 
𝜐50 Random error term for HDL intercept 0.0827 -0.040 <0.001 
HDL linear slope    
𝛼51 Population mean HDL linear slope 0.1241 0.034 <0.001 
𝜸𝟓𝟏 Age at baseline coefficient for HDL linear slope 0.0020 0.001 <0.001 
Sex coefficient for HDL linear slope 0.0041 0.007 0.558 
𝝉𝟓𝟏 Association between BMI intercept and HDL linear slope -0.0400 0.010 <0.001 
𝜐51 Random error term for HDL linear slope 0.0090 0.001 <0.001 
𝜀5 HDL measurement error variance 0.0333 0.001 <0.001 
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Table 77: Coefficient estimates for latent glycaemic measurement model 
 Parameter Description Estimated 
Mean 
Standard 
error 
p-value 
𝜇0 FPG intercept 4.2903 0.089 <0.001 
𝜃01 Glycaemic factor to FPG   1 NA NA 
𝜃02 Age to FPG 0.0031 0.001 0.022 
𝜃03 Sex to FPG 0.2129 0.021 <0.001 
𝜃04 Ethnicity to FPG 0.0100 0.037 0.786 
𝜃05 Family history of diabetes to FPG 0.1168 0.025 <0.001 
𝜀0 FPG measurement error variance 0.1649 0.007 <0.001 
𝜇1 2-hr Glucose intercept 0.5707 0.223 0.011 
𝜃11 Glycaemic factor to 2-hr glucose  2.4384 0.078 <0.001 
𝜃12 Age to 2-hr glucose 0.0716 0.003 <0.001 
𝜃13 Sex to 2-hr glucose -0.1411 0.058 0.014 
𝜃14 Ethnicity to 2-hr glucose 0.3047 0.100 0.002 
𝜃15 Family history of diabetes to 2-hr glucose 0.3496 0.068 <0.001 
𝜀1 2-hr measurement error variance 2.3679 0.054 <0.001 
𝜇2 HbA1c intercept 4.4769 0.073 <0.001 
𝜃21 Glycaemic factor to HBA1c 0.5074 0.016 <0.001 
𝜃22 Age to HBA1c 0.0101 0.001 <0.001 
𝜃23 Sex to HBA1c -0.0457 0.001 <0.001 
𝜃24 Ethnicity to HBA1c 0.1854 0.030 <0.001 
𝜃25 Family history of diabetes to HBA1c 0.0563 0.020 0.004 
𝜀2 HbA1c measurement error variance 0.1166 0.003 <0.001 
 
Table 78: Covariance matrix  𝜴  for individual random error  
 𝜐10 𝜐11 𝜐20 𝜐21 𝜐22 𝜐30 𝜐31 𝜐40 𝜐41 𝜐50 𝜐51 
𝜐10 0.1165           
𝜐11 0.0095 0.0131          
𝜐20 <0.0010 <0.0010 0.0851         
𝜐21 <0.0010 <0.0010 0.0222 0.0209        
𝜐22 <0.0010 <0.0010 <0.0010 <0.0010 0.0107       
𝜐30 <0.0010 <0.0010 0.0080 <0.0010 <0.0010 0.0085      
𝜐31 <0.0010 <0.0010 <0.0010 0.0018 <0.0010 <0.0017 0.0024     
𝜐40 <0.0010 <0.0010 0.0324 <0.0010 <0.0010 0.0031 <0.0010 0.8960    
𝜐41 <0.0010 <0.0010 <0.0010 -<0.0012 <0.0010 <0.0010 0.0066 -0.2229 0.1583   
𝜐50 <0.0010 <0.0010 -0.0118 <0.0010 <0.0010 0.0010 <0.0010 0.0273 <0.0010 0.0827  
𝜐51 <0.0010 <0.0010 <0.0010 -0.0059 <0.0010 <0.0010 0.0020 <0.0010 0.0159 0.0061 0.0090 
 
 HbA1c trajectory in individuals diagnosed with type 2 diabete s 15.2.1
The input parameters for the initial reduction in HbA1c and long term trend in HbA1c following 
diagnosis, derived from analysis of the UKPDS outcomes model (11), are reported in Table 79 and 
Table 80 respectively. 
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Table 79: Estimated change in HbA1c in first year following diabetes diagnosis 
 Distribution Parameter 1 Parameter 2 Central estimate 
Change in HbA1c Intercept NORMAL -2.9465 0.0444513 -2.9465 
HbA1c at baseline NORMAL 0.5184 0.4521958 0.5184 
 
Table 80: Estimated change in HbA1c following diabetes diagnosis over long term  
Parameter Description Distribution Parameter 1 Parameter 2 Central 
estimate 
Longitudinal HbA1c for diabetes 
intercept 
NORMAL -0.024 0.017 -0.024 
Longitudinal HbA1c for diabetes 
log(time since diagnosis) 
NORMAL 0.144 0.009 0.144 
Longitudinal HbA1c for diabetes 
Second year 
NORMAL -0.333 0.05 -0.333 
Longitudinal HbA1c for diabetes lag 
HbA1c 
NORMAL 0.759 0.004 0.759 
Longitudinal HbA1c for diabetes 
HbA1c at diagnosis 
NORMAL 0.085 0.004 0.0896 
 
 Systolic blood pressure and cholesterol trajectory following treatment  15.2.2
The changes in systolic blood pressure and total cholesterol following treatment with anti-
hypertensives or statins and statin uptake are reported in Table 81. 
Table 81: Treatment effects following treatment 
Parameter Description Distribution Parameter 1 Parameter 2 Central 
estimate 
Source 
Simvastatin treatment effects NORMAL -1.45 0.11 -1.45 (12) 
Anti-hypertensive treatment effect NORMAL -8.4 0.638 -8.4 (15) 
Statin Uptake UNIFORM 0.65 (0.4-0.9) 0.65 (13) 
 
 Metabolic Risk Factor screening  15.2.3
The distribution for the HbA1c threshold at which opportunistic screening for type 2 Diabetes is 
initiated even if the individual does not have a history of cardiovascular disease, microvascular 
disease or identified impaired glucose regulation is reported in Table 82. 
Table 82: Threshold for HbA1c opportunistic diagnosis 
Parameter Description Distribution Parameter 1 Parameter 2 Central 
estimate 
Source 
HbA1c at diagnosis NORMAL 8.1 0.073 8.1 (16) 
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15.3 COMORBID OUTCOMES AND MORTALITY 
 Cardiovascular disease 15.3.1
The parameter distributions for men and women based on the QRISK2 model (21) are reported in 
Table 83. 
Table 83: Input parameters of the QRISK2 risk model 
Parameter Description Distribution Parameter 1 Parameter 2 Central 
estimate 
QRISK female ethnicity 2 NORMAL 0.2163 0.0537 0.2163 
QRISK female ethnicity 3 NORMAL 0.6905 0.069 0.6905 
QRISK female ethnicity 4 NORMAL 0.3423 0.1073 0.3423 
QRISK female ethnicity 5 NORMAL 0.0731 0.1071 0.0731 
QRISK female ethnicity 6  NORMAL -0.0989 0.0619 -0.0989 
QRISK female ethnicity 7 NORMAL -0.2352 0.1275 -0.2352 
QRISK female ethnicity 8 NORMAL -0.2956 0.1721 -0.2956 
QRISK female ethnicity 9 NORMAL -0.1010 0.0793 -0.1010 
QRISK female smoke 2 NORMAL 0.2033 0.0152 0.2033 
QRISK female smoke 3 NORMAL 0.48200 0.0220 0.4820 
QRISK female smoke 4 NORMAL 0.6126 0.0178 0.6126 
QRISK female smoke 5 NORMAL 0.7481 0.0194 0.7481 
QRISK female age 1 NORMAL 5.0373 1.0065 5.0327 
QRISK female age 2 NORMAL -0.0108 0.0022 -0.0108 
QRISK female bmi NORMAL 0.4724 0.0423 0.4724 
QRISK female cholesterol NORMAL 0.6375 0.0143 0.6375 
QRISK female sbp NORMAL 0.0106 0.0045 0.0106 
QRISK female townsend NORMAL 0.060 0.0068 0.060 
QRISK female fibrillation NORMAL 1.3261 0.0310 1.3261 
QRISK female RA NORMAL 0.3626 0.0319 0.3626 
QRISK female Renal NORMAL 0.7636 0.0639 0.7636 
QRISK female Hypertension NORMAL 0.5421 0.0115 0.5421 
QRISK female diabetes NORMAL 0.8940 0.0199 0.8940 
QRISK female family history cvd NORMAL 0.5997 0.0122 0.5997 
QRISK female age1 * smoke 1 NORMAL 0.1774 0.0355 0.1774 
QRISK female age 1 * smoke 2 NORMAL -0.3277 0.0655 -0.3277 
QRISK age1 * smoke 3 NORMAL -1.1533 0.2307 -1.1533 
QRISK female age 1 * smoke 4  NORMAL -1.5397 0.3079 -1.5397 
QRISK female age 1 * atrial fibrillation NORMAL -4.6084 0.922 -4.6084 
QRISK female age 1 * renal NORMAL -2.6401 0.5280 -2.6401 
QRISK female age 1 * hypertension NORMAL -2.2480 0.4496 -2.2480 
QRISK female age 1 * diabetes NORMAL -1.8452 0.3690 -1.8452 
QRISK female age 1 * bmi NORMAL -3.0851 0.6170 -3.0851 
QRISK female age 1 * family history 
cvd 
NORMAL -0.2481 0.0496 -0.2481 
QRISK female age 1 * sbp NORMAL -0.0132 0.0026 -0.0132 
QRISK female age 1 * town NORMAL -0.0369 0.0074 -0.0369 
QRISK female age 2 * smoke 1 NORMAL -0.0053 0..0001 -0.0053 
QRISK female age 2 * smoke 2 NORMAL -0.0005 0.0001 -0.0005 
QRISK female age 2 * smoke 3 NORMAL -0.0105 0.0021 -0.0105 
QRISK female age 2 * smoke 4 NORMAL -0.0155 0.0031 -0.0155 
QRISK female age 2 * fibrillation NORMAL -0.0507 0.0101 -0.0507 
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QRISK female age 2 * renal NORMAL 0.0343 0.0069 0.0343 
QRISK female age 2 * hypertension NORMAL 0.0258 0.0051 0.0258 
QRISK female age 2 * diabetes NORMAL 0.0180 0.0036 0.0180 
QRISK female age 2 * bmi NORMAL 0.0345 0.0069 0.0345 
QRISK female age 2 * family history 
cardiovascular  
NORMAL -0.0062 0.0012 -0.0062 
QRISK female age 2 * sbp NORMAL -0.000029 0.000006 -0.000029 
QRISK female age 2 * townsend NORMAL -0.0011 0.0002 -0.0011 
QRISK female 1 year survival CONSTANT 0.9983 NA NA 
QRISK male ethnicity 2  NORMAL 0.3163 0.0425 0.3163 
QRISK male ethnicity 3 NORMAL 0.6092 0.0547 0.6092 
QRISK male ethnicity 4  NORMAL 0.5958 0.0727 0.5958 
QRISK male ethnicity 5  NORMAL 0.1142 0.0845 0.1142 
QRISK male ethnicity 6 NORMAL -0.3489 0.0641 -0.3489 
QRISK male ethnicity 7  NORMAL -0.3604 0.1094 -0.3604 
QRISK male ethnicity 8 NORMAL -0.2666 0.1538 -0.2666 
QRISK male ethnicity 9 NORMAL -0.1208 0.0734 -0.1208 
QRISK male SMOKE 2 NORMAL 0.2033 0.0152 0.2033 
QRISK male SMOKE 3 NORMAL 0.4820 0.0220 0.4820 
QRISK male SMOKE 4 NORMAL 0.6126 0.0178 0.6126 
QRISK male SMOKE 5 NORMAL 0.7481 0.0194 0.7481 
QRISK male age 1 NORMAL 47.316 9..4630 47.316 
QRISK male age 2 NORMAL -101.236 20.247 -101.236 
QRISK male bmi NORMAL 0.5425 0.0299 0.5425 
QRISK male cholesterol NORMAL 0.14425 0.0022 0.14425 
QRISK male sbp NORMAL 0.0081 0.0046 0.0081 
QRISK male  townsend NORMAL 0.0365 0.0048 0.0365 
QRISK male fibrillation NORMAL 0.7547 0.1018 0.7547 
QRISK male RA NORMAL 0.3089 0.0445 0.3089 
QRISK male renal NORMAL 0.7441 0.0702 0.7441 
QRISK male hypertension NORMAL 0.6965 0.011 0.6965 
QRISK male age 1 smoke 1 NORMAL -3.8805 0.7761 -3.8805 
QRISK male age 1 smoke 2 NORMAL -16.703 3.3406 -16.703 
QRISK male age 1 smoke 3 NORMAL -15.3738 3.5291 -15.3738 
QRISK male age 1 smoke 4 NORMAL -17.6453 3.5291 -17.6453 
QRISK male age 1 fibrillation NORMAL -7.0146 1.4056 -7.0282 
QRISK male age 1 renal NORMAL -17.015 3.4029 -17.015 
QRISK male age 1 hypertension NORMAL 33.9625 6.7925 33.9625 
QRISK male age 1 diabetes  NORMAL 12.7886 2.5577 12.7886 
QRISK  male age 1 bmi NORMAL 3.2680 0.6536 3.2680 
QRISK male age 1 fxcd NORMAL -17.9219 3.5844 -17.9219 
QRISK male age 1 sbp NORMAL -0.1511 0.030 -0.1511 
QRISK male age 1 town NORMAL -2.5502 0.5100 -2.5502 
QRISK male age 2 SMOKE 1 NORMAL 7.9709 1.5942 7.9709 
QRISK male age 2 SMOKE 2  NORMAL 23.6859 4.7372 23.6859 
QRISK male age 2 SMOKE 3 NORMAL 23.1371 4.6274 23.1371 
QRISK male age 2 SMOKE 4 NORMAL 26.8674 5.3735 26.8674 
QRISK male age 2 Fibrillation NORMAL  14.4518 2.8904 14.4518 
QRISK male age 2 renal NORMAL 28.2702 5.654 28.2702 
QRISK male age 2 hypertension NORMAL -18.8167 3.7633 -18.8167 
QRISK male age 2 diabetes NORMAL 0.9630 0.1926 0.963 
QRISK male age 2 bmi NORMAL 10.5517 2.1103 10.5517 
QRISK male age 2 FXCD NORMAL 26.6047 5.3209 26.6047 
QRISK male age 2 sbp NORMAL 0.2911 0.0582 0.2911 
QRISK male age 2 town  NORMAL 3.007 0.6014 3.007 
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QRISK2 male 1 year survival CONSTANT 0.997 NA NA 
 
The QRISK2 model was modified to allow a linear relationship between HbA1c and the risk of 
cardiovascular disease for individuals with Impaired Glucose tolerance and type 2 Diabetes 
(HbA1c>42 mmol/mol). The parameter distributions for these additional inputs are reported in Table 
84. 
Table 84: Additional parameters for linear relationship between HbA1c and cardiovascular disease 
Parameter Description Distribution Parameter 1 Parameter 2 Central estimate Source 
Female RR of MI due to HbA1c in 
diabetics 
LOGNORMAL 0.078 0.030 1.08 (19) 
Male RR of MI due to HbA1c in 
diabetics 
LOGNORMAL 0.108 0.023 1.11 (19) 
RR of stroke due to HbA1c in 
diabetics 
LOGNORMAL 0.092 0.026 1.096 (19) 
Log(RR) of cvd due to IGR NORMAL 0.223 0.043 1.25 (113) 
 
 Congestive Heart Failure 15.3.2
The parameter distributions for congestive heart failure based on the Framingham Heart Study (24) 
are reported in Table 85.  
Table 85: Input parameters for Congestive Heart Failure Risk model for men and women 
Parameter Description Distribution Parameter 1 Parameter 2 Central 
estimate 
Male Heart failure baseline hazard NORMAL -9.2087 0.9209 -9.2087 
Male Heart failure Age NORMAL 0.0412 0.0278 0.0412 
Male Heart failure LVH NORMAL 0.9026 1.0359 0.9026 
Male Heart failure Heart rate NORMAL 0.0166 0.0174 0.0166 
Male Heart failure Systolic blood 
pressure 
NORMAL 
0.00804 0.0117 0.00804 
Male Heart failure CHD NORMAL 1.6079 0.5336 1.6079 
Male Heart failure Valve disease NORMAL 0.9714 0.6557 0.9714 
Male Heart failure Diabetes NORMAL 0.2244 0.6682 0.2244 
Female Heart failure baseline hazard NORMAL -10.7988 1.0799 -10.7988 
Female Heart failure Age NORMAL 0.0503 0.0301 0.0503 
Female Heart failure LVH NORMAL 1.3402 0.8298 1.3402 
Female Heart failure Heart rate NORMAL 0.0105 0.0193 0.0105 
Female Heart failure Systolic blood 
pressure 
NORMAL 
0.00337 0.0109 0.00337 
Female Heart failure CHD NORMAL 1.5549 0.5973 1.5549 
Female Heart failure Valve disease NORMAL 1.3929 0.6707 1.3929 
Female Heart failure Diabetes NORMAL 1.3857 0.7105 1.3857 
Female Heart failure BMI NORMAL 0.0578 0.0555 0.0578 
Female Heart failure Valve disease NORMAL -0.986 1.4370 -0.986 
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 Microvascular Complications  15.3.3
The parameter distributions for the risk models for foot ulcer, blindness, renal failure, first 
amputation and second amputation are reported in Table 86. Parameters for renal failure were 
based on the UKPDS Outcomes Model 1 (11), whereas parameters for other microvascular 
complications were based on the UKPDS Outcomes Model 2 (19). 
Table 86: Input parameters for microvascular complications 
Parameter Description Distribution Parameter 1 Parameter 2 Central 
estimate 
Renal failure baseline hazard NORMAL -10.016 0.939 -10.016 
Renal failure Weibull shape NORMAL 1.865 1.4352 1.865 
Renal failure systolic blood pressure NORMAL 0.404 0.106 0.404 
Renal failure blindness NORMAL 2.082 0.551 2.082 
Foot ulcer baseline hazard NORMAL -11.295 1.13 -11.295 
Foot ulcer age at diagnosis NORMAL 0.043 0.014 0.043 
Foot ulcer female NORMAL -0.962 0.255 -0.962 
Foot ulcer BMI NORMAL 0.053 0.019 0.053 
Foot ulcer HbA1c NORMAL 0.16 0.056 0.16 
Foot ulcer PVD NORMAL 0.968 0.258 0.968 
Amputation baseline hazard NORMAL -14.844 1.205 -14.844 
Amputation age at diagnosis  NORMAL 0.023 0.011 0.023 
Amputation female NORMAL -0.445 0.189 -0.445 
Amputation atrial fibrillation NORMAL 1.088 0.398 1.088 
Amputation HbA1c NORMAL 0.248 0.042 0.248 
Amputation HDL NORMAL -0.059 0.032 -0.059 
Amputation heart rate NORMAL 0.098 0.05 0.098 
Amputation MMALB NORMAL 0.602 0.18 0.602 
Amputation peripheral vascular 
disease 
NORMAL 1.01 0.189 1.01 
Amputation white blood count NORMAL 0.04 0.017 0.04 
Amputation Stroke NORMAL 1.299 0.245 1.299 
Amputation shape NORMAL 2.067 0.193 2.067 
Amputation with Ulcer lambda NORMAL -0.881 0139 -0.881 
Amputation with Ulcer age at 
diagnosis 
NORMAL -0.065 0.027 -0.065 
Amputation with Ulcer PVD NORMAL 1.769 0.449 1.769 
Second Amputation baseline hazard NORMAL -3.455 0.565 -3.455 
Second Amputation HbA1c NORMAL 0.127 0.06 0.127 
Blindness baseline hazard NORMAL -10.6774 0.759 -10.6774 
Blindness age at diagnosis NORMAL 0.047 0.009 0.047 
Blindness HbA1c NORMAL 0.171 0.032 0.171 
Blindness heart rate NORMAL 0.08 0.039 0.08 
Blindness systolic blood pressure NORMAL 0.068 0.032 0.068 
Blindness white blood cells NORMAL 0.052 0.019 0.052 
Blindness CHF  NORMAL 0.841 0.287 0.841 
Blindness IHD NORMAL 0.61 0.208 0.61 
 
 Cancer 15.3.4
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The parameter distributions for the incidence and hazard ratios for breast cancer and colorectal 
cancer are reported in Table 87. 
Table 87: Input parameters for breast cancer and colorectal cancer risk models 
Parameter Description Distribution Parameter 1 Parameter 2 Central 
estimate 
Source 
Colorectal cancer men NORMAL 0.0011 0.0001 0.0011 (31) 
Colorectal cancer women NORMAL 0.0005 0.0000 0.0005 (31) 
Breast cancer pre-menopause NORMAL 0.0010 0.0001 0.0010 (29) 
Breast cancer post-menopause NORMAL 0.0028 0.0002 0.0028 (29) 
Colorectal cancer BMI relative 
risk for men 
LOGNORMAL 0.1906 0.0111 1.21 (30) 
Colorectal cancer BMI relative 
risk for women 
LOGNORMAL 0.0392 0.0151 1.04 (30) 
Breast cancer BMI relative risk  
for pre-menopause 
LOGNORMAL -0.1165 0.0251 0.89 (30) 
Breast cancer BMI relative risk  
for post-menopause 
LOGNORMAL 0.0862 0.0205 1.09 (30) 
 
The parameter distributions for breast and colorectal cancer mortality are reported in Table 88. 
Table 88: Input parameters for breast cancer and colorectal cancer mortality (35) 
Parameter Description Distribution Parameter 1 Parameter 2 Central 
estimate 
Breast cancer 5 year survival BETA 439.69 2354.44 0.157 
Colorectal cancer 5 year survival BETA 1457.56 1806.35 0.447 
 
 Osteoarthritis  15.3.5
The parameter distributions for the incidence and hazard ratios for osteoarthritis are reported 
below. 
Table 89: Input parameters for the osteoarthritis risk model (5) 
Parameter Description Distribution Parameter 1 Parameter 2 Central 
estimate 
Osteoarthritis incidence NORMAL 0.0053 0.0000004 0.0053 
Osteoarthritis RR of diabetes LOGNORMAL 0.723 0.317 2.06 
Osteoarthritis RR of BMI LOGNORMAL 0.073 0.026 1.076 
 
 Depression 15.3.6
The parameter distributions for the incidence and hazard ratios for depression are reported below. 
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Table 90: Input parameters for the depression risk model  
Parameter Description Distribution Parameter 1 Parameter 2 Central 
estimate 
Source 
Odds of depression BETA 336 8803 0.0397 (33) 
Odds ratio for diabetes LOGNORMAL 0.4187 0.1483 1.52 (33) 
Odds ratio for stroke LOGNORMAL 1.8406 0.5826 6.3 (34) 
 
 Mortality 15.3.7
The other cause mortality rates by age were assumed constant in the probabilistic sensitivity analysis 
(36). The parameter distribution for the hazard ratio for other cause mortality with diabetes is 
reported below.  
Table 91: Input parameters for mortality hazard ratio for diabetes (37) 
Parameter Description Distribution Parameter 1 Parameter 2 
Central 
estimate 
Mortality hazard ratio for diabetes LOGNORMAL 0.588 0.186 1.80 
 
15.4 UTILITIES 
The parameter distributions used to estimate health state utilities in the model are reported below. 
Table 92: Utility input parameters 
Parameter Description Distribution Parameter 1 Parameter 2 Central 
estimate 
Source 
Renal/ulcer baseline utility NORMAL 0.689 0.014 0.689 (64) 
Renal dialysis NORMAL -0.078 0.026 -0.078 (64) 
Foot ulcer NORMAL -0.099 0.013 -0.099 (64) 
Amputation/heart failure 
baseline utility 
NORMAL 
0.807 0.005 0.807 (19) 
Heart failure NORMAL -0.101 0.032 -0.101 (19) 
Amputation NORMAL -0.172 0.045 -0.172 (19) 
Stable angina multiplicative 
factor decrement 
NORMAL 
0.801 0.038 0.801 (13) 
Unstable angina multiplicative 
factor decrement 
NORMAL 
0.77 0.038 0.77 (13) 
MI multiplicative factor 
decrement 
NORMAL 
0.76 0.018 0.76 (13) 
Stroke multiplicative factor 
decrement 
NORMAL 
0.629 0.04 0.629 (13) 
Cancer baseline utility NORMAL 0.8 0.0026 0.8 (65) 
Cancer decrement NORMAL -0.06 0.008 -0.06 (65) 
Osteoarthritis utility NORMAL 0.69 0.069 0.69 (66) 
Depression baseline utility NORMAL 0.48 0.048 0.48 (68) 
Depression remitters NORMAL 0.31 0.031 0.31 (68) 
Depression responders NORMAL 0.20 0.020 0.20 (68) 
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Depression non-responders NORMAL 0.070 0.007 0.070 (68) 
Depression drop-outs NORMAL 0.050 0.005 0.050 (68) 
Weight loss utility decrement NORMAL -0.0025 0.001 -0.0025 (114;115) 
Age utility decrement NORMAL -0.004 0.0001 -0.004 (13) 
 
15.5 UNIT HEALTH CARE COSTS 
Parameter Description Distribution Parameter 1 Parameter 2 Central 
estimate 
Source 
Cost of insulin GAMMA 3.194 391.85 1251.5 (43) 
Cost of anti-hypertensives GAMMA 100 1.83 183.01 (44) 
Cost of GP appointment GAMMA 100 0.43 43 (38) 
Nurse appointment (Advanced) GAMMA 100 0.25 25 (38) 
Health care assistant appointment GAMMA 100 0.0417 4.17 (38) 
Eye screening GAMMA 15.366 1.478 22.709 (42) 
HbA1c test GAMMA 100 0.03 3 (39) 
Lipids test GAMMA 100 0.03 1 (39) 
LfT test GAMMA 100 0.03 1 (39) 
B12 test GAMMA 100 0.03 1 (39) 
Urine test GAMMA 100 0.03 1 (39) 
Nicotine replacement therapy GAMMA 100 1.02 102 (38) 
HbA1c diagnosis screening GAMMA 100 0.14 14 (39) 
Unstable Angina hospital admission GAMMA 311.79 3 1191.4 (12) 
Revascularisation in hospital  GAMMA 300 17 5638.6 (12) 
MI Hospital admission  GAMMA 248.48 5 1452.3 (12) 
First Outpatient appointment GAMMA 100 1 154.45 (12) 
Subsequent outpatient appointments GAMMA 75 1 102.8 (12) 
Fatal CHD  GAMMA 300 2 665.5 (47) 
Fatal Stroke  GAMMA 280 13 4149.5 (46) 
First year stroke cost  GAMMA 350 23 9075 (46) 
Subsequent year stroke cost GAMMA 100 26 2579 (12) 
Glytrin Spray CONSTANT 11.92 NA NA (12) 
Isosorbide mononitrate CONSTANT 12.79 NA NA (12) 
Verapamil CONSTANT 47.79 NA NA (12) 
Atenolol CONSTANT 34.42 NA NA (12) 
Aspirin CONSTANT 7.57 NA NA (12) 
Ramipril CONSTANT 85.47 NA NA (12) 
ARB CONSTANT 239.35 NA NA (12) 
Clopidogrel CONSTANT 523.92 NA NA (12) 
Congestive Heart Failure  GAMMA 67 43 2921 (45) 
Blindness year 1 GAMMA 24 47 1147 (45) 
Blindness subsequent years GAMMA 36 10 370 (45) 
Amputation year 1 GAMMA 27 405 11125 (45) 
Amputation subsequent years GAMMA 16 24 395 (45) 
Renal Haemodialysis GAMMA 100 397 39736 (48) 
Renal Automated Peritoneal dialysis GAMMA 100 257 25720 (48) 
Renal Ambulatory peritoneal dialysis GAMMA 100 187 18657 (48) 
Renal transplant GAMMA 100 224 22359 (50) 
Immunosuppressants GAMMA 100 66 6576 (50) 
Foot ulcer not infected GAMMA 100 1.59 158.53 (51) 
Foot ulcer with cellulitis GAMMA 100 4.19 419 (51) 
Foot ulcer with osteomyelitis GAMMA 100 7.76 776 (51) 
122 
 
Breast Cancer GAMMA 100 130.58 13058 (53) 
Colorectal cancer Dukes A GAMMA 100 95.36 9536 (54) 
Colorectal cancer Dukes B GAMMA 100  163.63 163.63 (54) 
Colorectal cancer Dukes C GAMMA 100 250.90 25090 (54) 
Colorectal cancer Dukes D GAMMA 100 157.11 15711 (54) 
Osteoarthritis GAMMA 100 9.09 909 (55) 
Depression – Practice nurse surgery GAMMA 100 0.09 8.83 (56) 
Depression – Practice nurse home GAMMA 100 0.27 26.50 (56) 
Depression – Practice nurse telephone GAMMA 100 0.09 8.83 (56) 
Depression – Health visitor GAMMA 100 0.36 35.50 (56) 
Depression – District nurse GAMMA 100 0.25 24.50 (56) 
Depression – Other nurse GAMMA 100 0.09 8.83 (56) 
Depression – HCA phlebotomist GAMMA 100 0.04 4.17 (56) 
Depression – Other primary care GAMMA 100 0.25 25.00 (56) 
Depression – Out of Hours GAMMA 100 0.25 25.39 (56) 
Depression – NHS Direct GAMMA 100 0.24 23.90 (56) 
Depression – Walk-in Centre GAMMA 100 0.37 36.70 (56) 
Depression – Prescribed medicines GAMMA 100 0.09 9.09 (56) 
Depression – Secondary Care GAMMA 100 1.09 109.00 (56) 
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16 ONE-WAY SENSITIVITY ANALYSES 
A series of one-way sensitivity analyses were carried out in order to test the strength of certain 
assumptions that we had made. These were of two types. Firstly, some of the assumptions based 
upon particularly weak data relating to the interventions were tested. In addition, we carried out 
sensitivity analyses related to some of the other parameters and assumptions used in the model. 
16.1 SENSITIVITY ANALYSIS AROUND THE INTERVENTIONS 
Much of the data for the five interventions is based upon assumptions and extrapolations from 
multiple data sources rather than from long term randomised controlled trials collecting data on 
multiple metabolic risk factor endpoints. We decided to test the sensitivity of the results to 
modifying those parameters that were based upon particularly weak data. They focus on three main 
areas of uncertainty; duration of intervention effect, intervention uptake and intervention efficacy. 
The one-way sensitivity analyses around the interventions are summarised in Table 93. 
Table 93: One-way sensitivity analyses used to test the strength of parameters 
Parameter 
Affected 
Modification Justification Interventions 
Affected 
Duration of 
Intervention 
Effect 
Make effects last for duration of 
lifetime 
Intervention is continuous due to 
policy change.  
A 
B 
Increase duration of effects - 
diminish over ten years 
Original five year duration based 
only on estimation  
C 
D 
E 
Reduce duration of effects - 
diminish over two years 
Original five year duration based 
only on estimation 
C 
D 
E 
Intervention 
Uptake 
Switch uptake rates between 
Intervention D and Intervention 
E. 
Would be useful to see how 
important uptake rates are on 
intervention success 
D 
E 
Reduce number of people 
affected by intervention B to 
50% of upper Townsend 
quintile. 
Unlikely that everyone in 
deprived areas is lacking good 
retail provision. 
B 
Intervention 
Efficacy 
Increase efficacy of intervention 
C by estimating extra effects on 
BMI and HbA1c due to reducing 
fried food/sweet puddings. 
Increasing the competitiveness of 
the workplace intervention. 
C 
Remove the effects of vitamin C 
and fat intake on HbA1c levels 
Cross-sectional studies used to 
provide data. Only show 
correlation, not causation. 
B 
C 
D 
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 Duration of Intervention Effect  16.1.1
For the majority of interventions no data exists for the duration of intervention effect, and so for all 
interventions it was estimated to be maximal in year one, then diminish to zero (compared with 
basecase) over the following five years. A fixed duration of effect across all interventions was chosen 
to allow comparisons of the interventions independent upon the duration of response. This 
assumption is particularly unrealistic for interventions A and B, as both a soft drinks tax and a retail 
policy resulting in better access to fruit and vegetables would be likely to have a persistent effect in 
changing habits and behaviours. For interventions C, D and E, we decided to test the strength of the 
original assumption by either increasing the duration of effect to 10 years or reducing it to two years.  
 Intervention Uptake 16.1.2
The uptake of interventions is likely to have a large implication for their efficacy in reducing disease 
prevalence on a population-wide basis. Interventions D (community weight loss intervention) and E 
(screening and intensive intervention in high risk individuals) have very different uptake rates; only 
11.4% of the eligible population choose to take up intervention D, whilst 42% choose to be screened 
and undergo intervention E. We decided to switch the uptake rates for interventions D and E to see 
how this affected their relative cost-effectiveness.  
We also thought that there was some uncertainty around the question of how many people currently 
have poor access to fresh fruit and vegetables, and therefore would benefit from the retail 
intervention (B). There is very little data on how many people are actually living in ‘food deserts’, but 
it would be reasonable to assume that at least some of the most deprived people do currently have 
good local retail access and therefore that our initial assumptions would overestimate the numbers 
who would benefit. To test the sensitivity of the results to this assumption, we decided to randomly 
select 50% of the most deprived quintile of the population to receive the intervention.  
 Intervention Efficacy  16.1.3
Although efficacy is based on good quality data for many of the interventions, there are still a few 
areas for uncertainty. For the workplace intervention (C), the data was particularly poor as no 
information was given about the magnitude of changes in consumption of fruit, sweet puddings and 
fried food (99). The latter two are particularly difficult to estimate due to a lack of data about 
potential food substitution, or what in particular is represented by a sweet pudding or fried food, and 
therefore they were not included in the original analysis. We thought it would be interesting to try to 
maximise the potential health benefits of intervention C by estimating (in a fairly arbitrary way) the 
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effect of reductions in fried food and sweet puddings on BMI and HbA1c (via fat intake) as reported 
by 5.3% and 5.5% of individuals respectively. A reduction in fried food was considered to be a 
replacement of one Big Mac meal with a healthy home cooked meal each week, resulting in a 
reduction of 1000 calories and 70g of fat per week. A reduction in sweet puddings was considered to 
be a replacement of one sponge pudding with a low fat yoghurt each week, resulting in a reduction 
of 500 calories and 27g of fat per week.   
Another area for uncertainty regarding intervention efficacy is surrounding two pieces of cross-
sectional data that were used to derive reductions in HbA1c levels dependent upon vitamin C intake 
and fat intake (105;109). The data indicates that there is a correlation between HbA1c levels and 
vitamin C/fat intake, but this does not imply that there is a causative link. Given the lack of better 
quality data, values from these sources were used to inform the analysis. We decided that it was 
important to test how sensitive the cost-effectiveness of interventions B, C and D were to the 
removal of parameters based upon these correlations.  
16.2 SENSITIVITY ANALYSIS AROUND OTHER PARAMETERS 
The list of other one-way sensitivity analyses carried out is presented in   
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Table 94. 
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Table 94: List of sensitivity analyses 
Description of Sensitivity Analysis 
Discount rate  0% 
Discount rate 3.5% 
Non-intervention costs at 2.5th CI 
Non-intervention costs at 97.5th CI 
Cardiovascular costs at 2.5th CI 
Cardiovascular costs at 97.5th CI 
Diabetes costs at 2.5th CI 
Diabetes costs at 97.5th CI 
Microvascular costs at 2.5th CI 
Microvascular costs at 97.5th CI 
All utility decrements at 2.5th CI 
All utility decrements 97.5th CI 
Cardiovascular utility decrements at 2.5th CI 
Cardiovascular utility decrements at 97.5th CI 
Microvascular utility decrements at 2.5th CI 
Microvascular utility decrements at 97.5th CI 
BMI utility decrements at 2.5th CI 
BMI utility decrements at 97.5th CI 
Statin uptake 50% 
Statin uptake 80% 
QRISK IGR hazard ratio 2.5th CI 
QRISK IGR hazard ratio 97.5th CI 
No BMI effect on cancer incidence 
No BMI or diabetes effect on osteoarthritis incidence 
No diabetes or stroke effect on depression incidence 
No diabetes effect on mortality 
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17 MODEL LIMITATIONS AND FURTHER RESEARCH 
17.1 MODEL LIMITATIONS 
Limited baseline sample data: The model is based on data from 8038 individuals from the HSE 2011. 
A large proportion of individuals were missing answers for at least one of the variables required for 
input into the model, so missing data had to be assumed or imputed. Imputation relied on an 
assumption that non-response was arbitrary for each variable, which may not be correct. For other 
variables, assumption of negative responses may underestimate the true numbers of individuals 
affected. Although the HSE should be broadly representative of the UK population, the relatively 
small numbers and the necessity to rely only on data from individuals who were willing to respond, 
means that data may be biased or skewed for some variables. The use of a UK adult population also 
means that the model may not be appropriate for modelling diabetes in other countries or in 
children. 
Whitehall trajectories: Use of a quadratic form is beneficial because glycaemia increases at an 
increasing rate as observed in other studies (116). This provides a better description of the 
implications of not screening for diabetes, because unscreened individuals will not be detected until 
their HbA1c levels are much higher. A linear slope would describe a much more shallow progression 
of HbA1c before diabetes is detected. However, a disadvantage of this functional form is that all 
individuals are simulated with the same timescale, therefore progression is slow in the short term 
but increases for all individuals as time increases.  
Poor quality intervention data: Many of the interventions are based upon poor quality data due to 
the lack of good information about the effect on metabolic factors, general lack of detail as to 
intervention efficacy and short follow-up times. In particular, the evidence relating fat intake or 
plasma vitamin C to HbA1c levels was based on two cross-sectional studies, which means the effect is 
only correlative and not necessarily causative. We have also had to make many assumptions in 
implementing interventions. The retail policy was assumed to affect all individuals living in deprived 
areas, but many of these people will now have good access to fruit and vegetable provision. The 
workplace intervention was assumed to affect 20% of the working population, although we have no 
data on how many individuals would really be affected. The workplace intervention data was also 
very vague in terms of quantifying diet changes and we were forced to assume its effects on fruit and 
vegetable consumption and milk switching. We also were unable to find studies relating intake of 
certain foods to effects on metabolic factors and as a consequence we have potentially 
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underestimated the efficacy of interventions. For example, we could not find any data linking sugar 
intake to HbA1c levels, or fruit and vegetable intake to cholesterol levels. 
Model complexity: The complexity of the simulation is necessary to encompass the multiple factors 
impacting on type 2 diabetes and the multiple outcomes of hyper-glycaemia. However, this 
complexity also means that the model is difficult to understand and it is very difficult to ensure 
removal of all potential errors. This means that we cannot guarantee that the model is free of errors 
that could potentially have effects on costs, QALYs and resulting cost-effectiveness of interventions.  
17.2 FURTHER RESEARCH 
Improvements to the Whitehall model for metabolic risk trajectories: The Whitehall II analysis 
assumed that all participants were observed at equal time intervals between phases of the study. 
This was necessary to be able to implement the analysis in MPlus software, in which the data needed 
to be specified in wide format. Analyses by age group were investigated but could not be completed 
because of the low proportion of observations between age groups. The variation in time intervals 
between phases was not large and was not expected to impact substantially on the results of these 
analyses. Nonetheless we would recommend that further research explores an alternative 
specification of the model in which time is a continuous variable. This would also allow a more 
flexible specification of the trajectory of HbA1c and may avoid assuming a quadratic functional form. 
The effect of changes in BMI on changes in glycaemia has been shown to be small in the Whitehall II 
analysis. It is likely that changes in physical activity and diet will have additional effects on changes in 
glycaemia, independent of their indirect effects on BMI. We have incorporated the effects of diet 
into the model using other data sources. However, further research should explore whether these 
factors could be incorporated into the Whitehall II analysis to allow them to be causally related to all 
metabolic risk factors in a longitudinal analysis. 
Incorporate a behavioural intervention to increase physical activity: We identified a systematic 
review and meta-analysis of randomised controlled trials for behavioural interventions targeting 
physical activity and exercise in type 2 diabetics (117). The study found that a range of targeted 
behavioural interventions were successful in significantly increasing physical activity in diagnosed 
diabetics, leading to corresponding improvements in BMI and HbA1c. The mean reduction in BMI 
was 1.05 kg/m2 and the mean reduction in HbA1c was 0.32% for follow-up times ranging from 1 
month to 2 years.  
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These values could be implemented directly into the model in a similar way to those used for the 
translational diabetes prevention programme (Section 14.6). As for the other interventions, the 
effect could be assumed to be maximal in the first year and diminish linearly over the next 5 years, 
although sensitivity analysis should test the possibility of a sustained reduction over a longer period 
of time, as this was suggested from the small number of trials with 2 year follow-up. Intervention 
costs were not calculated in the study and would have to be estimated directly from clinical trial data 
or other sources. Cost and efficacy can vary widely depending upon the nature of the intervention 
and the training given to interventionists, so ideally sensitivity analysis would be used to determine 
cost-effectiveness given a range of intervention costs and associated improvements in BMI and 
HbA1c. 
Incorporate fibre intake into dietary interventions: One of our stakeholders identified a meta-
analysis linking intake of dietary fibre to HbA1c levels (118). This could be incorporated into the 
model as part of a dietary intervention in which participants are encouraged to eat more fibre. None 
of the studies used in the meta-analysis involved participants eating more fruit and vegetables; 
rather the focus was on eating high fibre bread and cereals, or on adding fibre such as Guar gum 
directly to the normal diet. In theory, the amount of fibre in an average portion of fruit and 
vegetables could be calculated and the resulting effect on HbA1c determined. However, given that 
the effect of fruit and vegetable intake on HbA1c is already incorporated within the model via plasma 
vitamin C levels, and it is unclear whether effects of fibre and vitamin C on HbA1c are independent, 
further research is required before this option is taken. 
Investigate subgroup-specific differences in intervention uptake, efficacy or duration: Current 
analyses of high risk subgroups assume that interventions have the same uptake, the same efficacy in 
reducing metabolic trajectories and the same duration of action in different population subgroups. 
This is unlikely to be true as it is known for example, that individuals from deprived areas are less 
likely to take up screening opportunities. Further research is required to investigate the current 
evidence base on subgroup specific intervention effects and use the resulting data to tailor 
intervention effect accordingly.  
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